Antineoplastic drugs and their analysis: a state of the art review

Guichard, Nicolas; Guillarme, Davy; Bonnabry, Pascal; Fleury-Souverain, Sandrine

How to cite

GUICHARD, Nicolas et al. Antineoplastic drugs and their analysis: a state of the art review. In: Analyst, 2017, vol. 142, p. 2273–2321. doi: 10.1039/c7an00367f

This publication URL: https://archive-ouverte.unige.ch//unige:96003
Publication DOI: 10.1039/c7an00367f

Analyst

CRITICAL REVIEW

View Article Online
View Journal | View Issue

Cite this: *Analyst*, 2017, **142**, 2273

Antineoplastic drugs and their analysis: a state of the art review

Nicolas Guichard, [a,b] Davy Guillarme, [b] Pascal Bonnabry[a,b] and Sandrine Fleury-Souverain *[a]

Received 2nd March 2017,
Accepted 10th May 2017

DOI: 10.1039/c7an00367f

rsc.li/analyst

The number of patients suffering from cancer is constantly increasing and, consequently, the number of different chemotherapy treatments administered is increasing. Given the high reactivity and toxicity of antineoplastic drugs, analytical methods are required in all pharmaceutical fields, from drug development to their elimination in wastewater; including formulation quality control, environment and human exposure and therapeutic drug monitoring. The aim of this paper is to provide an overview of the analytical methods available for the determination of antineoplastic drugs in different matrices such as pharmaceutical formulations, biological and environmental samples. The applicability and performance of the reported methods will be critically discussed, with focus on the most commonly used antineoplastic drugs. Only conventional compounds and small molecules for targeted therapy will be considered in the present review.

1 Introduction

The World Health Organisation stated that the incidence of cancer increased from 12.7 million in 2008 to 14.1 million in 2012.[1] This trend is expected to continue with the number of new cancer cases increasing by 70% over the next two decades. This bleak prognosis leads to a growing prescription for antineoplastic drugs, which constitute, with surgery and/or radiotherapy, the main treatment in oncology. Two classes of antineoplastic drugs from different generations can be distinguished, namely conventional molecules and drugs from targeted therapy. Conventional chemotherapy appeared at the beginning of the 20th century with the development of chemical weapons[2]. One of the first families of antineoplastic drugs still administered today constitutes molecules with a structure related to mustard gas used on the battlefields of World War I. A side effect observed with this gas (that has a myelosuppressive action) initiated the development of the first antineoplas-

[a]*Pharmacy, Geneva University Hospitals (HUG), Geneva, Switzerland. E-mail: sandrine.fleury.souverain@hcuge.ch; Fax: +41 22 372 39 65; Tel: +41 22 372 39 78*
[b]*School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland*

Nicolas Guichard

Nicolas Guichard received his Masters degree in molecular and biological chemistry from the Swiss Federal Institute of Technology in Lausanne, Switzerland in 2013. Currently he is pursuing his Ph.D. in Pharmaceutical Sciences at Geneva University Hospitals and in the School of Pharmaceutical Sciences at the University of Geneva, Switzerland.

Davy Guillarme

Davy Guillarme holds a Ph.D. degree in analytical chemistry from the University of Lyon, France. He is now a senior lecturer at the University of Geneva, Switzerland. He has authored 170 journal articles related to pharmaceutical analysis. His expertise includes HPLC, UHPLC, HILIC, LC-MS, SFC, analysis of proteins, and monoclonal antibodies. He is an Editorial Advisory Board member of several journals including Journal of Chromatography A, Journal of Separation Science and LC-GC North America.

tic drugs against leukemia.[3] Driven by this success, the USA decided to launch several national programs with the main objective of developing new molecules for cancer treatment. Then, an unbridled race towards the discovery of new anticancer drugs, such as antifolate compounds, purine and pyrimidine analogues and also antibiotics, started for a period of 20 years. Most of the conventional antineoplastic drugs administered today were developed during this period. The war against cancer knew a second offensive with the apparition of targeted therapies in the '90s. However, in spite of the promising discovery of these new molecules which act with precision, thus reducing side effects, heavy weapons represented by the conventional antineoplastic drugs remain the first-line molecules for the chemical treatment of a large number of cancers.

The high chemical reactivity of conventional antineoplastic drugs is responsible for their anticancer activity, but also represents their main drawback. Indeed, this high chemical reactivity makes such molecules extremely unstable and strongly toxic. Particular attention has therefore been paid to these compounds in terms of safety and quality. In this context, numerous methods were reported for the analysis of antineoplastic drugs in different fields, from the development of stable pharmaceutical products to wastewater treatment, including quality control of the formulation and therapeutic drug monitoring.

It can be noted that products containing antineoplastic drugs are almost exclusively intermediate pharmaceutical forms available as a lyophilisate or a concentrated solution of the active drug. Under these conditions, the highest compound stability can be obtained, and thus the desired therapeutic effect can be guaranteed. A reconstitution step, usually performed extemporaneously by the hospital staff (nurse or pharmacy operators), converting the intermediate form to a formulation ready to be administered to the patient, has to be performed. The analysis of reconstituted formulations, which are considered as high-risk products, prior to patient administration, is an unavoidable step from a quality control point of view. Given the toxicity of these molecules, in the last ten years focus has been on the determination of antineoplastic drug traces in the environment (hospital pharmacies, care units or effluents) and in biological fluids from the person handling these compounds, to control exposure.

The aim of this paper is to complete a review already published in 2011 by our group.[4] A critical overview of the reported analytical methods for antineoplastic drugs is provided. A significant number of new references are added and the methods used for the analysis of small molecules from targeted therapy are also discussed. Biological agents such as monoclonal antibodies are not considered in the present review.

2 Conventional antineoplastic drugs

Three different families of conventional antineoplastic drugs can be distinguished according to their action on deoxyribonucleic acid (DNA):

- Molecules acting on DNA synthesis (antimetabolites);
- Molecules with a direct action on DNA, called DNA-interactive agents (alkylating agents, intercalating agents and topoisomerase inhibitors);
- Molecules with an action on mitosis (antitubulin agents).

2.1. Antimetabolites

Antimetabolites belong to one of the oldest families of antineoplastic drugs. They include molecules such as methotrexate, and more recent compounds such as gemcitabine (GemC). In all cases, the mechanism of action of these compounds is to prevent DNA replication. Antimetabolites inhibit the synthesis of DNA components by acting as lures. They are structural analogues of purine and pyrimidine bases (similar to nucleobases or nucleosides), and folic analogues (inhibition of nucleic acid synthesis). Table 1 reports analytical methods published for the determination of antimetabolites.

2.1.1. Folic analogues. These compounds target folic coenzymes involved in the synthesis of nitrogenous bases. The first folic acid antagonist, namely aminopterin, was discovered in the late '40s for the treatment of childhood leukemia.[5] It was rapidly replaced by a less active but also less toxic agent,

Pascal Bonnabry

Pascal Bonnabry holds a Ph.D. in pharmaceutical sciences from the University of Geneva, Switzerland. He is now an Associate Professor at the University of Geneva and Head of Pharmacy at Geneva University Hospitals. He has authored more than 80 peer-reviewed articles related to pharmacy.

Sandrine Fleury-Souverain

Sandrine Fleury-Souverain holds a Ph.D. in pharmaceutical sciences from the University of Geneva, Switzerland. She is now head of quality control at Geneva University Hospitals Pharmacy. She has authored 35 journal articles related to pharmaceutical analysis. Her main field of research is the analysis of therapeutic drugs by CE-UV, CE-C^4D, LC-UV and LC-MS.

Table 1 Analytical methods for the detection of antimetabolite drugs

Antimetabolites	Matrices	Techniques	Ref.
Methotrexate	Molecule/ formulations	LC-UV	13 and 47
		CE-UV	43, 48 and 49
	Biological matrices	LC-UV	11, 12, 45 and 46
		LC-MS	17, 21, 24, 26, 30–34
		CE-UV	35–40, 42, 45 and 133
		CE-LIF	44
	Environment	LC-MS	15, 16, 19, 20, 22, 23, 25, 27–29, 134 and 135
Pemetrexed	Molecule/ formulations	LC-UV	51, 53–56 and 60
	Biological matrices	LC-UV	50 and 52
		LC-MS	57 and 136
Raltitrexed	Molecule/ formulations	CE-UV	61
	Biological matrices	LC-MS	59
5-fluorouracil	Molecule/ formulations	LC-UV	66, 67, 72, 74 and 137
		CE-UV	108
	Biological matrices	LC-UV	67, 85, 89 and 93
		LC-MS	34, 80, 95, 100–102
		LC-FD	97
		CE-UV	39, 105 and 109
	Environment	LC-UV	138
		LC-MS	28, 29, 78 and 103
		CE-UV	106 and 107
		GC-MS	27, 113 and 114
Azacitidine	Biological matrices	LC-MS	82 and 83
Gemcitabine	Molecule/ formulations	LC-UV	66, 73, 74 and 137
	Biological matrices	LC-UV	68–70, 87, 88, 91, 92, 96, 98 and 99
		LC-MS	34, 75–77, 81, 94, 104 and 136
	Environment	LC-UV	114
		LC-MS	19, 29, 103 and 135
Cytarabine	Molecule/ formulations	LC-UV	13, 67, 71 and 74
		CE-UV	111
	Biological matrices	LC-UV	67
		LC-MS	34, 79, 86, 90 and 139
		CE-UV	110–112
	Environment	LC-MS	18, 19, 29 and 103
6-Mercaptopurine	Biological matrices	LC-UV	123
		LC-MS	33
		LC-FD	130
6-Thioguanine	Biological matrices	LC-UV	120
		LC-MS	33, 121 and 131
		LC-AD	129
		CE-UV	39
Azathioprine	Molecule/ formulations	LC-UV	119
		CE-UV	132
	Biological matrices	LC-UV	118 and 125
	Environment	LC-UV	122 and 140
		LC-MS	134
Fludarabine	Biological matrices	LC-MS	127
Cladribine	Biological matrices	LC-UV	128
		LC-MS	126
Clofarabine	Biological matrices	LC-MS	126

amethopterin, also known as methotrexate, which is still extensively used 70 years after its discovery (for the treatment of osteosarcomas, acute lymphoblastic leukemias, Hodgkin's disease, breast, bladder and lung cancers). In the '90s, new folic analogues emerged, including raltitrexed[6] and pemetrexed,[7] with the aim of preventing methotrexate resistance and toxicity. Fig. 1 shows the structure of folic acid and its antagonists.

Molecules with a structure close to that of folic acid are characterised by the presence of two carboxylic acid groups. Their solubility depends on the pH of the solution. Indeed, with pK_a values of the carboxylic acid groups between 3.3 (pemetrexed) and 4.7 (methotrexate), neutral or basic solutions are required for their solubilisation. The presence of an asymmetric carbon is another property of folic analogues. *S*-Methotrexate, *S*-pemetrexed and *S*-raltitrexed are active forms, while *R*-forms are considered as impurities.[8]

Since 1975, more than 100 articles have described different analytical methods for the extraction, separation and detection of methotrexate.[4,9,10] Most of the reported methods are based on the use of liquid chromatography (LC) coupled with UV spectrophotometry (UV)[11,12,13,14] or mass spectrometry (MS), when there was a need for high selectivity and/or sensitivity.[15–22,23,24,25,26,27,28,29,30,31,32,33,34] Limits of detection



Fig. 1 Structure of folic acid and its analogues.

(LOD) inferior to 1 ng mL^{-1} were usually reached with LC-MS.[24,32] Capillary electrophoresis (CE) coupled with UV detection[35–43] or laser induced fluorescence detection (LIF)[44] was also proposed as a suitable approach for the analysis of methotrexate, since the molecule is ionisable. To improve the sensitivity of CE methods, zeta cell[38] or conventional sample preparation steps were used (LOD in the order of μg mL^{-1}). Solid phase extraction (SPE),[15,16,20,22,35,39,41,32,33,34] liquid–liquid extraction (LLE)[40] and protein precipitation (PP)[24,30,31,11,14,17,36] were among the most widely used sample preparation techniques when analysing methotrexate in complex matrices. Column-switching methods with SPE coupled with the analytical system (column and detection) were also developed for methotrexate analysis.[26] Methotrexate enantiomers separation was carried out by LC-UV[45–47] and CE-UV.[48,49] Contrary to methotrexate, only a few analytical methods have been reported in the literature for the most recent compounds (*i.e.*, raltitrexed and pemetrexed). The analytical methods for pemetrexed were based on LC coupled to UV,[50–55,56] MS[57,58] or evaporative light scattering detector (ELSD).[51] In our opinion, ELSD is not recommended for analysing pemetrexed since this molecule is UV-active and ELSD is often less sensitive and selective than the commonly used UV detectors. A methodology including a PP step followed by LC-MS analysis was also developed for the determination of raltitrexed in human plasma with a limit of quantification (LOQ) of 2 ng mL^{-1}.[59] For impurity profiling of active ingredients, separation of pemetrexed and raltitrexed enantiomers were obtained by LC-UV[60] and CE-UV,[61] respectively. In LC-UV, a polysaccharide chiral stationary phase was employed, while the chiral selector (cyclodextrins) was directly added to the BGE in CE-UV.

2.1.2. Pyrimidine analogues. As the name suggests, these substances have structures close to the endogeneous pyrimidine bases (thymine, cytosine and uracil). Biochemical lures disrupt the synthesis of nucleic acids. The first compound, developed in the '50s,[62] was a uracil molecule with a fluorine atom in the 5-position, named 5-fluorouracil (5FU). This old substance remains the most prescribed molecule in oncology and its main application is the treatment of colorectal cancer. The structures of the most familiar compounds of this subfamily of antineoplastic agents are shown in Fig. 2.

Discovered in the late '50s/early '60s, following research on marine sponges, cytarabine paved the way for a series of cytidine analogues (cytosine nucleoside).[63] In 1964, azacitidine, whose structure differed by the presence of an additional nitrogen atom in the 5-position of the cytosine nucleus, was produced.[64] It was only in the '90s that GemC appeared in the arsenal of antineoplastic drugs, synthesized a decade earlier by Eli Lilly Laboratories.[65]

A wide range of analytical methods have been developed for pyrimidine analogues. Historically, the most commonly used technique was reversed phase LC (RPLC) coupled with UV[66–72,73,74,13] or MS.[18,19,75–82,83,84,29,34] LOD inferior to 1 ng mL^{-1} can be obtained for the analysis of pyrimidine analogues by LC-MS. For example, Marangon *et al.* developed an LC-MS method including a PP step, for the determination of GemC and its metabolite in plasma, achieving a LOD of 0.1 ng mL^{-1}.[77] The main limitation of these methods is the poor retention of pyrimidine analogues on a C18 stationary phase under RPLC conditions. Indeed, pyrimidine analogues are small hydrophilic molecules having log *P* values between −0.9 and −3.5. To have a sufficient retention for these relatively polar molecules, different strategies were applied in LC including the use of ion pairing reagents,[85–88] ion exchange chromatography,[89–92] porous graphitic carbon support,[93] the derivatisation of pyrimidine analogues prior to their analysis by RPLC,[94,95] or the use of normal phase chromatographic supports.[96–99] However, all of these approaches suffer from obvious limitations, including long column equilibration, poor kinetic performance, tedious sample preparation procedures, or incompatibility with MS.

More recently, hydrophilic interaction chromatography (HILIC) has been proposed as an alternative strategy for the analysis of 5FU[100,101,102] and cytidine analogues[103,104] as shown in Fig. 3. In brief, a polar stationary phase is used in HILIC, together with a mobile phase composed of a large proportion of acetonitrile and aqueous buffer. The limitations previously described for ion pairing chromatography, ion exchange chromatography or normal phase LC were all tackled with HILIC, and this is why this analytical technique was successfully applied for the analysis of pyrimidine analogues.

Various CE-UV methods have also been suggested for the analysis of 5FU[39,105–108,109] and cytarabine,[110–112] since CE



Fig. 2 Structures of pyrimidine bases and their analogues.



Fig. 3 Multiple reaction monitoring chromatograms of 5FU, GemC and its metabolite (dFdU) obtained for the analysis of calibration standards in (a) spiked hospital wastewater, and (b) hospital wastewater, by hydrophilic interaction chromatography coupled to MS. Adapted from ref. 103, 2009, with permission from Elsevier.

works with any type of ionisable substance, whatever the polarity. LOD of 1.7 ng mL^{-1} was reached for the analysis of 5FU in effluents using an SPE-CE-UV method.[106] Gas chromatography (GC) coupled to MS was also used for the analysis of 5FU,[113,114,27] but the time consuming and tedious derivatisation step means low popularity of GC for the analysis of these non-volatile compounds.

2.1.3. Purine analogues. Like pyrimidine analogues, purine analogues are incorporated into cell components to disrupt the synthesis of nucleic acids. Their structures are inspired by the endogenous purine bases (Fig. 4). Two generations of compounds can be discerned: nitrogenous base analogues (6-mercaptopurine, 6-thioguanine and azathioprine) and nucleoside analogues (fludarabine, cladribine and clofarabine). The first generation appeared in the '50s after a study of more than 100 purine analogues revealed their inhibitory activity on DNA synthesis of guanine and hypoxanthine compounds with a sulfur in the 6-position instead of an oxygen atom.[115,116] 6-Mercaptopurine and 6-thioguanine are mainly used for the treatment of leukemia, while azathioprine (6-mercaptopurine prodrug) is used for its myelosuppressive activity. Despite their significant adverse effects (myelosuppression and digestive disorders) and anticancer activity that is subject to a large inter-individual variation (metabolic pathway by a polymorphic enzyme: thiopurine methyltransferase (TPMT)), these three substances are still present in the chemotherapy arsenal. In the '80s, two additional molecules were discovered (fludarabine and cladribine) and were used ten years later as models for the synthesis of clofarabine, a more stable and active molecule.[117] This second generation of purine analogues are today used against leukemia.

Purine analogues are less hydrophilic than pyrimidine analogues. Thus, RPLC was the main technique employed for the analysis of both the first[118–125] and second generation[126–128] purine analogues. It should be noted that several studies were based on the analysis of the products resulting from the



Fig. 4 Structures of purine bases and their analogues.

metabolism of the first generation purine analogues, given their potential toxicity.[120,121,125] 6-Methylmercaptopurine produced by TPMT was frequently sought in globules of patients undergoing treatment to define their phenotyping, since TPMT deficiency led to severe toxicity.[121] In addition to UV detection (which was the most widely used), amperometric detection (AD),[129] fluorescence detection (FD)[130] and MS detection[121,126,127,131] were also coupled to LC for the determination of purine analogues. LOQ of 1 ng mL^{-1} were usually obtained for purine analogues determination by LC-MS.[127,126] Concentrations of 6-mercaptopurine at 0.0615 ng mL^{-1} in urine samples were detected by a LC-FD method using metal palladium to form coordination complexes and enhance the detection signal.[130] A CE-UV method based on the use of borate buffer as background electrolyte (BGE) were also successfully used for the analysis of azathiopurine and its impurities in formulations,[132] or 6-thioguanine in urine[39] with a LOD in the order of 1 μg mL^{-1}.

2.2. DNA interactive agents

2.2.1. Alkylating agents. Alkylating agents represent the oldest family of antineoplastic drugs with the introduction of chlormethine in the late '40s. This family originated from mustard gas, which was used as a chemical weapon during World War I. The observation of an aplastic anemia appearing with severe burns, a few days after exposure, was the starting point for the search for anticancer drugs with reduced side effects. Alkylating agents are organic compounds with one or more electrophilic groups that react with the nucleophilic groups of DNA nucleobases in double helix or proteins, by covalently incorporating alkyl groups (Fig. 5) thereby altering replication and transcription processes. Analytical methods for detecting alkylating agents are reported in Table 2. Today, seven classes of alkylating agents can be distinguished:

- Nitrogen mustard analogues;
- Oxazophosphorines;
- Ethylene imines;
- Nitrosoureas;
- Alkylsulfonates;
- Triazenes and hydrazines;
- Platinum derivatives.

2.2.1.1. Nitrogen mustard analogues. Nitrogen mustard analogues are characterised by the presence of bis(2-chloroethyl)amino groups generating an azyridium ion which binds preferentially to the nitrogen atom at the 7-position of guanine. Given the high reactivity and, consequently, instability in solution, nitrogen mustards are generally orally administered. Only chlormethine and mephalan are administered by injection. To overcome their instability in water, injectable formulations are dry forms that need to be solubilised extemporaneously (patient administration must be carried out within 1 h after solubilisation). This limits the hydrolysis of the molecule in aqueous media (chloride groups are substituted by hydroxy groups in water) which leads to an inactive compound.

The analysis of nitrogen mustard analogues is very difficult because of their instability. Chlormethine was usually analysed by LC-UV after a derivatisation step leading to a stable and UV detectable compound.[141–143] Products resulting from chlor-



Fig. 5 Structures of alkylating agents.

Table 2 Analytical methods for the detection of alkylating agents

Alkylating agents	Matrices	Techniques	Ref.
Chlorambucil	Biological matrices	LC-UV	45
		LC-MS	162
		CE-UV	45
Chloromethine	Molecule/ formulations	LC-UV	141, 142, 143
Estramustine	Biological matrices	LC-FD	163
		LC-MS	164
		GC-NPD	163
		GC-MS	163
Mephalan	Molecule/ formulations	LC-UV	146, 137
	Biological matrices	LC-UV	147, 148, 149
		LC-MS	153, 154, 155, 156–160 and 161
		LC-FD	150 and 151
		LC-EC	152
Cyclophosphamide	Molecule/ formulations	LC-UV	137 and 186
	Biological matrices	LC-UV	189
		LC-MS	21, 34, 78, 127, 136, 168–180, 193, 194, 305 and 306
	Environment	LC-UV	138
		LC-MS	15, 16, 19, 20, 22, 23, 25, 28, 29, 78, 134, 135 and 307
		GC-MS	27
Ifosfamide	Molecule/ formulations	LC-UV	137
	Biological matrices	LC-UV	188
		LC-MS	21, 34, 136, 170, 176, 179–181, 184, 185, 187 and 191
		GC-NPD	190
		GC-MS	195
	Environment	LC-UV	138
		LC-MS	19, 20, 22, 23, 25, 29, 78, 134, 135, 192 and 307
		GC-MS	27
Mitomycine	Molecule/ formulations	LC-UV	201, 203 and 205
		LC-MS	205
	Biological matrices	LC-UV	208, 209, 211, 212, 214 and 215
		LC-MS	210
	Environment	LC-UV	214 and 215
		LC-MS	29 and 213
Thiotepa	Molecule/ formulations	LC-UV	200, 202 and 204
	Biological matrices	LC-MS	171, 206 and 207
		GC-NPD	207
	Environment	LC-UV	140
Carmustine	Molecule/ formulations	LC-UV	220, 217 and 221
		LC-MS	219
Lomustine	Biological matrices	LC-UV	222 and 223
Busulfan	Molecule/ formulations	LC-UV	238
	Biological matrices	LC-UV	28, 233–237
		LC-FD	239
		LC-MS	178, 183, 240–249
		GC-MS	226–230
		GC-ECD	231 and 232
Procarbazine	Biological matrices	LC-MS	262
	Environment	LC-MS	308
Dacarbazine	Molecule/ formulations	LC-UV	250–252
	Biological matrices	LC-UV	260 and 45
		LC-MS	34 and 266
		CE-UV	45
Temozolomide	Molecule/ formulations	LC-UV	254 and 255
	Biological matrices	LC-UV	253, 256–259 and 261
		LC-MS	263 and 264
		CE-UV	267
	Environment	LC-MS	135
Procarbazine	Biological matrices	LC-MS	265
	Environment	LC-MS	22
Cisplatin	Molecule/ formulations	LC-UV	137
		CE-UV	4, 297, 303 and 304
		CE-MS	302
	Biological matrices	LC-UV	273
		LC-MS	274 and 278
		LC-ICP-MS	280, 283 and 284
		ICP-MS	287 and 21
		CE-UV	295 and 300
		Absorptive voltammetry	288, 289 and 290
	Environment	ICP-MS	286
		LC-ICP-MS	280, 282 and 285
		Absorptive voltammetry	288, 290 and 113
Carboplatin	Molecule/ formulations	LC-UV	269, 271 and 137
		CE-UV	4, 297 and 301
	Biological matrices	LC-UV	270
		LC-MS	275, 136 and 309
		LC-ICP-MS	280 and 283
		ICP-MS	287 and 21
		Absorptive voltammetry	289 and 290
	Environment	LC-MS	29
		ICP-MS	286
		LC-ICP-MS	280 and 282
		Absorptive voltammetry	290 and 113
Oxaliplatin	Molecule/ formulations	LC-UV	291
		CE-UV	4, 298 and 299
		CE-ICP-MS	279
	Biological matrices	LC-MS	276 and 277
		LC-ICP-MS	280, 281 and 283
		ICP-MS	287 and 21
		CE-UV	300
		Absorptive voltammetry	289 and 290
	Environment	LC-MS	310
		ICP-MS	286
		LC-ICP-MS	280
		Absorptive voltammetry	290 and 113

methine hydrolysis were determined either by LC-MS[144] or GC-MS[145] in biological matrices.

LC coupled to a wide range of detectors such as UV,[137,146–149] FD,[150,151] electrochemistry (EC)[152] and MS[153–160] were successfully used for melphalan assay. Based on the chemical structure of the molecule, there is no reason to use fluorescence since the molecule does not possess an extended π conjugation system in its structure. Indeed, similar LOD values (between 5 and 10 ng mL^{-1}) were obtained for LC-UV and LC-FD methods for the analysis of melphalan in plasma. With MS detection, LOQ of 1 ng mL^{-1} was reached for melphalan in biological samples.[154] Chlorambucil was determined by CE-UV and LC-UV in biological matrices with an inferior LOQ of 1 μg mL^{-1}.[45] Studies based on the analysis of DNA/nucleotide adducts with melphalan[155–160,161] and chlorambucil[162] in biological samples by LC-MS have also been published.

Finally, methods based on LC-FD,[163] LC-MS,[164] GC-MS and GC coupled to a nitrogen–phosphorus detector (NPD)[163] were developed for the analysis of estramustine and its main metabolites in biological matrices. With a simple PP step prior to LC-MS analysis, LOQ of 3 ng mL^{-1} was obtained for the estramustine assay in plasma.[164]

2.2.1.2. Oxazophosphorines. Oxazophosphorine compounds appeared in the '50s and are clearly less reactive than nitrogen mustards. They were derived from a concept designed to chemically mask the high reactivity of the active compound up to its target (tumor cell), where specific enzymes were responsible for the conversion to the active form.[165] Indeed, the nitrogen-phosphorus bond does not allow a direct ionisation of the bis(2-chloroethyl) group. The activation, including heterocycle opening resulting from the oxidation of the carbon in the 4-position and formation of chlorethylazirine responsible for the alkylation of DNA, is carried out by P450 cytochromes. The two spearheads of the oxazophosphorines are cyclophosphamide and ifosfamide which have multiple applications (blood cancers, sarcomas, breast cancers...).

Although many methods based on the use of thin layer chromatography (TLC) or GC have been developed for the analysis of oxazophosphorine compounds,[166,167] LC-MS[21,58,127,168–182,23,25,29,183,184,185] and LC-UV[186] remain the techniques of choice. The analysis of the active metabolite of cyclophosphamide (4-hydroxycyclophosphamide) requires an additional derivatisation step immediately after biological sampling, because of its very low stability (half-life of approximately 4 minutes). Various stabilizing agents, such as phenylhydrazine,[174] ansyldrazine,[177] methylhydroxylamine[169] and semicarbazide,[184,171] have been suggested.

Since oxazophosphorines, and more particularly cyclophosphamide, are the most prescribed antineoplastic agents and are administered at high concentrations (mg mL^{-1}), these compounds are often used as markers during studies of exposure to cytotoxic agents. Several LC-MS methods have been developed for the determination of oxazophosphorine traces in environmental and biological matrices, with LOD's lower than 1 ng mL^{-1}. For example, concentrations of 50 pg mL^{-1} oxazophosphorines in urine have been detected by LC-MS including LLE, during biological monitoring of hospital personnel exposed to antineoplastic drugs.[21]

Oxazophosphorine compounds are chiral molecules (asymmetric phosphorus) administered as a racemate mixture to the patient (the *S*-enantiomer has more potent anticancer activity). Protein-based columns[187–192] or polysaccharide-based columns[193,194] allow resolution of oxazophosphorine enantiomers. Ifosfamide enantiomers and their metabolites in urine and serum can be discriminated by a β-cyclodextrine capillary GC column.[195]

2.2.1.3. Ethylene imines. Ethylene imines contain one or more azyridine rings which lead to the formation of aziridinium ions responsible for the alkylating action of the compounds (such as nitrogen mustards). The absence of charge on the aziridine ring makes these molecules less reactive than nitrogen mustards. The first compound of this subfamily, called thiotepa, was discovered in the '50s.[196] Its main indications are ovary, breast and bladder cancers, but it remains scarcely used. The other important molecule belonging to this subfamily is mytomycin C, an antibiotic produced by a bacterium (*Streptomyces caespitosus*) also discovered in the late '50s.[197] It is inactive and requires an enzymatic reduction to induce the opening of the aziridine ring to obtain the alkylating molecule. Mitomycin C is mainly used for the treatment of cancers of the digestive system.

Ethylene imines are unstable in aqueous solution. Indeed, thiotepa degrades rapidly by opening cycles (P–N cleavage) to give the aziridinium ion, polymerising to an insoluble product.[198] In the case of mitomycin C, substitution of an amine group in the 7-position by a hydroxyl group (basic conditions), or loss of a methoxy group and opening of the aziridine ring (acid conditions), can occur.[199] Therefore, pharmaceutical formulations containing ethylene imine molecules are dry forms to be reconstituted and diluted before patient administration.

Due to their low stability in solution, different methods for both thiotepa and mitomycin C were used in degradation studies[140,200] or in stability studies of pharmaceutical formulations.[201–204,205] These methods were mainly based on LC-UV. Since thiotepa metabolism is still uncertain, LC-MS methods were also developed more recently for the identification of potential metabolites.[171,206,207] de Jonge *et al.* have developed an LC-MS method for the determination of thiotepa, cyclophosphosphamide and their main metabolites in plasma, and a LOQ of 5 ng mL^{-1} was achieved for thiotepa.[171] An LOQ of 25 ng mL^{-1} was obtained for the determination of thiotepa in urine by GC-NPD following LLE as the sample preparation step.[207] For mitomycin C, analyses are based on the use of LC-UV and LC-MS and allow the detection of the molecule in biological[208–212] and environmental matrices.[29,213–215] Similar sensitivities are usually obtained for mitomycin (LOD in the order of ng mL^{-1}) with each technique. However, given the high sensitivity and selectivity of MS, it is possible to make the sample preparation step quicker prior to LC analysis, for example a simple dilution of the sample can be included.[210]

2.2.1.4. Nitrosoureas. Nitrosourea compounds have the characteristic of giving, under basic conditions, the diazohydroxide moiety, which generates a highly reactive cation, responsible for the alkylating activity of this subfamily of antineoplastic drugs. The first compound (*N*-methyl-*N*′-nitro-*N*-nitrosoguanidine or MNNG) was developed in the '50s.[216] Studies carried out on MNNG allowed the development of new molecules such as:

- MNU (*N*-methyl-*N*-nitrosourea), in the early '60s, which demonstrated good permeability of the blood–brain barrier (treatment of brain tumors);
- BCNU (carmustine), in the late '60s;
- CCNU (lomustine) in the '70s.[216]

The main applications of these molecules are for the treatment of cerebral tumors and melanomas.

Given their relative lipophilic character (log *P* values between 1.5 and 2.5), nitrosourea compounds, in particular carmustine, are interesting for permeability studies on protective gloves[217–219] and for studies dealing with the interaction of substances with the usual containers of pharmaceutical formulations.[220,221] Reported methods are based on the use of spectrophotometry[218] and LC-UV.[217,219–221] Wallemacq *et al.* obtained an LOD of 59 ng mL^{-1} for carmustine in water using LC-UV.[219] Similar sensitivities were obtained with LC-UV methods for the determination of lomustine[222,223] in plasma.

2.2.1.5 Alkylsulfonates. Discovered in the '50s, busulfan is the only compound in this subfamily of alkylating agents.[224] Originally orally administered for the treatment of chronic myeloid leukemia, busulfan was also injected as part of the conditioning regimens for patients undergoing bone marrow transplants at the end of the 20th century. Busulfan is characterized by very low solubility and stability in water, pharmaceutical formulations contain solubilising agents (dimethylacetamide and polyethylene glycol 400) to limit rapid busulfan hydrolysis into tetrahydrofuran and methanesulfonic acid.[225]

Numerous methods have been developed for the analysis of busulfan in blood matrices. Indeed, due to wide inter-patient variation in the pharmacokinetics and the narrow therapeutic range of busulfan, it was essential to introduce pharmacological therapeutic monitoring during treatment with this antineoplastic drug. For this purpose, different analytical techniques were applied. GC coupled to MS,[226–230] or to an electron capture detector (ECD)[231,232] were published for the analysis of busulfan in blood, with an LOQ between 10 and 150 ng mL^{-1}. However, these methods require an additional derivatisation step prior to separation because busulfan is a non volatile and thermolabile compound. LC-UV is not an interesting approach for the determination of busulfan because it does not contain any chromophoric groups. This explains why all reported LC-UV methods also included a derivatisation step, often inspired by those used in GC with similar sensitivities.[28,233–237] An LC-UV method with a derivation step using diethylthiocarbamate provided a successful study of busulfan stability in injectable solutions contained in different medical devices in the concentration range 0.05–0.5 mg mL^{-1}.[238] A similar strategy was applied to the analysis of this compound in plasma by LC-FD with a LOD and LOQ of 9 ng mL^{-1} and 20 ng mL^{-1}, respectively.[239] The derivatisation step became redundant with LC-MS.[178,240–247,248,183] Busulfan concentrations of 0.2 ng mL^{-1} were quantified by a LC-MS, including PP sample preparation and only 100 μL plasma sample.[248]

To analyse busulfan in complex biological matrices, the use of several sample preparation techniques have been reported: LLE,[243,246] SPE on 96-well plates format[178] and in-line[241], as well as PP.[242,244,245,248,183] Recently, busulfan determination was also achieved by LC-MS in whole blood, using dried blood spots followed by methanol desorption[240] with an LOQ of 50 ng mL^{-1}. Danso *et al.* have developed a very fast SPE method coupled to MS for the analysis of busulfan in plasma with an LOQ of 25 ng mL^{-1}.[249] Selectivity was provided by the sample preparation (PP step prior to the SPE) and by the use of a triple quadrupole mass spectrometer.

2.2.1.6 Triazenes and hydrazines. Triazene compounds are characterised by the presence of 3 adjacent nitrogen atoms and are activated by hepatic cytochromes *via* the formation of a methyldiazonium ion (responsible for alkylating action). The two representative compounds of this subfamily are dacarbazine and temozolomide. Discovered in the '70s, dacarbazine is mainly used in the treatment of melanoma and Hodgkin's lymphoma in an injectable form. The development of temozolomide was more recent (late '80s, early '90s). Given its good stability under acidic conditions, possible oral administration, large distribution in the central nervous system and antitumor activity, temozolomide constitutes the treatment of choice for brain tumors (multiform glioblastomas).

Procarbazine is a hydrazine compound (two adjacent nitrogen atoms) developed first as a monoamine oxydase inhibitor in the '60s. In oncology, it is used for the treatment of Hodgkin's lymphoma. Its activation is also achieved by cytochrome enzymes, leading to the formation of diazonium ions.

LC-UV was mainly used for the determination of dacarbazine[250–252] and temozolomide[253–255] in stability/degradation studies. Few methods based on LC-UV[256–261] and LC-MS[262–266] were reported for the analysis of triazene compounds and procardazine in biological matrices. An LOQ of 0.5 ng mL^{-1} was achieved for the analysis of dacarbazine[266] and procarbazine[265] in plasma samples by LC-MS. Lower sensitivity (LOQ of 50 ng mL^{-1}) was reached with LC-MS for the temozolomide assay in plasma.[264]

A micellar electrokinetic chromatography (MEKC) method has also been reported for the determination of temozolomide and its degradation products in water and serum.[267] The choice of the MEKC method was based on: (i) the absence of charge on temozolomide in neutral and acidic conditions; and (ii) its low stability in solution.

2.2.1.7. Platine derivatives. All the compounds belonging to this subfamily of antineoplastic drugs contain a platinum atom in the oxidation state II, the nature of ligands reflects the history of their development.

Even if the first compound of this subfamily, cisplatin, was synthesised initially in 1844, its anticancer activity was accidentally discovered only in the '60s.[268] Its high toxicity (and

more particularly its nephrotoxicity) and various resistance phenomena led to the development of new molecules. The applied strategy focused on a reduction of toxicity by increasing water solubility and stability. In this perspective, the chlorine atoms were substituted by carboxylate chelating groups. Among all the molecules synthesised and evaluated, carboplatin (developed at the end of the '80s) was particularly interesting, due to its wider therapeutic index and reduced toxicity. The bidentate cyclobutanedicarboxylate ligand gives carboplatin greater stability than the chloride ligands. However, this second generation of compounds suffers, under chlorine-rich conditions, from a substitution of the carboxylate group by chlorine, leading to the formation of cisplatin. Therefore, manipulations of carboplatin should be avoided with solutions containing chlorine, to limit toxicity. In addition, because carboplatin has a close structure to cisplatin, it is also inactive against cisplatin-resistant tumors. Consequently, there was a need to develop a new molecule without these problems of resistance. Thus, the third generation of platinum derivatives appeared in the late '90s, with a 1,2-diaminocyclohexane group, whose anticancer activity against tumors resistant to cisplatin and carboplatin, has been demonstrated. Due to the presence of two bidentate ligands, oxaliplatin was the most stable platinum derivative. However, it can be noted that chloride ions are not recommended in the presence of oxaliplatin to avoid any substitution of the ligands by chlorine atoms, leading to highly reactive products (formation of mono or dichloro platinum complexes). Today, cisplatin is still prescribed in the treatment of solid tumors such as neuroblastomas, while carboplatin is mainly used in the treatment of ovarian cancers. Oxaliplatin is mainly used in the treatment of colorectal cancers.

Different analytical techniques were used for the determination of derivative platinum compounds. Given their low UV-absorbance and high instability, the development of methods for the platinum derivatives assay can be considered as difficult. Few LC-UV methods were reported but all of them suffered from poor sensitivity (limit of quantification (LOQ) in the order of a few μg mL^{-1}).[269–271] The introduction of an additional derivatisation step improved sensitivity (up to a factor of 100) with LC-UV methods.[272,273] Better LOQ's, between 2 and 25 ng mL^{-1}, were reached with LC-MS.[274–278] However, the technique of choice for the detection of platinum derivatives was undoubtedly inductively coupled plasma mass spectrometry (ICP-MS). ICP-MS coupled to a separation technique,[279–284,285] or not,[21,286,287] is characterised by an excellent LOQ, in the range 0.1 to 1 μg mL^{-1}. A chromatogram obtained for the analysis of platinum compounds by LC-ICP-MS is reported in Fig. 6.[280] Without separation prior to ICP-MS, the quantification of total platinum was performed. On the other hand, absorptive voltammetry was also successfully applied for the quantification of total platinum with an LOD in the order of pg mL^{-1} in biological matrices. However, similar to oxazophosphorine compounds, platin derivative agents belong to the most administered antineoplastic drugs (often in high concentrations too) and are often used as markers in exposure studies. Hence, all of these techniques are used even if absorptive voltammetry methods offer better sensitivity. This is because this analytical technique requires a sample degradation step *via* photolysis digestion.[113,288–290]



Fig. 6 Chromatogram obtained for the analysis of platinum compounds and degradation products of cisplatin (monoaquacisplatin, diaquacisplatin), carboplatin (CP2) and oxaliplatin (OP1) in water by LC-ICP-MS. Adapted from ref. 280 by permission of Springer, 2005.

For the separation step, different chromatographic supports were used, including reversed phase columns,[269,270,277,281,278] ion exchange columns,[275] HILIC support[285] or cellulose based columns for the enantiomer resolution of oxaliplatin.[291] CE was also reported as a promising technique for the separation of platinum derivatives.[292–294] MEKC methods with UV detection allowed a baseline resolution between cisplatin, carboplatin and oxaliplatin.[295–297] Detection limits in the order of 0.6 μg mL^{-1} were reported for cisplatin in serum after a sample preparation step based on ultrafiltration.[295] Microemulsion electrokinetic chromatography (MEEKC) methods coupled to UV detection were also developed in the context of fundamental studies.[298,299] An MEEKC method coupled to ICP-MS detection was reported for the characterisation of oxaliplatin and other platinum derivatives in drug development.[279] Due to the signal suppression effects of surfactants employed in MEEKC, the sensitivity was only improved by a factor of 1.5 compared to UV detection, to the detriment of the separation (peak broadening due to the interfacing and detector carry-over). More conventional CE methods were also developed in interaction studies (between platinum compounds and blood proteins)[300] and for the analysis of platinum derivatives and nucleoside adducts.[301–304] Under these conditions, the molecule to be analysed was a charged macromolecule.

2.2.2. Intercalating agents. Intercalating agents are planar polycyclic molecules that can be incorporated between contiguous base pairs of DNA. DNA replication and transcription are then inhibited. Direct action on topoisomerase II and I, or formation of free radicals are the two proposed modes of action of these intercalating agents. The structures of the main

intercalating agents and the analytical methods used for their analysis are reported in Fig. 7 and Table 3, respectively.

2.2.2.1 Anthracyclines. Anthracyclines are natural antibiotic molecules derived from pigments produced by *Streptomyces peucetius*.[311,312] They have a common structure composed of an anthracyclinone entity (responsible for their red coloration) and aminoglucoside. The first molecules of this subfamily were discovered in the early '60s and were called daunorubicin and doxorubicin. A slight difference in structure (C9 chain terminated with a primary alcohol for doxorubicin and methyl for daunorubin) resulted in significant changes in the activity spectra of these two molecules. Doxorubicin is used for the treatment of lymphomas, breast, stomach, ovarian and bladder cancers, while daunorubicin is indicated for the treatment of chronic lymphocytic leukemia. Both molecules exhibit high cardiotoxicity. Therefore, the following developments of new anthracyclines focused on molecules with lower side effects. Epirubicin, a semi-synthetic derivative of doxorubicin (an epimer in the hydroxyl group at the carbon in 4-position of aminoglycoside) appeared in the '80s. Although epirubicin has approximately the same indications as doxorubicin, differences in metabolism and pharmacokinetics of the molecule are observed, including an increase in distribution volume, 4-*O*-glucuronidation, an increase of clearance and a decrease of half-life. Thus, high doses of epirubicin can be administered without an increase in cardiotoxicity. At the same time, a semi-synthetic analog of daunorubicin, namely idarubicin, also appeared on the market. Compared to daunorubicin, idarubicin lost the C4 methoxy group, conferring greater lipophilicity. Idarubicin exhibits a wider spectrum of activity and lower cardiotoxicity. Treatment can be orally administered and its main indications are breast cancer and some types of leukemia. Anthracyclines are characterized by stability in solution within a very narrow pH range (between pH 5–7). Indeed under acid pH conditions, the molecules precipitate whereas at basic pH, they degrade rapidly. Liposomal injection solutions of doxorubicin and daunorubicin have been developed to reduce their cardiotoxicity by limiting their distribution to the heart.

Numerous LC and CE methods have been published for the analysis of anthracyclines in the last three decades. For most LC methods, reversed phase chromatographic supports were used. LC-UV methods were applied for the determination of anthracyclines in solution[67,313–317,74] or in biological matrices.[67,318,319] Given the high cardiotoxicity of anthracyclines (due to the accumulation of the drug in myocardium), drug monitoring of patients is generally required. The sensitivity of the developed method was of the utmost importance. For example, an LOD of 5 ng mL^{-1} and LOQ of 30 ng mL^{-1} were obtained for the determination of doxorubicin in different tissues by SPE-LC-UV.[319] Fluorescence spectrophotometry was found to be particularly well suited to the detection of anthracyclines, due to their anthracyclinone ring. Thus, method sensitivity was drastically improved.[320–330] LOD of 0.3–0.75 ng ml^{-1} and LOQ of 1–2.5 ng mL^{-1} were reached for the analysis of doxorubicin, epirubicin, daunorubicin and idarubicin in plasma and saliva (LLE was employed as a sample preparation step prior to LC-FD analysis).[323] The use of MS as a detection system offered even better sensitivity.[172,173,179,331–336,337,338] Indeed, an LOD and LOQ



Fig. 7 Structures of intercalating agents.

Table 3 Analytical methods for the detection of intercalating agents

Intercalating agents	Matrices	Techniques	Ref.
Doxorubicin	Molecule/ formulations	LC-UV	313, 314, 67 315 316 and 74
	Biological matrices	LC-UV	67, 318 and 319
		LC-FD	320, 322, 323, 324 325, 326, 327, 328, 329 and 330
		LC-MS	331, 172, 173, 333, 179, 335, 337, 338 and 34
		LC-LIF	339
		CE-LIF	341, 342, 343, 344, 345, 346, 347 and 349
		CE-UV	350 and 363
	Environment	LC-UV	138
		LC-MS	29, 78, 19, 22, 135 and 307
Epirubicin	Molecule/ formulations	LC-UV	313, 317 and 74
	Biological matrices	LC-UV	318
		LC-FD	321, 323, 324 and 325
		LC-MS	334, 179, 335 and 34
		CE-LIF	344, 345, 347 and 349
	Environment	LC-MS	19 and 307
Daunorubicin	Molecule/ formulations	LC-UV	313, 314 and 74
		LC-FD	323 and 324
		LC-ELSD	340
	Biological matrices	LC-UV	318
		LC-FD	364
		LC-MS	179, 335 and 336
		CE-LIF	345, 346, 347, 348 and 349
		CE-UV	350 and 363
Idarubicin	Molecule/ formulations	LC-UV	313 and 137
	Biological matrices	LC-FD	323 and 324
		LC-MS	335
		CE-LIF	345 and 346
Mitoxanthrone	Biological matrices	LC-UV	354 and 355
		LC-MS	361
Actinomycin D	Biological matrices	LC-MS	356–358 and 360

lower than 0.01 ng mL^{-1} and 0.1 ng mL^{-1} were obtained, respectively, for the LC-MS analysis of anthracyclines in urine treated by SPE.[335] LC-LIF-MS was also developed for studying *in vitro* metabolism of doxorubicin: quantification was performed on the results obtained with LIF detection (LOD ~ 1 μg mL^{-1}) and metabolites identification was performed with MS detection.[339] LC-ELSD was also applied for the analysis of daunorubicin and its degradation products for a stability study of injectable solution of anthracycline (0.25 mg mL^{-1} was the lowest concentration of standard solutions tested), but the interest of ELSD for anthracyclines is not obvious since these molecules can be easily detected by UV, FD and MS.[340]

As already mentioned, CE was another separation technique widely used for the determination of anthracyclines. LIF detection[341–349] is usually preferred to UV detection[350] to improve sensitivity. However, the poor UV sensitivity observed in CE (due to the narrow optical path of the capillaries) can be compensated for by a sweeping preconcentration step and an electrokinetic injection. Under such conditions, an LOD of 0.5 μg mL^{-1} was reached for anthracyclines in plasma.[350] LIF detection coupled to conventional CE[343,346,347,349] or MEKC methods[342,344,345] offered better sensitivities (LOD inferior to 1 ng mL^{-1}) without the need for a preconcentration step and using the hydrodynamic injection. The addition of a chiral modifier (hydroxy-propyl-γ-cyclodextrine) to the BGE used in CE provided a resolution baseline between doxorubicin and its metabolite doxorubicinol (slight structural difference: OH group instead of a carbonyl group in 13-carbon), responsible for the cardiotoxicity.[342] Finally, it can be noted that in the majority of the developed CE methods, an organic solvent was added in the BGE to improve the solubility and stability of the anthracyclines and reduce their adsorption on the capillary walls.[351] An electropherogram obtained for the analysis of three anthracycline compounds by CE-LIF and demonstrating the influence of organic solvent in the BGE on the separation efficiency is illustrated in Fig. 8.[349]

2.2.2.2 Mitoxantrone and actinomycin D. Mitoxanthrone and actinomycin D are molecules with a planar tricyclic structure (like anthracyclines). Discovered in the late '80s, mitoxantrone originated from an American program on the development of intercalating molecules.[352] Actinomycin D (or dactinomycin) is a peptide antibiotic isolated from strains of *Streptomyces parvullus* in the early '50s.[353] Mitoxantrone is available as a concentrated acid-buffered solution (because of hydrolysis in a basic medium) and is mainly used for the treatment of prostate cancers. Formulations containing actinomycin D are indicated for the treatment of nephroblastomas, neuroblastomas in children and testicular cancers.

LC was generally used for the determination of mitoxanthrone and actinomycin D. Developed methods were based on C18 stationary phase, coupled to UV[354,355] and MS detection.[356–361] An LOQ of 5 ng mL^{-1} was obtained for the LC-UV analysis of mitoxantrone in plasma.[354,355] For the same compound, a ten-fold increase in sensitivity was observed in LC-MS.[361] Due to the concomitant administration of vincristine and actinomycin D in the treatment of various pediatric cancers, several LC-MS methods have been developed for the simultaneous determination of these two anticancer drugs in biological matrices.[356–359] An LOD of 0.007 ng mL^{-1} and LOQ of 0.05 ng mL^{-1} were reached for the analysis of actinomycin D in plasma using a SPE-LC-MS procedure.[358] A CE method coupled to chemiluminescence detection was also reported for the determination of mitoxantrone in injectable solutions and biological samples.[362]

2.2.3. Topoisomerase inhibitors. Toposiomerases are enzymes responsible for the cleavage, annealing and topological state of DNA. Two categories of topoisomerases can be distinguished: topoisomerase I and topoisomerase II. Topoisomerase I acts on one strand of the DNA, while topoisomerase II acts on both strands of the DNA. Inhibitors of these enzymes are used primarily as anticancer agents (but also as antibacterial and antiparasitic agents). The structures



Fig. 8 Electropherograms of daunorubicine (DAN), doxorubicine (DOX) and epirubicine (EPI) obtained by CE-LIF analysis with BGE (105 mM borate pH 9.0) containing 30% methanol (a), and 10% methanol (b). Adapted from ref. 349, 2008, with permission from Wiley.

of the main topoisomerase inhibitors are depicted in Fig. 9. Analytical methods for the analysis of topoisomerase inhibitors are reported in Table 4.

2.2.3.1. Topoisomerase I inhibitors. Topoisomerase I inhibitors are derived from camptothecin first isolated in the '60s from the bark of an Asian tree named *Camptotheca acuminata*. Despite its anticancer activity, camptothecin was rapidly abandoned due to the high toxicity (hemorrhagic cystitis) of the soluble sodium salt. It appeared that the lactone ring of camptothecin is responsible for its anticancer activity. The fact that this cycle opened up in the preparation of sodium salts and could be reformed in the acid environment of the bladder, explained the toxicity of this molecule.[365] The interest in this molecule reappeared in the '80s with the discovery of camptothecin action on topoisomerase I. Thus, camptothecin served

Table 4 Analytical methods for the detection of topoisomerase inhibitors

Topoisomerase inhibitors	Matrices	Techniques	Ref.
Irinotecan	Biological matrices	LC-FD	371, 374, 372, 376, 377, 378 and 380
		LC-MS	370, 375, 373, 381, 375, 385, 387, 388, 389, 390 and 136
		CE-UV-LIF	391
	Environment	LC-MS	19, 135 and 307
Topotecan	Molecule/ formulations	LC-UV	382
	Biological matrices	LC-FD	379, 383 and 384
		LC-MS	386
Etoposide	Molecule/ formulations	LC-UV	67, 393, 394 and 137
		LC-FD	364
	Biological matrices	LC-UV	67
		LC-MS	395, 396, 136 and 34
		CE-LIF	397
		CE-UV	38
	Environment	LC-MS	19, 22, 134 and 135



Fig. 9 Structures of topoisomerase inhibitors.

as a model for the development of various water-soluble semi-synthetic compounds, by retaining a lactone ring in which the two main representative compounds were irinotecan and topotecan. Discovered in the '90s, irinotecan is indicated in colorectal cancers and topotecan in certain cancers of the ovary, cervix and lung. Irinotecan is a prodrug that is activated by liver carboxylesterases (active form SN-38: loss of the bipiperidylcarbonyl chain). Both molecules are stable at acid pH (if pH > 4: opening of the lactone ring leads to an inactive carboxylate form).

The methods developed for the analysis of camptothecins are essentially based on LC.[366–369] When developing an analytical method for the determination of camptothecins in biological matrices, several features have to be taken into account. First of all, it should be noted that the lactone and carboxylate forms of camptothecins coexist under biological conditions (equilibrium depending on pH and temperature). In other words, the method must allow the analysis of the desired form (s) (active lactone, inactive or total carboxylate). Then, the lactone (lipophilic) forms are able to diffuse through the cell membranes (and more particularly through the red blood cells) even within the sample. Moreover, the carboxylesterases present in the biological matrices contribute to the conversion of irinotecan into SN-38 within the sample as well. Thus, inactivation of carboxylesterases (in the case of irinotecan) and rapid extraction of the camptothecins contained in biological matrices (and in particular blood fluids) must be carried out rapidly after collection.

LC methods reported the analysis of the lactone form only,[344–346] lactone and carboxylate forms separately[347–351] and all the forms together with an equilibrium shift to the lactone form in acidic conditions. Usually, separations were performed on reversed phase supports. Several studies have succeeded in resolving the lactone forms and carboxylate forms by ion-pair chromatography to increase retention of the carboxylate forms.[377–380] In the case of irinotecan analysis, carboxylesterase inactivation was accomplished by the immediate addition of sodium dodecyl sulfate (SDS)[372] or zinc sulfate[373] to the sample.

Detection using, UV,[382] FD[371,372,377,379,380,383,384] and MS[370,373,375,381,385–390] were the most widespread. LC-UV methods were developed for the analysis of topotecan in pharmaceutical formulations and in blood samples with an LOQ of 0.070 μg mL^{-1}.[382] More sensitive detectors, such as FD or MS, allowed an LOQ in the order of 1 ng mL^{-1} to be reached for camptothecines in biological matrices. Finally, a quantification of SN-38 in plasma concentrations of 50 pg mL^{-1} was achieved thanks to a microfluidic chip-based nano-LC-MS method.[385]

A CE-UV-LIF method including solid-supported liquid extraction (SLE) was developed to quantify irinotecan and SN-38 in urine samples with an LOQ in the order of 30 ng mL^{-1} for both analytes.[391]

2.2.3.2. Topoisomerase II inhibitors. Two antineoplastic drugs act on topoisomerase II: anthracyclines (considered in this paper for their intercalating action) and podophyllotoxins.

Podophyllotoxins extracted from the plant roots of the *podophyllum* family are considered to be highly toxic molecules, even though they were used as medicinal remedies centuries ago thanks to their antimitotic action. In the '50s, a series of podophyllotoxin derivatives were synthesized and studied in the hope of finding a molecule that retained its anticancer action, but with less toxicity.[392] These studies led to etoposide in 1966. Its low solubility in water required the presence of numerous excipients in injectable formulations such as sorbate 80, polyethylene glycol 300 solubilizing agents and buffering agents such as citric acid (to avoid the *cis*-lactone epimerization of molecules occurring in basic conditions). However, precipitation of the molecule can be observed during dilution of the formulation and rapid administration of etoposide is hampered by the high volumes injected to cover the prescribed dose. The etoposide phosphate appeared in the '90s to overcome the solubility problem of the original molecule. This prodrug is rapidly converted in the blood to etoposide, by alkaline phosphatases.

Etoposide was mainly analysed by LC-UV,[67,393,394] LC-FD[364] and LC-MS.[58,395,396,34] UV sensitivity was sufficient to achieve etoposide analysis in pharmaceutical formulations.[393,394] However, more sensitive detectors such as FD (LOQ of 52.5 ng mL^{-1}) and MS (LOQ between 2 and 10 ng mL^{-1}) were required for etoposide assays in plasma samples. CE allowed the determination of etoposide in plasma with an LOQ of 0.1–0.2 μg mL^{-1}, using either a UV zeta-cell[38] or LIF detector.[397]

2.3. Antitubulin agents

Antitubulin agents interfere with microtubule dynamics (*i.e.*, spindle formation or disassembly), block division of the nucleus and lead to cell death. The main members of this family include vinca alkaloids and taxanes.

2.3.1. Vinca alkaloids. The antineoplastic properties of Madagascar periwinkle alkaloids (*Catharanthus roseus*) were discovered during research on its use as an antidiabetic by Malagasy people. The first anticancer alkaloids extracted from the leaves of the plant were vinblastine in 1958 and vincristine three years later. These two molecules consist of a catharanthine nucleus and a vindoline nucleus. The low natural abundance of these compounds (a few ppm in the leaves), the multitude of different alkaloids present in the leaves and their toxicity (neurotoxicity for vincristine and myelosuppression for vinblastine), have encouraged studies on the synthesis of structural analogues. The latter gave rise to two semi-synthetic molecules: vindesine and vinorelbine in the '80s. Recently, a fluorinated derivative also appeared, namely vinflunine, which is a molecule close to vinorelbine, but with two fluorine atoms in 20′-position and a single 3′–4′ bond. The structures of vinca alkaloids are reported in Fig. 10. Today, vinca alkaloids are used in the treatment of leukemias, lymphomas and some solid tumors. Table 5 reports the analytical methods for vinca alcaloids.

The analysis of vinca alkaloids has been carried out on plant extracts,[398–403] pharmaceutical formulations,[316,404] biological samples[358,359,405–420,421] and environmental



Fig. 10 Structures of vinca alkaloids.

Table 5 Analytical methods for the detection of vinca alcaloids

Vinca alcaloids	Matrices	Techniques	Ref.
Vincristine	Molecule/ formulations	LC-UV	316
		CE-UV	404
	Plant extracts	LC-UV	400, 402 and 403
		LC-MS	401
	Biological matrices	LC-UV	402
		LC-MS	34, 173, 356, 358, 359, 407, 409, 413 and 421
	Environment	LC-MS	19, 22, 28, 134 and 307
Vindesine	Molecule/ formulations	CE-UV	404
	Biological matrices	LC-MS	418
	Environment	LC-MS	307
Vinblastine	Molecule/ formulations	CE-UV	404
	Plant extracts	CE-MS	398
		LC-MS	399 and 401
		LC-UV	400, 402 and 403
	Biological matrices	LC-UV	402
		LC-MS	34, 173, 405, 410 and 411
	Environment	LC-MS	307
Vinorelbine	Molecule/ formulations	CE-UV	404
	Biological matrices	LC-MS	406, 408, 410, 414 and 416
		CE-ECL	423
Vinflunine	Biological matrices	LC-UV	419
		LC-MS	415, 417 and 420

samples.[18,19,134,307,422] Vinca alcaloid extraction from plants was generally performed by ultrasound in acid media followed by LLE.[45,398–401] For the sample preparation of biological samples, SPE,[358,359,405,407,408,411,414,418] LLE[409,410,413,415–417,419,421] and PP[420] were used. Although some methods based on CE have been published, LC was the most widely used separation technique for the analysis of vinca alkaloids.

Most of the LC methods are based on reversed phase C18 supports. Nevertheless, cyano,[419,420] pentafluorophenylpropyl[405] or HILIC[418] columns also allowed vinca alkaloids separation and quantification, with good analytical performance in terms of efficiency and reproducibility.

Detection of the molecules separated by LC was achieved by UV[316,400,402,419,403] or MS.[18,19,134,307,358,359,399,401,405,407–411,413–418,420,422] Acidic conditions were usually applied due to the good stability of vinca alkaloids at these pH values. Thus, MS detection was performed on the $[M + H]^+$ molecular ion or the doubly-charged $[M + 2H]^{2+}$ ion. The LOQ ranged from 1 ng mL^{-1} (or slightly lower) by MS to a few μg mL^{-1} by UV.

CE methods are scarcely reported for the determination of vinca alkaloids. A CE-UV method in non-aqueous conditions (NACE) allowed the separation of ten different vinca alkaloids in less than 10 min.[404] Extracts from *Catharanthus roseus* containing vinblastine were also successfully analysed by CE-MS.[398] Finally, the analysis of vinorelbine in urine samples was achieved by CE coupled to an electrochemiluminescence detection (ECL) with LOD in the order of 7 ng mL^{-1}.[423]

2.3.2. Taxanes. A compound extracted from the bark of *Taxus Brevifolia* demonstrated anticancer activity in the '60s, namely taxol or paclitaxel.[424] However, it appeared that the first clinical trials conducted on taxol raised toxicity problems linked to the formulation and not to the active molecule. Since taxol is a molecule poorly soluble in water and therapeutically

active at high concentrations, the presence of solubilizing agents is essential in the pharmaceutical formulation. The developed formulation contained a mixture of polyoxyethylated triglycerides (which are toxic and allergenic). In addition, more than 2500 trees needed to be felled to harvest 1 kg of taxol. A solution was introduced in the '80s by Pierre Potier (also author of the discovery of vinorelbine) with the hemi-synthesis of paclitaxel from a precursor (non-cytotoxic) available from a renewable source (*Taxus baccata* needles).[425] This route also gave rise to another taxane with anticancer properties, docetaxel. Slightly soluble in water, docetaxel injectable formulations contain ethanol and polysorbate 80 (a less toxic excipient). The main indication of docetaxel is the treatment of breast and lung cancer. Paclitaxel is also used in ovarian cancer. The structures of the taxanes and their analytical methods are shown in Fig. 11 and Table 6, respectively.

Most methods for taxanes analysis are based on RPLC coupled to MS[305,309,426–442] and UV detection.[138,269,443–453] LODs lower than 0.05 ng mL^{-1} were reached for the analysis of docetaxel in blood using a column-switching method involving a preconcentration step on a trapping column, prior to LC-MS analysis.[435] Paclitaxel in plasma was quantified down to a concentration of 45 ng mL^{-1} using an LLE-LC-UV procedure.[447] Several column-switching methods were proposed to reduce sample handling and/or concentrate paclitaxel[438] or docetaxel[429,434,435,442] as shown in Fig. 12. Given their strong binding to plasma proteins, free or bound fractions of taxanes were evaluated in biological samples. Thus, an ultrafiltration step was included at the start of the whole analytical procedure.[305,436]

CE was also employed for taxanes determination.[363,454] Different CE, MEEKC and MEKC methods coupled to UV





Fig. 11 Structures of taxanes.

Table 6 Analytical methods for the detection of taxanes

Taxanes	Matrices	Techniques	Ref.
Paclitaxel	Molecule/ formulations	LC-UV	269, 443–445, 447–449, 452 and 453
	Biological matrices	LC-UV	446, 447, 451 and 452
		LC-MS	34, 309, 410, 426, 428, 430, 431, 438 and 441
		CE-UV	454
	Environment	LC-UV	138
		LC-MS	28, 134, 135 and 307
Docetaxel	Molecule/ formulations	LC-UV	450
	Biological matrices	LC-MS	305, 410, 427 and 429, 431–437, 439, 440 and 442
		CE-UV	363
	Environment	LC-MS	134 and 307



Fig. 12 On-line SPE-LC-MS chromatograms of docetaxel[2] over the concentration range 10–200 μg L^{-1} in plasma with paclitaxel[1] as the internal standard. Adapted from ref. 435, 2013, with permission from Elsevier.

allowed the separation of docetaxel and several anthracyclines in plasma samples.[363] An LOD of 20 ng mL^{-1} was observed for the analysis of placlitaxel in plasma by LLE-MEKC-UV.[454]

3. Small molecules for targeted therapy

Conventional anticancer molecules act without discrimination between normal and tumor cells. This lack of specificity is

responsible for almost all the adverse effects of these anticancer treatments described so far. The apparition of molecules whose action is targeted specifically on tumor cells gave new breath to chemotherapy and new hope in the treatment of certain cancers. These "search-head missiles" are characterized by wider therapeutic indexes and reduced toxicity. Two main classes of molecules constitute targeted therapies: small molecules and monoclonal antibodies. Only small molecules are discussed in this paper.

3.1. Tyrosine kinase inhibitors

Tyrosine kinase inhibitors are low molecular weight compounds whose target is the inhibition of tyrosine kinase enzymes (TK). TK enzymes catalyse the transfer of phosphate to proteins from adenosine triphosphate (ATP) and play a major role in cell regulation such as proliferation, survival, migration and differentiation. TK inhibitors react with membranes (intracellular) or cytoplasmic enzymes, which induce molecule diffusion through the cell membrane. TK inhibitors are used in oncology when targeted TK's are activated by mutations and are responsible for tumor progression.[455]

Imatinib was the first TK inhibitor used as an anticancer agent. Discovered in the '90s, imatinib was derived from drug development efforts to target the bcr-abl protein. It corresponds to 2-phenylaminopyrimidine to which methyl and benzamide groups have been added to improve the interaction with the protein. Imatinib is indicated for the treatment of chronic myeloid leukemia. Two analogues appeared later on the market to tackle the phenomena of resistance and intolerance: dasatinib and nilotinib. Lapatinib and erlotinib, which act on epidermal growth factor receptors (EGFR), were commercialized in the 2000s for the treatment of breast cancer and some lung cancers, respectively. Sunitinib, used in the treatment of gastrointestinal and renal cancers, completes the family of TK inhibitors by targeting vascular endothelial growth factor (VEGFR) receptors. Fig. 13 shows the structures of TK inhibitors.

Different techniques have been used for the determination of TK inhibitors in pharmaceutical formulations, biological and environmental samples (Table 7). LC is the technique of choice as shown in the literature.[456] Indeed, 90% of the published methods are based on LC, while the remaining 10% involve another analytical technique (CE, GC or UV). LC was carried out essentially in the reversed phase mode, although the use of a HILIC column allows the simultaneous determination of imatinib, dasatinib and nilotinib in plasma.[457] An ion pairing LC method also contributed to the improvement of the imatinib peak shape compared to RPLC.[458] It may be noted that sunitinib can exist as two isomers (*cis* and *trans*). Available in the *cis* form in pharmaceutical formulations, sunitinib is converted into a *trans* form in solution under light. Several methods are able to resolve the two isomers using a conventional reversed phase column.[459,460]

Different sample preparations were used to extract TK inhibitors from biological matrices such as PP, LLE and SPE (off-line and on-line). Several methods involving column-switching systems were reported for the purification and concentration of the analytes before analytical separation. For example, Couchman *et al.* developed a method including a large particles support for the extraction of nine TK inhibitors and their metabolites in blood samples before separation on a C18 chromatographic support and MS detection.[461] With a sample volume of 50 μL, an LOQ of 1 ng mL^{-1} was obtained for dasatinib. Using a larger sample volume (100 μL after a PP step), an LOQ of 0.03 ng mL^{-1} was reached for the analysis of imatinib in biological matrices with a column-switching



Fig. 13 Structures of tyrosine kinase inhibitors.

Table 7 Analytical methods for the detection of TK inhibitors

TK inhibitors	Matrices	Techniques	Ref.
Imatinib	Molecule/ formulations	LC-UV	466–470
		CE-UV	58 and 471
	Biological matrices	LC-UV	458, 464, 472–485
		LC-MS	457, 461, 462, 472, 486–512
		CE-UV	39, 41 and 513
		CE-MS	514
	Environment	LC-MS	135
Dasatinib	Molecule/ formulations	LC-UV	515
		CE-UV	515
	Biological matrices	LC-UV	479, 474, 441, 516, 517 and 518
		LC-Fluo	465
		LC-MS	457, 461, 486, 491, 493, 494, 497, 500, 507, 510, 519 and 520
Nilotinib	Molecule/ formulations	LC-UV	521
	Biological matrices	LC-UV	463, 475, 479, 522, 523
		LC-MS	457, 461, 486, 491, 493–495, 497, 500, 507, 510, 524 and 525
Lapatinib	Molecule/ formulations	LC-UV	526 and 527
	Biological matrices	LC-UV	464, 528, 529
		LC-MS	461, 486, 491, 493, 495, 497, 500, 510, 520, 530 and 531
Erlotinib	Molecule/ formulations	LC-UV	532
	Biological matrices	LC-UV	464, 516, 533–536 and 529
		LC-MS	461, 486, 491, 492, 495, 500, 510, 537–544, 545, 546 and 547
		CE-UV	548
	Environment	LC-MS	135
Sunitinib	Molecule/ formulations	LC-MS	549
	Biological matrices	LC-UV	464, 550 and 551
		LC-MS	459–461, 486, 491, 495, 497, 500, 507, 510, 537, 552–559
		CE-MS	560

system and LC-MS.[462] A similar approach involving a sample preconcentration step and on-line extraction was applied for the analysis of nilotinib in plasma using UV detection.[463] In this case, an LOQ of 5 ng mL^{-1} was achieved. Garrido-Cano *et al.* developed an LC-UV method using a micellar mobile phase allowing direct injection of filtered plasma for the determination of 4 TK inhibitors.[464] A total analysis time of about 20 min and LOQ of 50 ng mL^{-1} were obtained. Finally, even if most of the TK inhibitors determination was performed with LC-UV and LC-MS, a LC-FD method was also published for the analysis of dasanitib in plasma with sensitivities close to those obtained in LC-UV (*i.e.*, 50 ng mL^{-1}).[465]

CE coupled to UV or MS was also used for the analysis of TK inhibitors. Conventional CE or NACE methods allow the determination of imatinib, erlotinib and sunitinib for drug purity testing or biological samples analysis (Table 1). A CE-UV method involving β-cyclodextrins in the BGE has demonstrated real potential for the quality control of imatinib (drug and impurities).[58] Concentration values of 5–10 ng mL^{-1} were quantified thanks to a stacking injection of large volume sample. Sunitinib and its main metabolites in urine were finally analysed by NACE-MS after a simple one-tenth dilution of the sample at concentrations between 0.5 and 50 μg mL^{-1}.[560]

3.2. Proteasome inhibitor

Synthesized in the '90s, the only representative compound of this anticancer family is bortezomib (Fig. 14). Bortezomib affects the capacity of cancer cells (myeloma cells) to interact with the microenvironment of the bone marrow and thus promotes cell death by its inhibitory action on the proteasome (a proteinaceous complex that degrades proteins). Bortezomib is produced as a trimer of boronic anhydride. The formulations are in the form of lyophilisates (also containing mannitol). Mannitol reacts with boroxine to form a stable monomeric diester which is hydrolysed in the reconstitution step (adding 0.9% NaCl) to bortezomib (active boric acid).[561] Bortezomib is used primarily in the treatment of multiple myelomas. Analytical methods for the analysis of bortezomib are reported in Table 8.

LC remains the main separation technique employed for the analysis of bortezomib in pharmaceutical formulations[562–564] or in biological samples.[486,565,566] A fast LC-MS (less than 2 min) method was developed for the determination of bortezomib within cultured myeloma cells and media. This ultra-fast analysis limits the degradation of bortezomib, which is known to be instable in solution.[565] MS detection was carried out on the dehydrated protonated molecular ion ($[M - H_2O + H]^+$) in positive ESI mode. Shu *et al.* developed an LC-MS method including an off-line SPE step for the quantification of bortezomib and 5 other drugs commonly used in multiple myeloma chemotherapy in biological



Bortezomib

Fig. 14 Bortezomib structure.

Table 8 Analytical methods for the detection proteasome inhibitor

Proteasome inhibitor	Matrices	Techniques	Ref.
Bortezomib	Molecule/ formulations	LC-UV	562, 563 and 564
	Biological matrices	LC-MS	486, 565, 566 and 306

matrices with an LOQ of 2 ng mL^{-1}.[306] Byrn *et al.* propose different methods to compare the contents and impurity profile of two pharmaceutical formulations available on the US market.[563] The presence of an additional impurity as well as a different inactive/active form ratio between the two formulations demonstrated that they were not strictly equivalent.

3.3. mTOR inhibitors

Discovered more than 30 years ago, sirolimus (or rapamycin) is a macrolide produced by *Streptomyces hygroscopicus* and was initially used as an immunosuppressant. It would be necessary to wait until the end of the '90s to witness its use in oncology. Its action is based on an intracellular serine/threonine kinase (mTOR for mammalian target of rapamycin), which is an enzyme involved in several cellular processes such as angiogenesis, metabolic modulation, cell cycle and apoptosis. This protein complex is involved in the tumor progression of certain cancers. In the mid-2000s, a water-soluble sirolimus ester was developed, namely temsirolimus, which is a prodrug whose active form is sirolimus (rapid hydrolysis). A few years later, a second analogue of sirolimus, everolimus, enlarged the family of mTOR inhibitors. Although widely used as immunosuppressants after organ transplantation, mTOR inhibitors can also be used for the treatment of kidney and lymphoma cancers. Fig. 15 shows the structures of the major inhibitors of mTOR and Table 9 lists the reported analytical methods.

Inhibitors of mTOR were mainly analysed in biological matrices even if some methods were published for their determination in solution or in pharmaceutical formulations, as in the case of stability studies or for quality control purposes.[567–570] Their narrow therapeutic window and highly variable blood levels (for the same administered dose) make mTOR inhibitors analysis in whole blood essential (mTOR inhibitors are concentrated in the red blood cells). In recent years, many analytical methods have been reported for the analysis of mTOR inhibitors in biological samples.[571–574,84]

Table 9 Analytical methods for the detection of mTOR inhibitors

mTOR inhibitors	Matrices	Techniques	Ref.
Sirolimus	Molecule/ formulations	LC-UV	567 and 570
	Biological matrices	LC-UV	575, 576, 578, 581, 586, 592, 593, 594, 595, 596 and 597
		LC-MS	577, 580, 582, 584, 585, 598, 599, 602, 603, 605, 606, 607, 609, 617, 618, 619, 600, 601, 604, 608, 610, 620, 621, 624 and 626
		LC-EC	627
		CE-UV	628
		CE-MS	630
Temsirolimus	Molecule/ formulations	LC-UV	569
Everolimus	Molecule/ formulations	LC-UV	568
	Biological matrices	LC-UV	589, 590 and 591
		LC-MS	577, 579, 583, 587, 588, 598, 599, 602, 612, 603, 605, 613, 614, 606, 607, 609, 615, 622, 616, 617, 618, 619, 625 and 626

Two analytical techniques can be discerned: immunoassays and LC. The comparison of these two approaches shows their comparable performances.[575–586,587,588] The main limitation of immunoassays is the cross-reactivity with metabolites. Only separative techniques are considered in this review.

LC-UV is an interesting technique for the analysis of mTOR inhibitors in blood.[575,576,578,581,589–597] Nevertheless, the achieved sensitivity was too limited and an additional extrac-



Fig. 15 Structures of mTOR inhibitors.

tion step allowing purification and preconcentration of the analyte was required, such as LLE[575,581,591,592,595–597] or SPE including a prior PP.[580,589,590,593,594,596] As an example, an LLE-LC-UV method allowed the determination of everolimus in whole blood at concentrations between 1 and 200 ng mL^{-1}.[589] The sensitivity and selectivity provided by MS helped to ease sample preparation in clinical chemistry laboratories. Column-switching systems coupling the extraction support to the chromatographic column before MS detection were also used for the analysis of sirolimus[598–611] and everolimus[598,599,602,603,605–607,609,612–614] in whole blood. LLE[615] or SPE[616] on 96-well plates constitutes another approach for sample preparation automatisation. The automatisation of a PP step with a liquid handling platform was also applied for the LC-MS analysis of mTOR inhibitors in blood.[617] Blood sample analysis on blotting paper was particularly useful in the case of mTOR inhibitors by facilitating the collection and processing of the sample prior to LC-MS analysis.[618–622]

Under such conditions, concentrations in the order of ng mL^{-1} were detected. It can be noted that MS detection of mTOR inhibitors was mainly performed *via* adducts formation including sodium adducts[601,602] or ammonia adducts[623,624,625] because of the neutral character of these molecules. An LOQ often inferior to 1 ng mL^{-1} was obtained with MS detection.[626] Electrochemistry detection was also successfully used for sirolimus analysis in blood at concentrations of 1 to 50 ng mL^{-1}.[627]

CE was also used for the determination of mTOR inhibitors. A CE-UV method with a BGE containing SDS and acetonitrile allowed the analysis of sirolimus in blood with an LOQ of 0.2 ng mL^{-1} thanks to a preconcentration factor of 10 obtained with SPE and a large injection volume (focusing technique).[628] Screening for mTOR inhibitors in extracts from natural products was finally performed by CE-LIF.[629]

4 Conclusion

The analytical procedures developed for the analysis of anticancer agents chronologically follow progress in the field of analytical sciences. Two major periods can be distinguished. The first one corresponds more or less to the second half of the 20th century. During this period, the majority of analytical methods developed for the determination of antineoplastic drugs were based on chromatographic techniques such as LC or GC using poorly selective and sensitive detectors. These analytical tools were mostly used in the quality control framework of the anticancer molecule (impurity profiling) and in therapeutic drug monitoring (dose adjustment). Then, there has been increasing interest on the impact of these highly toxic molecules on humans and the environment. To deal with these more complex matrices and attain sufficient limits of detection, the introduction of highly sensitive and selective techniques such as LC-MS opened the era of trace analysis of antineoplastic drugs. Indeed, most analytical methods published since the early 2000s were based on LC-MS. Even if these methods are mainly applied for therapeutic drug monitoring of antineoplastic agents, an increasing numbers of publications concerned exposure studies. The trace detection in humans handling these molecules (other than patients) and in the environment, is becoming more and more powerful thanks to more efficient analytical techniques, which raise discussion on their real impact on health at very low concentrations.

References

1 B. W. Stewart, WC, World Cancer Report 2014, International Agency for Research on Cancer, 2014.
2 V. T. DeVita Jr. and E. Chu, A history of cancer chemotherapy, *Cancer Res.*, 2008, **68**(21), 8643–8653. PubMed PMID: 18974103. Epub 2008/11/01. eng.
3 E. B. Krumbhaar and H. D. Krumbhaar, The Blood and Bone Marrow in Yelloe Cross Gas (Mustard Gas) Poisoning: Changes produced in the Bone Marrow of Fatal Cases, *J. Med. Res.*, 1919, **40**(3), 497–508. 3. PubMed PMID: 19972497. Pubmed Central PMCID: PMC2104437. Epub 1919/09/01. eng.
4 S. Nussbaumer, P. Bonnabry, J. L. Veuthey and S. Fleury-Souverain, Analysis of anticancer drugs: a review, *Talanta*, 2011, **85**(5), 2265–2289. PubMed PMID: 21962644. Epub 2011/10/04. eng.
5 S. Farber and L. K. Diamond, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid, *N. Engl. J. Med.*, 1948, **238**(23), 787–793. PubMed PMID: 18860765. Epub 1948/06/03. eng.
6 A. L. Jackman, F. T. Boyle and K. R. Harrap, Tomudex (ZD1694): from concept to care, a programme in rational drug discovery, *Invest. New Drugs*, 1996, **14**(3), 305–316. PubMed PMID: 8958186. Epub 1996/01/01. eng.
7 E. C. Taylor, D. Kuhnt, C. Shih, S. M. Rinzel, G. B. Grindey, J. Barredo, *et al.*, A dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthase, *J. Med. Chem.*, 1992, **35**(23), 4450–4454.
8 European Pharmacopoeia, (2008).
9 F. M. Rubino, Separation methods for methotrexate, its structural analogues and metabolites, *J. Chromatogr., B: Biomed. Appl.*, 2001, **764**(1–2), 217–254. PubMed PMID: 11817030. Epub 2002/01/31. eng.
10 H. Patel, P. Giri, A. Ghoghari, P. Delvadia, M. Syed and N. R. Srinivas, Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives, *Biomed. Chromatogr.*, 2017, **31**(1), DOI: 10.1002/bmc.3849. PubMed PMID: 27623319. Epub 2016/10/19. eng.
11 I. Duran Meras, A. Espinosa Mansilla and M. J. Rodriguez Gomez, Determination of methotrexate, several pteridines, and creatinine in human urine, previous oxidation with potassium permanganate, using HPLC with photo-

metric and fluorimetric serial detection, *Anal. Biochem.*, 2005, **346**(2), 201–209. PubMed PMID: 16213456. Epub 2005/10/11. eng.

12 X. Liu, J. Liu, Y. Huang, R. Zhao, G. Liu and Y. Chen, Determination of methotrexate in human serum by high-performance liquid chromatography combined with pseudo template molecularly imprinted polymer, *J. Chromatogr. A*, 2009, **1216**(44), 7533–7538.

13 R. Olmos-Jimenez, A. Espuny-Miro, M. S. Diaz-Carrasco, E. Fernandez-Varon, M. Valderrey-Pulido and C. Carceles-Rodriguez, Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use, *J. Oncol. Pharm. Pract.*, 2016, **22**(5), 659–665. PubMed PMID: 26271105. Epub 2015/08/15. eng.

14 Y. D. Li, Y. Li, N. S. Liang, F. Yang and Z. P. Kuang, A reversed-phase high performance liquid chromatography method for quantification of methotrexate in cancer patients serum, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2015, **1002**, 107–112. PubMed PMID: 26319303. Epub 2015/09/01. eng.

15 A. Garcia-Ac, P. A. Segura, C. Gagnon and S. Sauve, Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extraction liquid chromatography coupled to polarity-switching electrospray tandem mass spectrometry, *J. Environ. Monit.*, 2009, **11**(4), 830–838. PubMed PMID: 19557238. Epub 2009/06/27. eng.

16 A. Garcia-Ac, P. A. Segura, L. Viglino, A. Furtos, C. Gagnon, M. Prevost, *et al.*, On-line solid-phase extraction of large-volume injections coupled to liquid chromatography-tandem mass spectrometry for the quantitation and confirmation of 14 selected trace organic contaminants in drinking and surface water, *J. Chromatogr. A*, 2009, **1216**(48), 8518–8527. PubMed PMID: 19875124. Epub 2009/10/31. eng.

17 P. Koufopantelis, S. Georgakakou, M. Kazanis, C. Giaginis, A. Margeli, S. Papargiri, *et al.*, Direct injection liquid chromatography/positive ion electrospray ionization mass spectrometric quantification of methotrexate, folinic acid, folic acid and ondansetron in human serum, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(30), 3850–3856.PubMed PMID: 19828383. Epub 2009/10/16. eng.

18 S. Nussbaumer, S. Fleury-Souverain, P. Antinori, F. Sadeghipour, D. F. Hochstrasser, P. Bonnabry, *et al.*, Simultaneous quantification of ten cytotoxic drugs by a validated LC-ESI-MS/MS method, *Anal. Bioanal. Chem.*, 2010, **398**(7–8), 3033–3042. PubMed PMID: 20927508. Epub 2010/10/12. eng.

19 S. Nussbaumer, L. Geiser, F. Sadeghipour, D. Hochstrasser, P. Bonnabry, J. L. Veuthey, *et al.*, Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces, *Anal. Bioanal. Chem.*, 2012, **402**(8), 2499–2509. PubMed PMID: 21701850. Epub 2011/06/28. eng.

20 K. Touzin, J. F. Bussieres, E. Langlois and M. Lefebvre, Evaluation of surface contamination in a hospital hematology–oncology pharmacy, *J. Oncol. Pharm. Pract.*, 2009, **15**(1), 53–61. PubMed PMID: 18772214. Epub 2008/09/06. eng.

21 R. Turci, C. Sottani, A. Ronchi and C. Minoia, Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents, *Toxicol. Lett.*, 2002, **134**(1–3), 57–64. PubMed PMID: 12191861. Epub 2002/08/23. eng.

22 J. Yin, Y. Yang, K. Li, J. Zhang and B. Shao, Analysis of Anticancer Drugs in Sewage Water By Selective SPE and UPLC-ESI-MS-MS, *J. Chromatogr. Sci.*, 2010, **48**(10), 781–789.

23 C. Poupeau, C. Tanguay, N. J. Caron and J. F. Bussieres, Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals, *J. Oncol. Pharm. Pract.*, 2016, DOI: 10.1177/1078155216676632. PubMed PMID: 27799608. Epub 2016/11/02. eng.

24 S. Veeraraghavan, S. R. Thappali, S. Viswanadha, S. Vakkalanka and M. Rangaswamy, Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study, *Sci. Pharm.*, 2016, **84**(2), 347–359. PubMed PMID: 27222609, Pubmed Central PMCID: PMC4871186. Epub 2016/05/26. eng.

25 A. Janes, C. Tanguay, N. J. Caron and J. F. Bussieres, Environmental Contamination with Cyclophosphamide, Ifosfamide, and Methotrexate: A Study of 51 Canadian Centres, *Can. J. Hosp. Pharm.*, 2015, **68**(4), 279–289. PubMed PMID: 26327701, Pubmed Central PMCID: PMC4552228. Epub 2015/09/04. eng.

26 R. C. Schofield, L. V. Ramanathan, K. Murata, M. Grace, M. Fleisher, M. S. Pessin, *et al.*, Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2015, **1002**, 169–175. PubMed PMID: 26322588. Pubmed Central PMCID: PMC4982141. Epub 2015/09/01. eng.

27 E. Heath, M. Cesen, N. Negreira, M. L. de Alda, L. Ferrando-Climent, L. Blahova, *et al.*, First inter-laboratory comparison exercise for the determination of anticancer drugs in aqueous samples, *Environ. Sci. Pollut. Res.*, 2016, **23**(15), 14692–14704. PubMed PMID: 26169820. Epub 2015/07/15. eng.

28 C. Effting, A. de Moraes Arantes, L. V. Queiroz Labre, W. J. Carneiro, J. R. de Oliveira Neto, C. Bariani, *et al.*, Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization, *Ther. Drug Monit.*, 2015, **37**(1), 66–70.

29 F. Dal Bello, V. Santoro, V. Scarpino, C. Martano, R. Aigotti, A. Chiappa, *et al.*, Antineoplastic drugs determination by HPLC-HRMS(n) to monitor occupational exposure, *Drug Test. Anal.*, 2015, DOI: 10.1002/dta.1827.

30 J. Bluett, I. Riba-Garcia, K. Hollywood, S. M. Verstappen, A. Barton and R. D. Unwin, A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence, *Analyst*, 2015, **140**(6), 1981–1987. PubMed PMID: 25671614. Epub 2015/02/12. eng.

31 D. Wu, Y. Wang, Y. Sun, N. Ouyang and J. Qian, A simple, rapid and reliable liquid chromatography-mass spectrometry method for determination of methotrexate in human plasma and its application to therapeutic drug monitoring, *Biomed. Chromatogr.*, 2015, **29**(8), 1197–1202. PubMed PMID: 25641007. Epub 2015/02/03. eng.

32 K. Sharma, K. Giri, V. Dhiman, A. Dixit, M. Zainuddin and R. Mullangi, A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study, *Biomed. Chromatogr.*, 2015, **29**(5), 722–732. PubMed PMID: 25298296. Epub 2014/10/10. eng.

33 M. A. Al-Ghobashy, S. A. Hassan, D. H. Abdelaziz, N. M. Elhosseiny, N. A. Sabry, A. S. Attia, *et al.*, Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1038**, 88–94. PubMed PMID: 27802917. Epub 2016/11/03. eng.

34 G. Fabrizi, M. Fioretti and L. Mainero Rocca, Dispersive solid-phase extraction procedure coupled to UPLC-ESI-MS/MS analysis for the simultaneous determination of thirteen cytotoxic drugs in human urine, *Biomed. Chromatogr.*, 2016, **30**(8), 1297–1308. PubMed PMID: 26762960. Epub 2016/01/15. eng.

35 H. L. Cheng, Y. M. Liao, S. S. Chiou and S. M. Wu, On-line stacking capillary electrophoresis for analysis of methotrexate and its eight metabolites in whole blood, *Electrophoresis*, 2008, **29**(17), 3665–3673. PubMed PMID: 18803181. Epub 2008/09/23. eng.

36 C. Y. Kuo, S. S. Chiou and S. M. Wu, Solid-phase extraction and large-volume sample stacking with an electroosmotic flow pump in capillary electrophoresis for determination of methotrexate and its metabolites in human plasma, *Electrophoresis*, 2006, **27**(14), 2905–2909. PubMed PMID: 16721905. Epub 2006/05/25. eng.

37 C. Y. Kuo, H. L. Wu, H. S. Kou, S. S. Chiou, D. C. Wu and S. M. Wu, Simultaneous determination of methotrexate and its eight metabolites in human whole blood by capillary zone electrophoresis, *J. Chromatogr., A*, 2003, **1014**(1–2), 93–101. PubMed PMID: 14558615. Epub 2003/10/16. eng.

38 Y. Mrestani and R. Neubert, Separation of etoposide phosphate and methotrexate by capillary zone electrophoresis using UV detection with a high sensitivity cell, *Electrophoresis*, 1998, **19**(16–17), 3022–3025. PubMed PMID: 9870407. Epub 1998/12/31. eng.

39 J. Rodríguez Flores, J. J. Berzas Nevado, G. Castañeda Peñalvo and M. I. Rodríguez Cáceres, Direct capillary electrophoretic determination of three chemotherapeutic drugs in human urine, *Chromatographia*, 2003, **57**(7), 493–496.

40 J. Rodriguez Flores, J. J. Berzas Nevado, I. Duran Meras and M. J. Rodriguez Gomez, Capillary electrophoretic determination of triamterene, methotrexate, and creatinine in human urine, *J. Sep. Sci.*, 2005, **28**(7), 658–664. PubMed PMID: 15912736. Epub 2005/05/26. eng.

41 J. Rodriguez Flores, G. C. Penalvo, A. E. Mansilla and M. J. Gomez, Capillary electrophoretic determination of methotrexate, leucovorin and folic acid in human urine, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2005, **819**(1), 141–147. PubMed PMID: 15797531. Epub 2005/03/31. eng.

42 F. Sczesny, G. Hempel, J. Boos and G. Blaschke, Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites, *J. Chromatogr., B: Biomed. Appl.*, 1998, **718**(1), 177–185. PubMed PMID: 9832374. Epub 1998/12/01. eng.

43 Z. Szakacs and B. Noszal, Determination of dissociation constants of folic acid, methotrexate, and other photolabile pteridines by pressure-assisted capillary electrophoresis, *Electrophoresis*, 2006, **27**(17), 3399–3409. PubMed PMID: 16944455. Epub 2006/09/01. eng.

44 Y. Suzuki, H. Arakawa and M. Maeda, The immunoassay of methotrexate by capillary electrophoresis with laser-induced fluorescence detection, *Anal. Sci.*, 2003, **19**(1), 111–115. PubMed PMID: 12558033. Epub 2003/02/01. eng.

45 D. Abd El-Hady, H. M. Albishri and R. Rengarajan, Eco-friendly ionic liquid assisted capillary electrophoresis and alpha-acid glycoprotein-assisted liquid chromatography for simultaneous determination of anticancer drugs in human fluids, *Biomed. Chromatogr.*, 2015, **29**(6), 925–934. PubMed PMID: 25400220. Epub 2014/11/18. eng.

46 E. Brandsteterova, K. Marcincinova, J. Lehotay, A. Zbojova and J. Halko, HPLC analysis of optical isomers of leucovorin and methotrexate using achiral-chiral system, *Neoplasma*, 1993, **40**(4), 241–245. PubMed PMID: 8272151. Epub 1993/01/01. eng.

47 D. A. el-Hady, N. A. el-Maali, R. Gotti, C. Bertucci, F. Mancini and V. Andrisano, Methotrexate determination in pharmaceuticals by enantioselective HPLC, *J. Pharm. Biomed. Anal.*, 2005, **37**(5), 919–925. PubMed PMID: 15862667. Epub 2005/05/03. eng.

48 R. Gotti, D. A. El-Hady, V. Andrisano, C. Bertucci, N. A. El-Maali and V. Cavrini, Determination of the chiral and achiral related substances of methotrexate by cyclodextrin-modified micellar electrokinetic chromatography, *Electrophoresis*, 2004, **25**(16), 2830–2837. PubMed PMID: 15352016. Epub 2004/09/08. eng.

49 C. Y. Kuo, H. L. Wu and S. M. Wu, Enantiomeric analysis of methotrexate in pharmaceuticals by cyclodextrin-modified capillary electrophoresis, *Anal. Chim. Acta*, 2002, **471**(2), 211–217.

50 C. L. Hamilton and J. A. Kirkwood, Column-switching high-performance liquid chromatographic method for the determination of a thymidylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1994, **654**(2), 297–303.

51 R. Respaud, J. F. Tournamille, C. Croix, H. Laborie, C. Elfakir and M. C. Viaud-Massuard, Development of an ion-pairing reversed-phase liquid chromatography method using a double detection analysis (UV and evaporative light scattering detection) to monitor the stability of Alimta(R)-pemetrexed preparations: identification and quantification of L-glutamic acid as a potential degradation product, *J. Pharm. Biomed. Anal.*, 2011, **54**(2), 411–416. PubMed PMID: 20869830. Epub 2010/09/28. eng.

52 L. P. Rivory, S. J. Clarke, M. Boyer and J. F. Bishop, Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2001, **765**(2), 135–140.

53 Y. Zhang and L. A. Trissel, Physical and chemical stability of pemetrexed solutions in plastic syringes, *Ann. Pharmacother.*, 2005, **39**(12), 2026–2028. PubMed PMID: 16227449. Epub 2005/10/18. eng.

54 Y. Zhang and L. A. Trissel, Physical instability of frozen pemetrexed solutions in PVC bags, *Ann. Pharmacother.*, 2006, **40**(7–8), 1289–1292. PubMed PMID: 16822897. Epub 2006/07/11. eng.

55 Y. Zhang and L. A. Trissel, Physical and chemical stability of pemetrexed in infusion solutions, *Ann. Pharmacother.*, 2006, **40**(6), 1082–1085. PubMed PMID: 16720706. Epub 2006/05/25. eng.

56 A. Warner, I. Piraner, H. Weimer and K. White, Development of a purity control strategy for pemetrexed disodium and validation of associated analytical methodology, *J. Pharm. Biomed. Anal.*, 2015, **105**, 46–54. PubMed PMID: 25527981. Epub 2014/12/22. eng.

57 C. Bobin-Dubigeon, M. B. Amiand, C. Herrenknecht and J. M. Bard, Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(24), 2451–2456. PubMed PMID: 19560408. Epub 2009/06/30. eng.

58 J. Li, Y. Huang, L. Huang, L. Ye, Z. Zhou, G. Xiang, *et al.*, Determination of imatinib mesylate and related compounds by field amplified sample stacking with large volume sample injection capillary electrophoresis, *J. Pharm. Biomed. Anal.*, 2012, **70**, 26–31.

59 J. Hu, L. Ding, Q. Song, Y. Gao and S. Qing, Determination of raltitrexed in human plasma by high performance liquid chromatography–electrospray ionization-mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2007, **853**(1–2), 147–153.

60 K. Ramulu, B. M. Rao, P. Madhavan, M. Lalitha Devi, M. K. Srinivasu and K. B. Chandrasekhar, A Validated Chiral LC Method for the Determination of Enantiomeric Purity of Pemetrexed Disodium on an Amylose-Based Chiral Stationary Phase, *Chromatographia*, 2006, **65**(3), 249–252.

61 Y. Liu, X. Fu, C. Ma, J. Zhong, Y. Liao and H. Liu, Chiral separation of raltitrexed by cyclodextrin-modified micellar electrokinetic chromatography, *Anal. Bioanal. Chem.*, 2009, **393**(1), 321–326. PubMed PMID: 18931995. Epub 2008/10/22. eng.

62 C. Heidelberger, N. K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, *et al.*, Fluorinated pyrimidines, a new class of tumour-inhibitory compounds, *Nature*, 1957, **179**(4561), 663–666. PubMed PMID: 13418758. Epub 1957/03/30. eng.

63 H. Steinhagen, The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs, By Enrique Raviña, *ChemMedChem*, 2011, **6**(9), 1746–1747.

64 F. Sorm, A. Piskala, A. Cihak and J. Vesely, 5-Azacytidine, a new, highly effective cancerostatic, *Experientia*, 1964, **20**(4), 202–203. PubMed PMID: 5322617. Epub 1964/04/15. eng.

65 G. B. Grindey, L. W. Hertel and W. Plunkett, Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidine (Gemcitabine), *Cancer Invest.*, 1990, **8**(2), 313. PubMed PMID: 2400957. Epub 1990/01/01. eng.

66 V. Castagne, H. Habert, C. Abbara and E. Rudant, Bonhomme-Faivre L, Cytotoxics compounded sterile preparation control by HPLC during a 16-month assessment in a French university hospital: importance of the mixing bags step, *J. Oncol. Pharm. Pract.*, 2011, **17**(3), 191–196. PubMed PMID: 20630921. Epub 2010/07/16. eng.

67 O. T. Fahmy, M. A. Korany and H. M. Maher, High performance liquid chromatographic determination of some co-administered anticancer drugs in pharmaceutical preparations and in spiked human plasma, *J. Pharm. Biomed. Anal.*, 2004, **34**(5), 1099–1107. PubMed PMID: 15019044. Epub 2004/03/17. eng.

68 B. Keith, Y. Xu and J. L. Grem, Measurement of the anticancer agent gemcitabine in human plasma by high-performance liquid chromatography, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2003, **785**(1), 65–72. PubMed PMID: 12535839. Epub 2003/01/22. eng.

69 C. Lanz, M. Fruh, W. Thormann, T. Cerny and B. H. Lauterburg, Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC, *J. Sep. Sci.*, 2007, **30**(12), 1811–1820. PubMed PMID: 17638352. Epub 2007/07/20. eng.

70 N. M. Lin, S. Zeng, S. L. Ma, Y. Fan, H. J. Zhong and L. Fang, Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector, *Acta Pharmacol. Sin.*, 2004, **25**(12), 1584–1589. PubMed PMID: 15569401. Epub 2004/12/01. eng.

71 A. F. Mistiran, A. A. Dzarr and S. H. Gan, HPLC method development and validation for simultaneous detection of Arabinoside-C and doxorubicin, *Toxicol. Mech. Methods*,

2010, **20**(8), 472–481. PubMed PMID: 20626302. Epub 2010/07/16. eng.

72 V. R. Sinha, R. V. Kumar and J. R. Bhinge, A Stability-Indicating RP-HPLC Assay Method for 5-Fluorouracil, *Indian J. Pharm. Sci.*, 2009, **71**(6), 630–637. PubMed PMID: 20376215. Pubmed Central PMCID: PMC2846467. Epub 2010/04/09. eng.

73 G. Chen, D. Svirskis and J. Wen, Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies, *J. Pharm. Pharmacol.*, 2015, **67**(11), 1528–1536. PubMed PMID: 26369422. Epub 2015/09/16. eng.

74 G. Brachet, C. Bruno, D. Boulay, J. F. Tournamille, E. Gyan, M. C. Viaud-Massuard, *et al.*, An ion-pairing, reversed-phase liquid chromatography method to assess the cross-contamination of cancer chemotherapy infusions prepared in a dual-operator aseptic isolator, *Drug Test. Anal.*, 2016, **8**(9), 985–990. PubMed PMID: 26480955. Epub 2015/10/21. eng.

75 R. Honeywell, A. C. Laan, C. J. van Groeningen, E. Strocchi, R. Ruiter, G. Giaccone, *et al.*, The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2007, **847**(2), 142–152. PubMed PMID: 17056304. Epub 2006/10/24. eng.

76 H. Khoury, A. Deroussent, L. H. Reddy, P. Couvreur, G. Vassal and A. Paci, Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2007, **858**(1–2), 71–78. PubMed PMID: 17851141. Epub 2007/09/14. eng.

77 E. Marangon, F. Sala, O. Caffo, E. Galligioni, M. D'Incalci and M. Zucchetti, Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry, *J. Mass Spectrom.*, 2008, **43**(2), 216–223. PubMed PMID: 17941128. Epub 2007/10/18. eng.

78 J. R. Pretty, T. H. Connor, I. Spasojevic, K. S. Kurtz, J. L. McLaurin, C. B'Hymer, *et al.*, Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment, *J. Oncol. Pharm. Pract.*, 2012, **18**(1), 23–36. PubMed PMID: 21183556. Pubmed Central PMCID: PMC4681574. Epub 2010/12/25. eng.

79 Y. Sun, J. Sun, B. Wen, S. Shi, Y. Xu, Y. Chen, *et al.*, High-performance liquid chromatography/tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2008, **870**(1), 121–125. PubMed PMID: 18571482. Epub 2008/06/24. eng.

80 K. Wang, M. Nano, T. Mulligan, E. D. Bush and R. W. Edom, Derivatization of 5-fluorouracil with 4-bromomethyl-7-methoxycoumarin for determination by liquid chromatography-mass spectrometry, *J. Am. Soc. Mass Spectrom.*, 1998, **9**(9), 970–976. PubMed PMID: 9725015. Epub 1998/09/02. eng.

81 Y. Xu, B. Keith and J. L. Grem, Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry, *J. Chromatogr. B: Anal. Technol.Biomed. Life Sci.*, 2004, **802**(2), 263–270. PubMed PMID: 15018786. Epub 2004/03/17. eng.

82 M. Zhao, M. A. Rudek, P. He, C. Hartke, S. Gore, M. A. Carducci, *et al.*, Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2004, **813**(1–2), 81–88. PubMed PMID: 15556519. Epub 2004/11/24. eng.

83 N. M. Anders, T. M. Wanjiku, P. He, N. S. Azad and M. A. Rudek, A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine, *Biomed. Chromatogr.*, 2016, **30**(3), 494–496. PubMed PMID: 26174363. Pubmed Central PMCID: PMC4713385. Epub 2015/07/16. eng.

84 A. J. McShane, D. R. Bunch and S. Wang, Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry, *Clin. Chim. Acta*, 2016, **454**, 1–5. PubMed PMID: 26721314. Epub 2016/01/02. eng.

85 M. Barberi-Heyob, J. L. Merlin and B. Weber, Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography, *J. Chromatogr.*, 1992, **573**(2), 247–252. PubMed PMID: 1534812. Epub 1992/01/17. eng.

86 Y. Hsieh and C. J. Duncan, An ion-pairing liquid chromatography/tandem mass spectrometric method for the determination of cytarabine in mouse plasma, *Rapid Commun. Mass Spectrom.*, 2007, **21**(4), 573–578. PubMed PMID: 17252621. Epub 2007/01/26. eng.

87 M. N. Kirstein, I. Hassan, D. E. Guire, D. R. Weller, J. W. Dagit, J. E. Fisher, *et al.*, High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2006, **835**(1–2), 136–142. PubMed PMID: 16584929. Epub 2006/04/06. eng.

88 R. Losa, M. I. Sierra, M. O. Gion, E. Esteban and J. M. Buesa, Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2006, **840**(1), 44–49. PubMed PMID: 16725385. Epub 2006/05/27. eng.

89 P. Compagnon, L. Thiberville, N. Moore, C. Thuillez and C. Lacroix, Simple high-performance liquid chromatographic method for the quantitation of 5-fluorouracil in

human plasma, *J. Chromatogr., B: Biomed. Appl.*, 1996, **677**(2), 380–383. PubMed PMID: 8704945. Epub 1996/03/03. eng.

90 Y. Hsieh, C. J. Duncan and M. Liu, A mixed-mode liquid chromatography-tandem mass spectrometric method for the determination of cytarabine in mouse plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2007, **854**(1–2), 8–12. PubMed PMID: 17448737. Epub 2007/04/24. eng.

91 R. Nishi, T. Yamauchi and T. Ueda, A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography, *Cancer Sci.*, 2006, **97**(11), 1274–1278. PubMed PMID: 17034368. Epub 2006/10/13. eng.

92 R. W. Sparidans, M. Crul, J. H. Schellens and J. H. Beijnen, Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2002, **780**(2), 423–430. PubMed PMID: 12401370. Epub 2002/10/29. eng.

93 R. Z. Hahn, A. F. Galarza, A. Schneider, M. V. Antunes, G. Schwartsmann and R. Linden, Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase, *Clin. Biochem.*, 2015, **48**(13–14), 915–918. PubMed PMID: 25940841. Epub 2015/05/06. eng.

94 C. Bowen, S. Wang and H. Licea-Perez, Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(22), 2123–2129. PubMed PMID: 19546035. Epub 2009/06/24. eng.

95 H. Licea-Perez, S. Wang and C. Bowen, Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(11–12), 1040–1046. PubMed PMID: 19285927. Epub 2009/03/17. eng.

96 K. B. Freeman, S. Anliker, M. Hamilton, D. Osborne, P. H. Dhahir, R. Nelson, *et al.*, Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection, *J. Chromatogr., B: Biomed. Appl.*, 1995, **665**(1), 171–181. PubMed PMID: 7795789. Epub 1995/03/10. eng.

97 C. Jochheim, P. Janning, U. Marggraf, T. M. Loffler, F. Hasse and M. Linscheid, A procedure for the determination of 5-fluorouracil in tissue using microbore HPLC and fluorescence detection, *Anal. Biochem.*, 1994, **217**(2), 285–291. PubMed PMID: 8203757. Epub 1994/03/01. eng.

98 B. Yilmaz, Y. Y. Kadioglu and Y. Aksoy, Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2003, **791**(1–2), 103–109. PubMed PMID: 12798170. Epub 2003/06/12. eng.

99 B. Yilmaz, Y. Y. Kadioglu and Y. Aksoy, Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography, *Anal. Biochem.*, 2004, **332**(2), 234–237. PubMed PMID: 15325290. Epub 2004/08/25. eng.

100 J. E. Kosovec, M. J. Egorin, S. Gjurich and J. H. Beumer, Quantitation of 5-fluorouracil (5FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2008, **22**(2), 224–230. PubMed PMID: 18085512. Epub 2007/12/19. eng.

101 R. Pisano, M. Breda, S. Grassi and C. A. James, Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues, *J. Pharm. Biomed. Anal.*, 2005, **38**(4), 738–745. PubMed PMID: 15967302. Epub 2005/06/22. eng.

102 H. Ishii, M. Shimada, H. Yamaguchi and N. Mano, A simultaneous determination method for 5-fluorouracil and its metabolites in human plasma with linear range adjusted by in-source collision-induced dissociation using hydrophilic interaction liquid chromatography-electrospray ionization-tandem mass spectrometry, *Biomed. Chromatogr.*, 2016, **30**(11), 1882–1886. PubMed PMID: 27078498. Epub 2016/04/15. eng.

103 L. Kovalova, C. S. McArdell and J. Hollender, Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry, *J. Chromatogr., A*, 2009, **1216**(7), 1100–1108. PubMed PMID: 19135206. Epub 2009/01/13. eng.

104 Y. Mano, K. Sakamaki, T. Ueno, K. Kita, T. Ishii, K. Hotta, *et al.*, Validation of a hydrophilic interaction ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of gemcitabine in human plasma with tetrahydrouridine, *Biomed. Chromatogr.*, 2015, **29**(9), 1343–1349. PubMed PMID: 25641274. Epub 2015/02/03. eng.

105 H. J. Lu, Y. L. Guo, H. Zhang and Q. Y. Ou, Rapid determination of 5-fluorouracil in plasma using capillary electrophoresis, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2003, **788**(2), 291–296. PubMed PMID: 12705969. Epub 2003/04/23. eng.

106 S. N. Mahnik, B. Rizovski, M. Fuerhacker and R. M. Mader, Determination of 5-fluorouracil in hospital effluents, *Anal. Bioanal. Chem.*, 2004, **380**(1), 31–35. PubMed PMID: 15365668. Epub 2004/09/15. eng.

107 A. Prochazkova, S. Liu, H. Friess, S. Aebi and W. Thormann, Determination of 5-fluorouracil and 5-fluoro-2′-deoxyuridine-5′-monophosphate in pancreatic cancer cell line and other biological materials using capillary electrophoresis, *J. Chromatogr. A*, 2001, **916**(1–2), 215–224. PubMed PMID: 11382294. Epub 2001/05/31. eng.

108 Y. Yang, Q. Liu, W. Tao, L. Nie and S. Yao, Improved determination of 5-fluorouracil and its prodrug tegafur in phar-

maceuticals by large-volume sample stacking in CE, *J. Sep. Sci.*, 2007, **30**(18), 3296–3301. PubMed PMID: 18008283. Epub 2007/11/17. eng.

109 M. Forough, K. Farhadi, R. Molaei, H. Khalili, R. Shakeri, A. Zamani, *et al.*, Capillary electrophoresis with online stacking in combination with AgNPs@MCM-41 reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from cancer patients, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2017, **1040**, 22–37. PubMed PMID: 27898365. Epub 2016/11/30. eng.

110 P. Houze, F. Deschamps, H. Dombret, B. Bousquet and B. Gourmel, Micellar electrokinetic capillary chromatography quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum, *J. Chromatogr., B: Biomed. Appl.*, 2001, **754**(1), 185–192. PubMed PMID: 11318414. Epub 2001/04/25. eng.

111 L. Krivankova, A. Kostalova, G. Vargas, J. Havel and P. Bocek, Separation of aracytidine and cytidine by capillary electrophoretic techniques, *Electrophoresis*, 1996, **17**(12), 1954–1958. PubMed PMID: 9034782. Epub 1996/12/01. eng.

112 D. K. Lloyd, A. M. Cypess and I. W. Wainer, Determination of cytosine-beta-D-arabinoside in plasma using capillary electrophoresis, *J. Chromatogr.*, 1991, **568**(1), 117–124. PubMed PMID: 1770090. Epub 1991/07/17. eng.

113 G. Schmaus, R. Schierl and S. Funck, Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry, *Am. J. Health-Syst. Pharm.*, 2002, **59**(10), 956–961. PubMed PMID: 12040735. Epub 2002/06/04. eng.

114 A. Bohlandt, S. Groeneveld, E. Fischer and R. Schierl, Cleaning Efficiencies of Three Cleaning Agents on Four Different Surfaces after Contamination by Gemcitabine and 5-fluorouracile, *J. Occup. Environ. Hyg.*, 2015, **12**(6), 384–392. PubMed PMID: 25751496. Epub 2015/03/10. eng.

115 G. B. Elion, The purine path to chemotherapy, *Science*, 1989, **244**(4900), 41–47. PubMed PMID: 2649979. Epub 1989/04/07. eng.

116 G. B. Elion, G. H. Hitchings and H. Vanderwerff, Antagonists of nucleic acid derivatives, VI, Purines, *J. Biol. Chem.*, 1951, **192**(2), 505–518. PubMed PMID: 14907641. Epub 1951/10/01. eng.

117 P. L. Bonate, L. Arthaud, W. R. Cantrell, Jr., K. Stephenson, J. A. Secrist, 3rd and S. Weitman, Discovery and development of clofarabine: a nucleoside analogue for treating cancer, *Nat. Rev. Drug Discovery*, 2006, **5**(10), 855–863. PubMed PMID: 17016426. Epub 2006/10/04. eng.

118 T. Binscheck, H. Meyer and H. H. Wellhoner, High-performance liquid chromatographic assay for the measurement of azathioprine in human serum samples, *J. Chromatogr., B: Biomed. Appl.*, 1996, **675**(2), 287–294. PubMed PMID: 8852717. Epub 1996/01/26. eng.

119 P. M. Davadra, V. V. Mepal, M. R. Jain, C. G. Joshi and A. H. Bapodra, A validated UPLC method for the determination of process-related impurities in Azathioprine bulk drug, *Anal. Methods*, 2011, **3**(1), 198–204.

120 T. Dervieux and R. Boulieu, Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC, *Clin. Chem.*, 1998, **44**(3), 551–555. PubMed PMID: 9510860. Epub 1998/03/25. eng.

121 T. Dervieux, G. Meyer, R. Barham, M. Matsutani, M. Barry, R. Boulieu, *et al.*, Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy, *Clin. Chem.*, 2005, **51**(11), 2074–2084. PubMed PMID: 16166171. Epub 2005/09/17. eng.

122 T. T. Fazio, A. K. Singh, E. R. Kedor-Hackmann and M. I. Santoro, Quantitative determination and sampling of azathioprine residues for cleaning validation in production area, *J. Pharm. Biomed. Anal.*, 2007, **43**(4), 1495–1498. PubMed PMID: 17118615. Epub 2006/11/23. eng.

123 Z. Sahnoun, F. Serre-Debeauvais, J. Lang, G. Faucon and M. Gavend, Determination of 6-mercaptopurine and its metabolites in plasma or serum by high performance liquid chromatography, *Biomed. Chromatogr.*, 1990, **4**(4), 144–147. PubMed PMID: 2207374. Epub 1990/07/01. eng.

124 E. C. Van Os, J. A. McKinney, B. J. Zins, D. C. Mays, Z. H. Schriver, W. J. Sandborn, *et al.*, Simultaneous determination of azathioprine and 6-mercaptopurine by high-performance liquid chromatography, *J. Chromatogr., B: Biomed. Appl.*, 1996, **679**(1–2), 147–154. PubMed PMID: 8998554. Epub 1996/04/26. eng.

125 S. Weller, P. Thurmann, N. Rietbrock, J. Gossmann and E. H. Scheuermann, HPLC analysis of azathioprine metabolites in red blood cells, plasma and urine in renal transplant recipients, *Int. J. Clin. Pharmacol. Ther.*, 1995, **33**(12), 639–645. PubMed PMID: 8963480. Epub 1995/12/01. eng.

126 Y. Hsieh, C. J. Duncan, S. Lee and M. Liu, Comparison of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma, *J. Pharm. Biomed. Anal.*, 2007, **44**(2), 492–497. PubMed PMID: 17368998. Epub 2007/03/21. eng.

127 L. H. Silvertand, F. Vazvaei, P. Weigl, H. Rosing, M. J. Hillebrand, M. J. van Maanen, *et al.*, Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2005, **19**(24), 3673–3680. PubMed PMID: 16287039. Epub 2005/11/16. eng.

128 P. K. Yeung, C. Ferguson, A. Jarrar, B. King and M. L. Li, Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in

rats, *J. Pharm. Pharm. Sci.*, 2007, **10**(2), 231–236. PubMed PMID: 17706181. Epub 2007/08/21. eng.

129 N. Karadas-Bakirhan, A. Sarakbi, M. Vandeput, S. A. Ozkan and J. M. Kauffmann, Liquid Chromatography with Amperometric Detection at a Silver Based Detector for the Determination of Thiocompounds: Application to the Assay of Thiopurine Antimetabolites in Urine, *Anal. Chem.*, 2015, **87**(13), 6730–6735. PubMed PMID: 26024436. Epub 2015/05/30. eng.

130 A. P. Li, J. D. Peng, M. Zhou and J. Zhang, Resonance light scattering determination of 6-mercaptopurine coupled with HPLC technique, *Spectrochim. Acta, Part A*, 2016, **154**, 1–7. PubMed PMID: 26479445. Epub 2015/10/20. eng.

131 D. Zochowska, J. Zegarska, E. Hryniewiecka, E. Samborowska, R. Jazwiec, W. Tszyrsznic, *et al.*, Determination of Concentrations of Azathioprine Metabolites 6-Thioguanine and 6-Methylmercaptopurine in Whole Blood With the Use of Liquid Chromatography Combined With Mass Spectrometry, *Transplant. Proc.*, 2016, **48**(5), 1836–1839. PubMed PMID: 27496503. Epub 2016/08/09. eng.

132 A. Shafaati and B. J. Clark, Determination of azathioprine and its related substances by capillary zone electrophoresis and its application to pharmaceutical dosage forms assay, *Drug Dev. Ind. Pharm.*, 2000, **26**(3), 267–273. PubMed PMID: 10738644. Epub 2000/03/30. eng.

133 J. Rodríguez-Flores, J. J. Berzas Nevado, A. M. Contento Salcedo and M. P. Cabello Díaz, Non-aqueous capillary electrophoresis method for the analysis of gleevec and its main metabolite in human urine, *J. Chromatogr., A*, 2005, **1068**(1), 175–182.

134 L. Ferrando-Climent, S. Rodriguez-Mozaz and D. Barceló, Development of a UPLC-MS/MS method for the determination of ten anticancer drugs in hospital and urban wastewaters, and its application for the screening of human metabolites assisted by information-dependent acquisition tool (IDA) in sewage samples, *Anal. Bioanal. Chem.*, 2013, **405**(18), 5937–5952.

135 N. Negreira, M. López de Alda and D. Barceló, On-line solid phase extraction–liquid chromatography–tandem mass spectrometry for the determination of 17 cytostatics and metabolites in waste, surface and ground water samples, *J. Chromatogr. A*, 2013, **1280**, 64–74.

136 J. Zhou, S. Gao, F. Zhang, B. Jiang, Q. Zhan, F. Cai, *et al.*, Liquid chromatography-tandem mass spectrometry method for simultaneous determination of seven commonly used anticancer drugs in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2012, **906**, 1–8.

137 A. Delmas, J. B. Gordien, J. M. Bernadou, M. Roudaut, A. Gresser, L. Malki, *et al.*, Quantitative and qualitative control of cytotoxic preparations by HPLC-UV in a centralized parenteral preparations unit, *J. Pharm. Biomed. Anal.*, 2009, **49**(5), 1213–1220. PubMed PMID: 19362442. Epub 2009/04/14. eng.

138 R. R. Larson, M. B. Khazaeli and H. K. Dillon, Development of an HPLC method for simultaneous analysis of five antineoplastic agents, *Appl. Occup. Environ. Hyg.*, 2003, **18**(2), 109–119. PubMed PMID: 12519685. Epub 2003/01/10. eng.

139 D. Wang, Q. Xiao, W. Yang, W. Qian and J. Yang, HPLC-MS/MS method for the simultaneous determination of MB07133 and its metabolites, cytarabine and arabinofuranosyluracil, in rat plasma, *J. Pharm. Biomed. Anal.*, 2016, **120**, 228–234. PubMed PMID: 26760240. Epub 2016/01/14. eng.

140 J. Barek, J. Cvacka, M. de Méo, M. Laget, J. Michelon and M. Castegnaro, Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa, *Ann. Occup. Hyg.*, 1998, **42**(4), 259–266.

141 J. Cummings, A. MacLellan, S. J. Langdon and J. F. Smyth, The long term stability of mechlorethamine hydrochloride (nitrogen mustard) ointment measured by HPLC, *J. Pharm. Pharmacol.*, 1993, **45**(1), 6–9. PubMed PMID: 8094449. Epub 1993/01/01. eng.

142 J. C. Reepmeyer, Analysis of the nitrogen mustard mechlorethamine in topical pharmaceutical preparations by high-performance liquid chromatography, *J. Chromatogr. A*, 2005, **1085**(2), 262–269. PubMed PMID: 16106707. Epub 2005/08/19. eng.

143 J. C. Reepmeyer, W. Ye and W. A. Ritschel, Modifications and insights into a method for the analysis of the nitrogen mustard mechlorethamine by high-performance liquid chromatography, *Anal. Chim. Acta*, 2008, **616**(1), 78–84. PubMed PMID: 18471487. Epub 2008/05/13. eng.

144 S. W. Lemire, D. L. Ashley and A. M. Calafat, Quantitative determination of the hydrolysis products of nitrogen mustards in human urine by liquid chromatography-electrospray ionization tandem mass spectrometry, *J. Anal. Toxicol.*, 2003, **27**(1), 1–6. PubMed PMID: 12587675. Epub 2003/02/18. eng.

145 I. Ohsawa and Y. Seto, Determination of nitrogen mustard hydrolysis products, ethanolamines by gas chromatography-mass spectrometry after tert-butyldimethylsilyl derivatization, *J. Chromatogr. A*, 2006, **1122**(1–2), 242–248. PubMed PMID: 16707130. Epub 2006/05/19. eng.

146 K. Brightman, G. Finlay, I. Jarvis, T. Knowlton and C. T. Manktelow, A stability-indicating method for the determination of melphalan and related impurity content by gradient HPLC, *J. Pharm. Biomed. Anal.*, 1999, **20**(3), 439–447. PubMed PMID: 10701960. Epub 2000/03/04. eng.

147 Y. Kato, H. Kaneko, T. Matsushita, K. Inamori, S. Egi, A. Togawa, *et al.*, Direct injection analysis of melphalan in plasma using column-switching high-performance liquid chromatography, *Ther. Drug Monit.*, 1992, **14**(1), 66–71. PubMed PMID: 1546392. Epub 1992/02/01. eng.

148 F. Pinguet, J. M. Joulia, P. Martel, P. Y. Grosse, C. Astre and F. Bressolle, High-performance liquid chromatographic assay for melphalan in human plasma, *Application to pharmacokinetic studies, J. Chromatogr., B:*

Biomed. Appl., 1996, **686**(1), 43–49. PubMed PMID: 8953191. Epub 1996/11/08. eng.

149 R. W. Sparidans, L. Silvertand, F. Dost, J. Rothbarth, G. J. Mulder, J. H. Schellens, *et al.*, Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue, *Biomed. Chromatogr.*, 2003, **17**(7), 458–464. PubMed PMID: 14598330. Epub 2003/11/05. eng.

150 D. Romanova, J. Netriova, P. Bozek, Z. Ovesna, K. Kroupa, E. Valovicova, *et al.*, Rapid HPLC analysis of melphalan applied to hyperthermic isolation limb perfusion, *Neoplasma*, 2003, **50**(2), 120–124. PubMed PMID: 12740646. Epub 2003/05/13. eng.

151 Z. Y. Wu, M. J. Thompson, M. S. Roberts, R. S. Addison, G. R. Cannell, A. J. Grabs, *et al.*, High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions, *J. Chromatogr., B: Biomed. Appl.*, 1995, **673**(2), 267–279. PubMed PMID: 8611961. Epub 1995/11/17. eng.

152 L. Silvestro, I. Viano, C. Baiocchi, G. Saini, F. Marmont and R. Ferro, Quantitation of melphalan in plasma of patients by reversed-phase high-performance liquid chromatography with electrochemical detection, *J. Chromatogr.*, 1991, **563**(2), 443–450. PubMed PMID: 2056009. Epub 1991/02/15. eng.

153 T. W. Bauer, M. Gutierrez, D. J. Dudrick, J. Li, I. A. Blair, C. Menon, *et al.*, A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan, *Surgery*, 2003, **133**(4), 420–428. PubMed PMID: 12717360. Epub 2003/04/30. eng.

154 A. Mirkou, B. Vignal, S. Cohen, M. Guillaumont, O. Glehen and J. Guitton, Assays for the quantification of melphalan and its hydrolysis products in human plasma by liquid chromatography-tandem mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(27), 3089–3096. PubMed PMID: 19674945. Epub 2009/08/14. eng.

155 D. Mohamed and M. Linscheid, Separation and identification of trinucleotide-melphalan adducts from enzymatically digested DNA using HPLC-ESI-MS, *Anal. Bioanal. Chem.*, 2008, **392**(5), 805–817.

156 B. Van den Driessche, E. L. Esmans, A. Van der Linden, W. Van Dongen, E. Schaerlaken, F. Lemière, *et al.*, First results of a quantitative study of DNA adducts of melphalan in the rat by isotope dilution mass spectrometry using capillary liquid chromatography coupled to electrospray tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2005, **19**(14), 1999–2004.

157 B. Van den Driessche, F. Lemiere, W. Van Dongen and E. L. Esmans, Alkylation of DNA by melphalan: investigation of capillary liquid chromatography-electrospray ionization tandem mass spectrometry in the study of the adducts at the nucleoside level, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2003, **785**(1), 21–37. PubMed PMID: 12535835. Epub 2003/01/22. eng.

158 B. Van den Driessche, F. Lemière, W. Van Dongen and E. L. Esmans, Structural characterization of melphalan modified 2′-oligodeoxynucleotides by miniaturized LC-ES MS/MS, *J. Am. Soc. Mass Spectrom.*, 2004, **15**(4), 568–579.

159 B. Van den Driessche, F. Lemiere, W. Van Dongen, A. Van der Linden and E. L. Esmans, Qualitative study of in vivo melphalan adduct formation in the rat by miniaturized column-switching liquid chromatography coupled with electrospray mass spectrometry, *J. Mass Spectrom.*, 2004, **39**(1), 29–37. PubMed PMID: 14760610. Epub 2004/02/05. eng.

160 B. Van den Driessche, W. Van Dongen, F. Lemière and E. L. Esmans, Implementation of data-dependent acquisitions in the study of melphalan DNA adducts by miniaturized liquid chromatography coupled to electrospray tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2004, **18**(17), 2001–2007.

161 D. Dewaele, F. Sobott and F. Lemiere, Covalent adducts of melphalan with free amino acids and a model peptide studied by liquid chromatography/tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2016, **30**(6), 719–730. PubMed PMID: 26864525. Epub 2016/02/13. eng.

162 D. Mohamed, S. Mowaka, J. Thomale and M. W. Linscheid, Chlorambucil-adducts in DNA analyzed at the oligonucleotide level using HPLC-ESI MS, *Chem. Res. Toxicol.*, 2009, **22**(8), 1435–1446.

163 K. Edman, L. Svensson, B. Eriksson and P. O. Gunnarsson, Determination of estramustine phosphate and its metabolites estromustine, estramustine, estrone and estradiol in human plasma by liquid chromatography with fluorescence detection and gas chromatography with nitrogen-phosphorus and mass spectrometric detection, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2000, **738**(2), 267–279.

164 M. Breda, G. Basileo and C. A. James, Simultaneous determination of estramustine phosphate and its four metabolites in human plasma by liquid chromatography-ionspray mass spectrometry, *Biomed. Chromatogr.*, 2004, **18**(5), 293–301.

165 N. Brock, The history of the oxazaphosphorine cytostatics, *Cancer*, 1996, **78**(3), 542–547.

166 F. Baumann and R. Preiss, Cyclophosphamide and related anticancer drugs, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2001, **764**(1–2), 173–192.

167 M. Malet-Martino, V. Gilard and R. Martino, The analysis of cyclophosphamide and its metabolites, *Curr. Pharm. Des.*, 1999, **5**(8), 561–586.

168 F. Bai, C. H. Fraga, M. Tagen, P. Schaiquevich, N. Hagedorn and C. F. Stewart, Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS), *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(18–19), 1709–1715. PubMed PMID: 19447687. Pubmed Central PMCID: PMC2689924. Epub 2009/05/19. eng.

169 F. Baumann, C. Lorenz, U. Jaehde and R. Preiss, Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1999, **729**(1–2), 297–305.

170 C. B'Hymer and K. L. Cheever, Evaluation of a procedure for the simultaneous quantification of 4-ketocyclophosphamide, cyclophosphamide, and Ifosfamide in human urine, *J. Chromatogr. Sci.*, 2010, **48**(5), 328–333.

171 M. E. de Jonge, S. M. van Dam, M. J. X. Hillebrand, H. Rosing, A. D. R. Huitema, S. Rodenhuis, *et al.*, Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry, *J. Mass Spectrom.*, 2004, **39**(3), 262–271.

172 R. DiFrancesco, J. J. Griggs, J. Donnelly and R. DiCenzo, Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2007, **852**(1–2), 545–553.

173 G. Hamscher, S. A. I. Mohring, A. Knobloch, N. Eberle, H. Nau, I. Nolte, *et al.*, Determination of drug residues in urine of dogs receiving anti-cancer chemotherapy by liquid chromatography-electrospray ionization- tandem mass spectrometry: is there an environmental or occupational risk?, *J. Anal. Toxicol.*, 2010, **34**(3), 142–148.

174 T. F. Kalhorn, W. N. Howald, S. Cole, B. Phillips, J. Wang, J. T. Slattery, *et al.*, Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2006, **835**(1–2), 105–113.

175 D. Kasel, A. Jetter, S. Harlfinger, W. Gebhardt and U. Fuhr, Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2004, **18**(13), 1472–1478.

176 F. Li, A. D. Patterson, C. C. Höfer, K. W. Krausz, F. J. Gonzalez and J. R. Idle, Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics, *Biochem. Pharmacol.*, 2010, **80**(7), 1063–1074.

177 W. Shu, X. Wang, X. Yang, L. Liang, J. Li, Z. Chen, *et al.*, Simultaneous determination of cyclophosphamide and 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry - application to Chinese systemic lupus erythematosus patients, *Clin. Chem. Lab. Med.*, 2011, **49**(12), 2029–2037.

178 C. Skoglund, F. Bassyouni and M. Abdel-Rehim, Monolithic packed 96-tips set for high-throughput sample preparation: determination of cyclophosphamide and busulfan in whole blood samples by monolithic packed 96-tips and LC-MS, *Biomed. Chromatogr.*, 2013, **27**(6), 714–719.

179 C. Sottani, P. Rinaldi, E. Leoni, G. Poggi, C. Teragni, A. Delmonte, *et al.*, Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation, *Rapid Commun. Mass Spectrom.*, 2008, **22**(17), 2645–2659.

180 C. Sottani, G. Tranfo, P. Faranda and C. Minoia, Highly sensitive high-performance liquid chromatography/selective reaction monitoring mass spectrometry method for the determination of cyclophosphamide and ifosfamide in urine of health care workers exposed to antineoplastic agents, *Rapid Commun. Mass Spectrom.*, 2005, **19**(19), 2794–2800.

181 T. Storme, L. Mercier, A. Deroussent, M. Re, T. Martens, J. Royer, *et al.*, Liquid chromatography-mass spectrometry assay for quantitation of ifosfamide and its N-deschloroethylated metabolites in rat microsomal medium, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2005, **820**(2), 251–259.

182 L. Yang, J. Feng, F. Zhang, B. Jiang, S. Gao and W. Chen, Fast quantification of cyclophosfamide and its N-dechloroethylated metabolite 2-dechloroethylcyclophosphamide in human plasma by UHPLC-MS/MS, *Biomed. Chromatogr.*, 2014, **28**(10), 1303–1305.

183 S. Deng, M. Kiscoan, C. Frazee, S. Abdel-Rahman, J. Dalal and U. Garg, A Simple Liquid Chromatography Tandem Mass Spectrometry Method for Quantitation of Plasma Busulfan, *Methods Mol. Biol.*, 2016, **1383**, 79–87. PubMed PMID: 26660176. Epub 2015/12/15. eng.

184 A. Deroussent, C. Skarbek, A. Maury, H. Chapuis, E. Daudigeos-Dubus, L. Le Dret, *et al.*, Simultaneous quantification of preactivated ifosfamide derivatives and of 4-hydroxyifosfamide by high performance liquid chromatography-tandem mass spectrometry in mouse plasma and its application to a pharmacokinetic study, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2015, **992**, 30–35. PubMed PMID: 25939095. Epub 2015/05/06. eng.

185 L. M. Torres, L. Rivera-Espinosa, J. L. Chavez-Pacheco, C. F. Navas, J. A. Demetrio, R. Alemon-Medina, *et al.*, A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours, *PLoS One*, 2015, **10**(11), e0143421. PubMed PMID: 26600181. Pubmed Central PMCID: PMC4657950. Epub 2015/11/26. eng.

186 R. Kennedy, D. Groepper, M. Tagen, R. Christensen, F. Navid, A. Gajjar, *et al.*, Stability of cyclophosphamide in extemporaneous oral suspensions, *Ann. Pharmacother.*, 2010, **44**(2), 295–301.

187 K. Aleksa, A. Nava-Ocampo and G. Koren, Detection and Quantification of (R) and (S)-Dechloroethylifosfamide Metabolites in Plasma from Children by Enantioselective LC/MS/MS, *Chirality*, 2009, **21**(7), 674–680.

188 S. A. Corlett and H. Chrystyn, Enantiomeric separation of R- and S-ifosfamide and their determination in serum

from clinical subjects, *J. Chromatogr., B: Biomed. Appl.*, 1994, **654**(1), 152–158.

189 S. A. Corlett and H. Chrystyn, High-performance liquid chromatographic determination of the enantiomers of cyclophosphamide in serum, *Chromatogr., B: Biomed. Appl.*, 1996, **682**(2), 337–342.

190 G. P. Kaijser, J. H. Beijnen, A. Bult, H. J. Keizer and W. J. Underberg, Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1997, **690**(1–2), 131–138.

191 R. V. Oliveira, J. M. Onorato, D. Siluk, C. M. Walko, C. Lindley and I. W. Wainer, Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma, *J. Pharm. Biomed. Anal.*, 2007, **45**(2), 295–303.

192 D. Camacho-Munoz and B. Kasprzyk-Hordern, Multi-residue enantiomeric analysis of human and veterinary pharmaceuticals and their metabolites in environmental samples by chiral liquid chromatography coupled with tandem mass spectrometry detection, *Anal. Bioanal. Chem.*, 2015, **407**(30), 9085–9104. PubMed PMID: 26462925. Epub 2015/10/16. eng.

193 F. Attié de Castro, G. dS. Scatena, Q. B. Cass, B. P. Simões and V. L. Lanchote, Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2014, **971**, 14–19.

194 C. De Miranda Silva, B. J. Dumêt Fernandes, M. P. Marques Pereira, L. M. da Silva, E. A. Donadi, A. do Carmo Silva Matthes, *et al.*, Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients, *Chirality*, 2009, **21**(3), 383–389.

195 C. P. Granville, B. Gehrcke, W. A. König and I. W. Wainer, Determination of the enantiomers of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection, *J. Chromatogr.*, 1993, **622**(1), 21–31.

196 M. P. Sykes, D. A. Karnofsky, F. S. Philips and J. H. Burchenal, Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity, *Cancer*, 1953, **6**(1), 142–148.

197 J. Kumazawa and M. Yagisawa, The history of antibiotics: the Japanese story, *J. Infect. Chemother.*, 2002, **8**(2), 125–133.

198 M. J. v Maanen, C. J. M. Smeets and J. H. Beijnen, Chemistry, pharmacology and pharmacokinetics of N,N′,N″ -triethylenethiophosphoramide (ThioTEPA), *Cancer Treat. Rev.*, 2000, **26**(4), 257–268.

199 J. H. Beijnen and W. J. M. Underberg, Degradation of mitomycin C in acidic solution, *Int. J. Pharm.*, 1985, **24**(2–3), 219–229.

200 M. J. van Maanen, A. C. Brandt, J. M. Damen and J. H. Beijnen, Degradation study of thiotepa in aqueous solutions, *Int. J. Pharm.*, 1999, **179**(1), 55–64.

201 J. H. Beijnen, R. van Gijn and W. J. Underberg, Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation, *J. Parenter. Sci. Technol.*, 1990, **44**(6), 332–335.

202 K. M. Murray, D. Erkkila, W. R. Gombotz and S. Pankey, Stability of thiotepa (lyophilized) in 0,9% sodium chloride injection, *Am. J. Health-Syst. Pharm.*, 1997, **54**(22), 2588–2591. PubMed PMID: 9397220. Epub 1997/12/16. eng.

203 T. Velpandian, V. Saluja, A. K. Ravi, S. S. Kumari, R. Mathur, N. Ranjan, *et al.*, Evaluation of the stability of extemporaneously prepared ophthalmic formulation of mitomycin C, *J. Ocul. Pharmacol. Ther.*, 2005, **21**(3), 217–222.

204 Q. A. Xu, L. A. Trissel, Y. Zhang, J. F. Martinez and D. L. Gilbert, Stability of thiotepa (lyophilized) in 5% dextrose injection at 4 and 23 degrees C, *Am. J. Health-Syst. Pharm.*, 1996, **53**(22), 2728–2730. PubMed PMID: 8931815. Epub 1996/11/15. eng.

205 R. M. Kinast, K. K. Akula, A. E. DeBarber, G. T. Barker, S. K. Gardiner, E. Whitson, *et al.*, The Degradation of Mitomycin C Under Various Storage Methods, *J. Glaucoma*, 2016, **25**(6), 477–481. PubMed PMID: 26020687. Epub 2015/05/29. eng.

206 F. Li, A. D. Patterson, C. C. Höfer, K. W. Krausz, F. J. Gonzalez and J. R. Idle, A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics, *Biochem. Pharmacol.*, 2011, **81**(8), 1043–1053.

207 M. J. van Maanen, A. D. Huitema, S. Rodenhuis and J. H. Beijnen, Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin, *Anti-Cancer Drugs*, 2001, **12**(6), 519–524.

208 G. Joseph, W. Biederbick, U. Woschée, M. Theisohn and W. Klaus, Sensitive and convenient high-performance liquid chromatographic method for the determination of mitomycin C in human plasma, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1997, **698**(1–2), 261–267.

209 W. Y. Li, S. K. Seah and R. T. Koda, Determination of mitomycin C in human aqueous humor and serum by high-performance liquid chromatography, *J. Chromatogr.*, 1993, **619**(1), 148–153.

210 M. J. Nozal, J. L. Bernal, M. T. Martín, J. Bernal, R. M. Torres and J. Merayo, LC-ESI-MSD fast determination of residual mitomycin C in hen aqueous humour after corneal refractive surgery, *J. Pharm. Biomed. Anal.*, 2006, **40**(1), 100–104.

211 D. Song and J. L. Au, Direct injection isocratic high-performance liquid chromatographic analysis of mitomycin C in plasma, *J. Chromatogr., B: Biomed. Appl.*, 1996, **676**(1), 165–168.

212 X. Xiong, B. A. Lim, M. Lat-Luna, P. Chew and D. Tan, Quantitation of mitomycin C in human ocular tissues by

high-performance liquid chromatography-photo-diode array detection, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2001, **755**(1–2), 65–72.

213 C. B'Hymer, T. Connor, D. Stinson and J. Pretty, Validation of an HPLC-MS/MS and wipe procedure for mitomycin C contamination, *J. Chromatogr. Sci.*, 2015, **53**(4), 619–624.

214 K. Schmid, M. I. Boettcher, J. O. W. Pelz, T. Meyer, G. Korinth, J. Angerer, *et al.*, Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C, *Eur. J. Surg. Oncol.*, 2006, **32**(10), 1222–1225.

215 O. A. Stuart, A. D. Stephens, L. Welch and P. H. Sugarbaker, Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C, *Ann. Surg. Oncol.*, 2002, **9**(2), 186–191.

216 A. W. Prestayko, L. H. Baker and S. T. Crooke, *Nitrosoureas*, Elsevier, 2013, 436 p.

217 T. H. Connor, Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs, *Am. J. Health-Syst. Pharm.*, 1999, **56**(23), 2450–2453.

218 M. Klein, N. Lambov, N. Samev and G. Carstens, Permeation of cytotoxic formulations through swatches from selected medical gloves, *Am. J. Health-Syst. Pharm.*, 2003, **60**(10), 1006–1011.

219 P. E. Wallemacq, A. Capron, R. Vanbinst, E. Boeckmans, J. Gillard and B. Favier, Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions, *Am. J. Health-Syst. Pharm.*, 2006, **63**(6), 547–556.

220 C. Beitz, T. Bertsch, D. Hannak, W. Schrammel, C. Einberger and M. Wehling, Compatibility of plastics with cytotoxic drug solutions-comparison of polyethylene with other container materials, *Int. J. Pharm.*, 1999, **185**(1), 113–121.

221 L. A. Trissel, Q. A. Xu and M. Baker, Drug compatibility with new polyolefin infusion solution containers, *Am. J. Health-Syst. Pharm.*, 2006, **63**(23), 2379–2382.

222 L. Dirikolu, T. Chakkath, T. Fan and N. R. Mente, Synthesis of trans- and cis-4′-hydroxylomustine and development of validated analytical method for lomustine and trans- and cis-4′-hydroxylomustine in canine plasma, *J. Anal. Toxicol.*, 2009, **33**(9), 595–603.

223 H. Kastrissios, N. J. Chao and T. F. Blaschke, Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients, *Cancer Chemother. Pharmacol.*, 1996, **38**(5), 425–430.

224 D. A. Galton, Myleran in chronic myeloid leukaemia; results of treatment, *Lancet*, 1953, **264**(6753), 208–213.

225 M. Hassan and H. Ehrsson, Degradation of busulfan in aqueous solution, *J. Pharm. Biomed. Anal.*, 1986, **4**(1), 95–101.

226 M. Abdel-Rehim, Z. Hassan, L. Blomberg and M. Hassan, On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS), *Ther. Drug Monit.*, 2003, **25**(3), 400–406.

227 I. Athanasiadou, Y. S. Angelis, E. Lyris, H. Archontaki, C. Georgakopoulos and G. Valsami, Gas chromatographic-mass spectrometric quantitation of busulfan in human plasma for therapeutic drug monitoring: a new on-line derivatization procedure for the conversion of busulfan to 1,4-diiodobutane, *J. Pharm. Biomed. Anal.*, 2014, **90**, 207–214.

228 I. El-Serafi, Y. Terelius, B. Twelkmeyer, A.-L. Hagbjörk, Z. Hassan and M. Hassan, Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2013, **913–914**, 98–105.

229 W. K. Lai, C. P. Pang, L. K. Law, R. Wong, C. K. Li and P. M. Yuen, Routine analysis of plasma busulfan by gas chromatography-mass fragmentography, *Clin. Chem.*, 1998, **44**(12), 2506–2510.

230 M. H. Quernin, B. Poonkuzhali, C. Montes, R. Krishnamoorthy, D. Dennison, A. Srivastava, *et al.*, Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1998, **709**(1), 47–56.

231 R. B. Burns, J. R. Heggie and L. Embree, A gas-chromatographic assaymethod for busulfan with sensitivity for test dose therapeutic monitoring, *J. Pharm. Biomed. Anal.*, 1995, **13**(9), 1073–1078.

232 L. Embree, R. B. Burns, J. R. Heggie, G. L. Phillips, D. E. Reece, J. J. Spinelli, *et al.*, Gas-chromatographic analysis of busulfan for therapeutic drug monitoring, *Cancer Chemother. Pharmacol.*, 1993, **32**(2), 137–142.

233 J. Blanz, C. Rosenfeld, B. Proksch, G. Ehninger and K. P. Zeller, Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis, *J. Chromatogr.*, 1990, **532**(2), 429–437.

234 N. Bleyzac, P. Barou and G. Aulagner, Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2000, **742**(2), 427–432.

235 D. S. Chow, H. P. Bhagwatwar, S. Phadungpojna and B. S. Andersson, Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1997, **704**(1–2), 277–288.

236 A. Jenke, U. Renner, U. S. Schuler, S. Wauer, T. Leopold, E. Schleyer, *et al.*, Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2004, **805**(1), 147–153.

237 K. Kolbe, A. Karstens and I. Krämer, Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules, *J. Oncol. Pharm. Pract.*, 2010, **16**(3), 151–159.

238 M. Houot, V. Poinsignon, L. Mercier, C. Valade, R. Desmaris, F. Lemare, *et al.*, Physico-chemical stability of busulfan in injectable solutions in various administration packages, *Drugs R&D*, 2013, **13**(1), 87–94.

239 J. E. Peris, J. A. Latorre, V. Castel, A. Verdeguer, S. Esteve and F. Torres-Molina, Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1999, **730**(1), 33–40.

240 M. Ansari, C. R. S. Uppugunduri, J. Déglon, Y. Théorêt, F. Versace, F. Gumy-Pause, *et al.*, A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2012, **26**(12), 1437–1446.

241 D. R. Bunch, C. Heideloff, J. C. Ritchie and S. Wang, A fast and simple assay for busulfan in serum or plasma by liquid chromatography-tandem mass spectrometry using turbulent flow online extraction technology, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2010, **878**(31), 3255–3258.

242 S. Desire, E. P. Mohanan, B. George, V. Mathews, M. Chandy, A. Srivastava, *et al.*, A rapid & sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation, *Indian J. Med. Res.*, 2013, **137**, 777–784.

243 E. O. dos Reis, R. Vianna-Jorge, G. Suarez-Kurtz, E. L. dS. Lima and D. dA. Azevedo, Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2005, **19**(12), 1666–1674.

244 D. French, K. K. Sujishi, J. R. Long-Boyle and J. C. Ritchie, Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan, *Ther. Drug Monit.*, 2014, **36**(2), 169–174.

245 S. Y. Moon, M. K. Lim, S. Hong, Y. Jeon, M. Han, S. H. Song, *et al.*, Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry, *Ann. Lab. Med.*, 2014, **34**(1), 7–14.

246 M. H. Quernin, M. Duval, C. Litalien, E. Vilmer and E. J. Aigrain, Quantification of busulfan in plasma by liquid chromatography-ion spray mass spectrometry, Application to pharmacokinetic studies in children, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2001, **763**(1–2), 61–69.

247 M. L. Snyder and J. C. Ritchie, Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS/MS), *Methods Mol. Biol.*, 2010, **603**(Chapter 12), 129–136.

248 T. R. Nadella, V. Suryadevara, S. R. Lankapalli, V. B. Mandava and D. Bandarupalli, LC-MS/MS method development for quantification of busulfan in human plasma and its application in pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2016, **120**, 168–174. PubMed PMID: 26736033. Epub 2016/01/07. eng.

249 D. Danso, P. J. Jannetto, R. Enger and L. J. Langman, High-Throughput Validated Method for the Quantitation of Busulfan in Plasma Using Ultrafast SPE-MS/MS, *Ther. Drug Monit.*, 2015, **37**(3), 319–324. PubMed PMID: 25970507. Epub 2015/05/15. eng.

250 M. El Aatmani, S. Poujol, C. Astre, F. Malosse and F. Pinguet, Stability of dacarbazine in amber glass vials and polyvinyl chloride bags, *Am. J. Health-Syst. Pharm.*, 2002, **59**(14), 1351–1356. PubMed PMID: 12132562. Epub 2002/07/23. eng.

251 B. V. Shetty, R. L. Schowen, M. Slavik and C. M. Riley, Degradation of dacarbazine in aqueous solution, *J. Pharm. Biomed. Anal.*, 1992, **10**(9), 675–683.

252 J. T. Stewart, F. W. Warren, D. T. King, T. G. Venkateshwaran, G. W. Ponder and J. L. Fox, Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags, *Am. J. Health-Syst. Pharm.*, 1997, **54**(8), 915–920.

253 G. Huang, N. Zhang, X. Bi and M. Dou, Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity, *Int. J. Pharm.*, 2008, **355**(1–2), 314–320.

254 M. Jedynak Ł, Puchalska, M. Zezula, M. Łaszcz, W. Łuniewski and J. Zagrodzka, Stability of sample solution as a crucial point during HPLC determination of chemical purity of temozolomide drug substance, *J. Pharm. Biomed. Anal.*, 2013, **83**, 19–27.

255 N. Wauthoz, P. Deleuze, A. Saumet, C. Duret, R. Kiss and K. Amighi, Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment, *Pharm. Res.*, 2011, **28**(4), 762–775.

256 E. Gilant, M. Kaza, A. Szlagowska, K. Serafin-Byczak and P. J. Rudzki, Validated HPLC method for determination of temozolomide in human plasma, *Acta Pol. Pharm.*, 2012, **69**(6), 1347–1355.

257 D. Jain, R. Athawale, A. Bajaj and S. Shrikhande, Double-salting out assisted liquid-liquid extraction (SALLE) HPLC method for estimation of temozolomide from biological samples, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2014, **970**, 86–94.

258 H. Kim, P. Likhari, D. Parker, P. Statkevich, A. Marco, C. C. Lin, *et al.*, High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma, *J. Pharm. Biomed. Anal.*, 2001, **24**(3), 461–468.

259 H. K. Kim, C. C. Lin, D. Parker, J. Veals, J. Lim, P. Likhari, *et al.*, High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1997, **703**(1–2), 225–233.

260 S. L. Safgren, J. M. Reid, R. Rios and M. M. Ames, Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)

imidazole-4-carboxamide, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2001, **754**(1), 91–96.

261 F. Shen, L. A. Decosterd, M. Gander, S. Leyvraz, J. Biollax and F. Lejeune, Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1995, **667**(2), 291–300.

262 F. Baumann, C. Mauz-Körholz, D. Clauss, S. Borrmann, A. Giannis, N. Merkel, *et al.*, Determination of terephthalic acid isopropylamide in urine with a liquid chromatography/mass spectrometry (LC/MS) method, *J. Clin. Lab. Anal.*, 2008, **22**(1), 21–28.

263 S. K. Chowdhury, D. Laudicina, N. Blumenkrantz, M. Wirth and K. B. Alton, An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma, *J. Pharm. Biomed. Anal.*, 1999, **19**(5), 659–668.

264 L. Goldwirt, N. Zahr, R. Farinotti and C. Fernandez, Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study, *Biomed. Chromatogr.*, 2013, **27**(7), 889–893.

265 X. He, T. T. Batchelor, S. Grossman and J. G. Supko, New Approaches to Brain Tumor Therapy CNSC, Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2004, **799**(2), 281–291.

266 Y. Liu, W. Zhang and Y. Yang, Validated hydrophilic interaction LC-MS/MS method for simultaneous quantification of dacarbazine and 5-amino-4-imidazole-carboxamide in human plasma, *Talanta*, 2008, **77**(1), 412–421.

267 M. Andrasi, R. Bustos, A. Gaspar, F. A. Gomez and A. Klekner, Analysis and stability study of temozolomide using capillary electrophoresis, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2010, **878**(21), 1801–1808.

268 A. S. Abu-Surrah and M. Kettunen, Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin, *Curr. Med. Chem.*, 2006, **13**(11), 1337–1357.

269 A. Mittal, D. Chitkara and N. Kumar, HPLC method for the determination of carboplatin and paclitaxel with cremophorEL in an amphiphilic polymer matrix, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2007, **855**(2), 211–219.

270 N. Villarino, S. Cox, J. Yarbrough and T. Martín-Jiménez, Determination of carboplatin in canine plasma by high-performance liquid chromatography, *Biomed. Chromatogr.*, 2010, **24**(8), 908–913.

271 A. L. Myers, Y. P. Zhang, J. D. Kawedia, V. A. Trinh, H. Tran, J. A. Smith, *et al.*, Stability study of carboplatin infusion solutions in 0,9% sodium chloride in polyvinyl chloride bags, *J. Oncol. Pharm. Pract.*, 2016, **22**(1), 31–36. PubMed PMID: 25122633. Epub 2014/08/15. eng.

272 M. E. Bosch, A. J. R. Sánchez, F. S. Rojas and C. B. Ojeda, Analytical methodologies for the determination of cisplatin, *J. Pharm. Biomed. Anal.*, 2008, **47**(3), 451–459.

273 A. Toro-Cordova, F. Ledezma-Gallegos, L. Mondragon-Fuentes, R. Jurado, L. A. Medina, J. M. Perez-Rojas, *et al.*, Determination of Liposomal Cisplatin by High-Performance Liquid Chromatography and Its Application in Pharmacokinetic Studies, *J. Chromatogr. Sci.*, 2016, **54**(6), 1016–1021. PubMed PMID: 27013666. Pubmed Central PMCID: PMC4901840. Epub 2016/03/26. eng.

274 R. Bandu, H. S. Ahn, J. W. Lee, Y. W. Kim, S. H. Choi, H. J. Kim, *et al.*, Distribution study of cisplatin in rat kidney and liver cancer tissues by using liquid chromatography electrospray ionization tandem mass spectrometry, *J. Mass Spectrom.*, 2015, **50**(6), 844–853.

275 C. Desjardins, P. Saxton, S. X. Lu, X. Li, C. Rowbottom and Y. N. Wong, A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2008, **875**(2), 373–382.

276 H. Ito, H. Yamaguchi, A. Fujikawa, N. Tanaka, A. Furugen, K. Miyamori, *et al.*, A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates, *J. Pharm. Biomed. Anal.*, 2012, **71**, 99–103.

277 W. Zhang, L. Seymour and E. X. Chen, Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2008, **876**(2), 277–282.

278 A. N. Shaik, D. A. Altomare, L. J. Lesko and M. N. Trame, Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2017, **1046**, 243–249. PubMed PMID: 28162967. Epub 2017/02/07. eng.

279 A. K. Bytzek, M. R. Reithofer, M. Galanski, M. Groessl, B. K. Keppler and C. G. Hartinger, The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes, *Electrophoresis*, 2010, **31**(7), 1144–1150.

280 S. Hann, Z. Stefánka, K. Lenz and G. Stingeder, Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS, *Anal. Bioanal. Chem.*, 2005, **381**(2), 405–412.

281 G. Koellensperger and S. Hann, Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine, *Anal. Bioanal. Chem.*, 2010, **397**(1), 401–406.

282 K. Lenz, G. Koellensperger, S. Hann, N. Weissenbacher, S. N. Mahnik and M. Fuerhacker, Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents, *Chemosphere*, 2007, **69**(11), 1765–1774.

283 A. Martinčič, M. Cemazar, G. Sersa, V. Kovač, R. Milačič and J. Ščančar, A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection, *Talanta*, 2013, **116**, 141–148.

284 A. R. Timerbaev, S. S. Aleksenko, K. Polec-Pawlak, R. Ruzik, O. Semenova, C. G. Hartinger, *et al.*, Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin, *Electrophoresis*, 2004, **25**(13), 1988–1995.

285 J. Vidmar, A. Martincic, R. Milacic and J. Scancar, Speciation of cisplatin in environmental water samples by hydrophilic interaction liquid chromatography coupled to inductively coupled plasma mass spectrometry, *Talanta*, 2015, **138**, 1–7. PubMed PMID: 25863363. Epub 2015/04/13. eng.

286 E. E. Brouwers, A. D. Huitema, E. N. Bakker, J. W. Douma, K. J. Schimmel, G. van Weringh, *et al.*, Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry, *Int. Arch. Occup. Environ. Health*, 2007, **80**(8), 689–699. PubMed PMID: 17377802. Pubmed Central PMCID: PMC1915587. Epub 2007/03/23. eng.

287 E. E. M. Brouwers, M. M. Tibben, H. Rosing, M. J. X. Hillebrand, M. Joerger, J. H. M. Schellens, *et al.*, Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate, *J. Mass Spectrom.*, 2006, **41**(9), 1186–1194.

288 O. Nygren and C. Lundgren, Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy, *Int. Arch. Occup. Environ. Health*, 1997, **70**(3), 209–214.

289 O. Nygren, G. T. Vaughan, T. M. Florence, G. M. Morrison, I. M. Warner and L. S. Dale, Determination of platinum in blood by adsorptive voltammetry, *Anal. Chem.*, 1990, **62**(15), 1637–1640.

290 R. Schierl, Environmental monitoring of platinum in air and urine, *Microchem. J.*, 2000, **67**(1–3), 245–248.

291 B. Gallinella, L. Bucciarelli, L. Zanitti, R. Ferretti and R. Cirilli, Direct separation of the enantiomers of oxaliplatin on a cellulose-based chiral stationary phase in hydrophilic interaction liquid chromatography mode, *J. Chromatogr. A*, 2014, **1339**, 210–213.

292 C. G. Hartinger and B. K. Keppler, CE in anticancer metallodrug research–an update, *Electrophoresis*, 2007, **28**(19), 3436–3446.

293 C. G. Hartinger, A. R. Timerbaev and B. K. Keppler, Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges, *Electrophoresis*, 2003, **24**(12–13), 2023–2037.

294 A. R. Timerbaev, A. Küng and B. K. Keppler, Capillary electrophoresis of platinum-group elements, Analytical, speciation and biochemical studies, *J. Chromatogr. A*, 2002, **945**(1–2), 25–44.

295 Z. Huang, A. R. Timerbaev, B. K. Keppler and T. Hirokawa, Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques, *J. Chromatogr. A*, 2006, **1106**(1–2), 75–79.

296 S. Nussbaumer, S. Fleury-Souverain, J. Schappler, S. Rudaz, J.-L. Veuthey and P. Bonnabry, Quality control of pharmaceutical formulations containing cisplatin, carboplatin, and oxaliplatin by micellar and microemulsion electrokinetic chromatography (MEKC, MEEKC), *J. Pharm. Biomed. Anal.*, 2011, **55**(2), 253–258.

297 B. W. Wenclawiak and M. Wollmann, Separation of platinum(II) anti-tumour drugs by micellar electrokinetic capillary chromatography, *J. Chromatogr. A*, 1996, **724**(1–2), 317–326.

298 S. Oszwałdowski and A. R. Timerbaev, Development of quantitative structure-activity relationships for interpretation of the migration behavior of neutral platinum(II) complexes in microemulsion electrokinetic chromatography, *J. Chromatogr. A*, 2007, **1146**(2), 258–263.

299 C. Rappel, M. Galanski, A. Yasemi, L. Habala and B. K. Keppler, Analysis of anticancer platinum(II)-complexes by microemulsion electrokinetic chromatography: separation of diastereomers and estimation of octanol-water partition coefficients, *Electrophoresis*, 2005, **26**(4–5), 878–884.

300 A. V. Rudnev, S. S. Aleksenko, O. Semenova, C. G. Hartinger, A. R. Timerbaev and B. K. Keppler, Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method, *J. Sep. Sci.*, 2005, **28**(2), 121–127.

301 A. Küng, A. Zenker, M. Galanski and B. K. Keppler, Capillary electrophoretic study of carboplatin and analogues with nucleoside monophosphates, di- and trinucleotides, *J. Inorg. Biochem.*, 2001, **83**(2–3), 181–186.

302 U. Warnke, C. Rappel, H. Meier, C. Kloft, M. Galanski, C. G. Hartinger, *et al.*, Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5′-monophosphate O6-N7 chelation, *ChemBioChem*, 2004, **5**(11), 1543–1549.

303 A. Zenker, M. Galanski, T. L. Bereuter, B. K. Keppler and W. Lindner, Capillary electrophoretic study of cisplatin interaction with nucleoside monophosphates, di- and trinucleotides, *J. Chromatogr. A*, 1999, **852**(1), 337–346.

304 A. Zenker, M. Galanski, T. L. Bereuter, B. K. Keppler and W. Lindner, Kinetics of binding properties of 5′-GMP with cisplatin under simulated physiological conditions by capillary electrophoresis, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2000, **745**(1), 211–219.

305 P. Du, X. Han, N. Li, H. Wang, S. Yang, Y. Song, *et al.*, Development and validation of an ultrafiltration-UPLC-MS/MS method for rapid quantification of

unbound docetaxel in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2014, **967**, 28–35.

306 C. Shu, T. Zeng, S. Gao, T. Xia, L. Huang, F. Zhang, *et al.*, LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1028**, 111–119. PubMed PMID: 27336703. Epub2016/06/24. eng.

307 S. Maeda and Y. Miwa, Multicomponent high-performance liquid chromatography/tandem mass spectrometry analysis of ten chemotherapeutic drugs in wipe samples, *J. Chromatogr., B: Biomed. Appl.*, 2013, **921–922**, 43–48.

308 J. Yin, B. Shao, J. Zhang and K. Li, A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China, *Bull. Environ. Contam. Toxicol.*, 2010, **84**(1), 39–45. PubMed PMID: 19795089. Epub 2009/10/02. eng.

309 J. Mo, P. K. Eggers, C. L. Raston and L. Y. Lim, Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles, *Anal. Bioanal. Chem.*, 2014, **406**(11), 2659–2667.

310 M. Jeronimo, M. Colombo, G. Astrakianakis and C. Y. Hon, A surface wipe sampling and LC-MS/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers, *Anal. Bioanal. Chem.*, 2015, **407**(23), 7083–7092. PubMed PMID: 26141324. Epub 2015/07/05. eng.

311 G. Minotti, P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, *Pharmacol. Rev.*, 2004, **56**(2), 185–229.

312 F. M. Muggia and M. D. Green, New anthracycline antitumor antibiotics, *Crit. Rev. Oncol./Hematol.*, 1991, **11**(1), 43–64.

313 I. Badea, L. Lazăr, D. Moja, D. Nicolescu and A. Tudose, A HPLC method for the simultaneous determination of seven anthracyclines, *J. Pharm. Biomed. Anal.*, 2005, **39**(1–2), 305–309.

314 J. Cielecka-Piontek, A. Jelińska, M. Zając, M. Sobczak, A. Bartold and I. Oszczapowicz, A comparison of the stability of doxorubicin and daunorubicin in solid state, *J. Pharm. Biomed. Anal.*, 2009, **50**(4), 576–579.

315 N. Ohnishi, H. Tomida, Y. Ito, K. Tahara and H. Takeuchi, Characterization of a Doxorubicin Liposome Formulation by a Novel in Vitro Release Test Methodology Using Column-Switching High-Performance Liquid Chromatography, *Chem. Pharm. Bull.*, 2014, **62**(6), 538–544.

316 A. S. Rodrigues, A. R. Lopes, A. Leão, A. Couceiro, A. B. S. Ribeiro, F. Ramos, *et al.*, Development of an analytical methodology for simultaneous determination of vincristine and doxorubicin in pharmaceutical preparations for oncology by HPLC-UV, *J. Chromatogr. Sci.*, 2009, **47**(5), 387–391.

317 A. Sobczak, A. Jelińska, M. Leśniewska, A. Firlej and I. Oszczapowicz, Stability of epidoxorubicin in solid state, *J. Pharm. Biomed. Anal.*, 2011, **54**(4), 869–872.

318 S. Bermingham, R. O'Connor, F. Regan and G. P. McMahon, Simultaneous determination of anthracyclines and taxanes in human serum using online sample extraction coupled to high performance liquid chromatography with UV detection, *J. Sep. Sci.*, 2010, **33**(11), 1571–1579.

319 T. Hu, Q. Le, Z. Wu and W. Wu, Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-β-hydroxybutyrate microspheres, *J. Pharm. Biomed. Anal.*, 2007, **43**(1), 263–269.

320 K. Alhareth, C. Vauthier, C. Gueutin, G. Ponchel and F. Moussa, HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly (alkylcyanoacrylate) nanoparticles, *J. Chromatogr., B: Biomed. Appl.*, 2012, **887–888**, 128–132.

321 W. I. W. Dodde, J. G. Maring, G. Hendriks, F. M. Wachters, H. J. M. Groen, E. G. E de Vries, *et al.*, Determination of Epirubicin and Its Metabolite Epirubicinol in Saliva and Plasma by HPLC, *Ther. Drug Monit.*, 2003, **25**(4), 433–440.

322 C. M. Gilbert, R. P. McGeary, L. J. Filippich, R. L. G. Norris and B. G. Charles, Simultaneous liquid chromatographic determination of doxorubicin and its major metabolite doxorubicinolin parrot plasma, *J. Chromatogr., B: Biomed. Appl.*, 2005, **826**(1–2), 273–276.

323 K. E. Maudens, C. P. Stove, V. F. J. Cocquyt, H. Denys and W. E. Lambert, Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva, *J. Chromatogr., B: Biomed. Appl.*, 2009, **877**(30), 3907–3915.

324 K. E. Maudens, C. P. Stove and W. E. Lambert, Optimization of a liquid chromatographic separation for the simultaneous determination of four anthracyclines and their respective 13- S-dihydro metabolites, *J. Sep. Sci.*, 2008, **31**(6–7), 1042–1049.

325 M. Pieri, L. Castiglia, P. Basilicata, N. Sannolo, A. Acampora and N. Miraglia, Biological Monitoring of Nurses Exposed to Doxorubicin and Epirubicin by a Validated Liquid Chromatography/Fluorescence Detection Method, *Ann. Occup. Hyg.*, 2010, **54**(4), 368–376.

326 L. H. Reddy, N. Meda and R. R. Murthy, Rapid and sensitive HPLC method for the estimation of doxorubicin in dog blood–the silver nitrate artifact, *Acta Pharm.*, 2005, **55**(1), 81–91.

327 K. Sakai-Kato, E. Saito, K. Ishikura and T. Kawanishi, Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2010, **878**(19), 1466–1470.

328 S. R. Urva, B. S. Shin, V. C. Yang and J. P. Balthasar, Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(8–9), 837–841.

329 G. Wei, S. Xiao, D. Si and C. Liu, Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations, *Biomed. Chromatogr.*, 2008, **22**(11), 1252–1258.

330 Q. Zhou and B. Chowbay, Determination of doxorubicin and its metabolites in rat serum and bile by LC: application to preclinical pharmacokinetic studies, *J. Pharm. Biomed. Anal.*, 2002, **30**(4), 1063–1074.

331 R. Arnold, Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy, *J. Chromatogr., B: Biomed. Appl.*, 2004, **808**(2), 141–152.

332 Y. Liu, Y. Yang, X. Liu and T. Jiang, Quantification of pegylated liposomal doxorubicin and doxorubicinol in rat plasma by liquid chromatography/electrospray tandem mass spectroscopy: Application to preclinical pharmacokinetic studies, *Talanta*, 2008, **74**(4), 887–895.

333 C. Mazuel, J. Grove, G. Gerin and K. P. Keenan, HPLC-MS/MS determination of a peptide conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and doxorubicin, in dog and rat plasma, *J. Pharm. Biomed. Anal.*, 2003, **33**(5), 1093–1102.

334 C. Sottani, E. Leoni, B. Porro, B. Montagna, A. Amatu, F. Sottotetti, *et al.*, Validation of an LC–MS/MS method for the determination of epirubicin in human serum of patients undergoing Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE), *J. Chromatogr., B: Biomed. Appl.*, 2009, **877**(29), 3543–3548.

335 C. Sottani, G. Tranfo, M. Bettinelli, P. Faranda, M. Spagnoli and C. Minoia, Trace determination of anthracyclines in urine: a new high-performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel, *Rapid Commun. Mass Spectrom.*, 2004, **18**(20), 2426–2436.

336 Y. Yang, Development and validation of a high-performance liquid chromatography-tandem mass spectrometric method for quantification of daunorubicin in rat plasma, *Talanta*, 2007, **71**(2), 596–604.

337 S. Mazzucchelli, A. Ravelli, F. Gigli, M. Minoli, F. Corsi, P. Ciuffreda, *et al.*, LC-MS/MS method development for quantification of doxorubicin and its metabolite 13-hydroxy doxorubicin in mice biological matrices: Application to a pharmaco-delivery study, *Biomed. Chromatogr.*, 2017, **31**(4), DOI: 10.1002/bmc.3863. PubMed PMID: 27714830. Epub 2016/10/08. eng.

338 W. Ma, J. Wang, Q. Guo and P. Tu, Simultaneous determinationof doxorubicin and curcumin in rat plasma by LC-MS/MS and its application to pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2015, **111**, 215–221. PubMed PMID: 25910045. Epub 2015/04/25. eng.

339 J. B. Katzenmeyer, C. V. Eddy and E. A. Arriaga, Tandem Laser-Induced Fluorescence and Mass Spectrometry Detection for High-Performance Liquid Chromatography Analysis of the in Vitro Metabolism of Doxorubicin, *Anal. Chem.*, 2010, **82**(19), 8113–8120.

340 R. Respaud, L. Quenum, C. Plichon, J. F. Tournamille, E. Gyan, D. Antier, *et al.*, A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i,v, infusion fluids, *J. Pharm. Biomed. Anal.*, 2013, **83**, 164–170.

341 A. B. Anderson, J. Gergen and E. A. Arriaga, Detection of doxorubicin and metabolites in cell extracts and in single cells by capillary electrophoresis with laser-induced fluorescence detection, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2002, **769**(1), 97–106.

342 A. R. Eder, J. S. Chen and E. A. Arriaga, Separation of doxorubicin and doxorubicinol by cyclodextrin-modified micellar electrokinetic capillary chromatography, *Electrophoresis*, 2006, **27**(16), 3263–3270.

343 H. S. Kim and I. W. Wainer, Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence, *J. Pharm. Biomed. Anal.*, 2010, **52**(3), 372–376.

344 J. Mbuna, T. Kaneta and T. Imasaka, Measurement of intracellular accumulation of anthracyclines in cancerous cells by direct injection of cell lysate in MEKC/LIF detection, *Electrophoresis*, 2010, **31**(8), 1396–1404.

345 J. Mbuna, T. Kaneta and T. Imasaka, Micellar electrokinetic chromatographic analysis for in vitro accumulation of anthracyclines enhanced by inhibitors of cell membrane transporter-proteins in cancer cells, *Biomed. Chromatogr.*, 2011, **25**(10), 1168–1174.

346 T. Pérez-Ruiz, C. Martínez-Lozano, A. Sanz and E. Bravo, Simultaneous determination of doxorubicin, daunorubicin, and idarubicin by capillary electrophoresis with laser-induced fluorescence detection, *Electrophoresis*, 2001, **22**(1), 134–138.

347 N. J. Reinhoud, U. R. Tjaden, H. Irth and J. van der Greef, Bioanalysis of some anthracyclines in human plasma by capillary electrophoresis with laser-induced fluorescence detection, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1992, **574**(2), 327–334.

348 N. Siméon, E. Chatelut, P. Canal, M. Nertz and F. Couderc, Anthracycline analysis by capillary electrophoresis, *J. Chromatogr., A*, 1999, **853**(1–2), 449–454.

349 G. Whitaker, A. Lillquist, S. A. Pasas, R. O'Connor, F. Regan, C. E. Lunte, *et al.*, CE-LIF method for the separation of anthracyclines: Application to protein binding analysis in plasma using ultrafiltration, *J. Sep. Sci.*, 2008, **31**(10), 1828–1833.

350 A. Gavenda, J. Ševčík, J. Psotová, P. Bednář, P. Barták, P. Adamovský, *et al.*, Determination of anthracycline antibiotics doxorubicin and daunorubicin by capillary electrophoresis with UV absorption detection, *Electrophoresis*, 2001, **22**(13), 2782–2785.

351 E. Tomlinson and L. Malspeis, Concomitant Adsorption and Stability of Some Anthracycline Antibiotics, *J. Pharm. Sci.*, 1982, **71**(10), 1121–1125.

352 R. J. White and F. E. Durr, Development of mitoxantrone, *Invest. New Drugs*, 1985, **3**(2), 85–93.

353 S. A. Waksman and I. Actinomycin, Historical; nature and cytostatic action, *Antibiot. Chemother.*, 1954, **4**(5), 502–510.
354 G. An and M. E. Morris, HPLC analysis of mitoxantrone in mouse plasma and tissues: Application in a pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2010, **51**(3), 750–753.
355 J. Johnson, A. Ahmad, S. Khan, Y. Wang, A. Abuqare, J. Ayoub, *et al.*, Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation, *J. Chromatogr., B: Biomed.Appl.*, 2004, **799**(1), 149–155.
356 C. W. N. Damen, T. Israëls, H. N. Caron, J. H. M. Schellens, H. Rosing and J. H. Beijnen, Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2009, **23**(6), 763–774.
357 C. W. N. Damen, H. Rosing, J. H. M. Schellens and J. H. Beijnen, Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D, *Anal. Bioanal. Chem.*, 2009, **394**(4), 1171–1182.
358 J. I. Lee, J. M. Skolnik, J. S. Barrett and P. C. Adamson, A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer, *J. Mass Spectrom.*, 2007, **42**(6), 761–770.
359 J. M. Skolnik, J. S. Barrett, H. Shi and P. C. Adamson, A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer, *Cancer Chemother. Pharmacol.*, 2006, **57**(4), 458–464.
360 G. J. Veal, J. Errington, J. Sludden, M. J. Griffin, L. Price, A. Parry, *et al.*, Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography–mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2003, **795**(2), 237–243.
361 P. Zhang, G. Ling, J. Sun, Y. Sun, X. Pu, Z. Wang, *et al.*, Determination of mitoxantrone in rat plasma by liquid chromatography–tandem mass spectrometry method: Application to a pharmacokinetic study, *J. Chromatogr., B: Biomed. Appl.*, 2010, **878**(24), 2260–2265.
362 S. Han and H. Wang, On-line chemiluminescence determination of mitoxantrone by capillary electrophoresis, *J. Chromatogr., B: Biomed. Appl.*, 2010, **878**(28), 2901–2904.
363 Y. Shakalisava and F. Regan, CE separation approaches for combinations of anthracyclines and taxanes, *Electrophoresis*, 2009, **30**(17), 3110–3113.
364 M. Krogh-Madsen, S. H. Hansen and P. H. Honore, Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2010, **878**(22), 1967–1972. PubMed PMID: 20542475. Epub 2010/06/15. eng.
365 N. H. Oberlies and D. J. Kroll, Camptothecin and Taxol: Historic Achievements in Natural Products Research, *J. Nat. Prod.*, 2004, **67**(2), 129–135.
366 W. J. Loos, P. de Bruijn, J. Verweij and A. Sparreboom, Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography, *Anti-Cancer Drugs*, 2000, **11**(5), 315–324.
367 M. Palumbo, C. Sissi, B. Gatto, S. Moro and G. Zagotto, Quantitation of camptothecin and related compounds, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2001, **764**(1–2), 121–140.
368 M. Ramesh, P. Ahlawat and N. R. Srinivas, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives, *Biomed. Chromatogr.*, 2010, **24**(1), 104–123.
369 L. Zufia, A. Aldaz and J. Giraldez, Separation methods for camptothecin and related compounds, *J. Chromatogr., B: Biomed. Appl.*, 2001, **764**(1–2), 141–159. PubMed PMID: 11817025. Epub 2002/01/31. eng.
370 X. Chen, C. J. Peer, R. Alfaro, T. Tian, S. D. Spencer and W. D. Figg, Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization, *J. Pharm. Biomed. Anal.*, 2012, **62**, 140–148.
371 Z.-P. Hu, X.-X. Yang, X. Chen, E. Chan, W. Duan and S.-F. Zhou, Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performanceliquid chromatography: Application to cellular metabolism and accumulation studies, *J. Chromatogr., B: Biomed. Appl.*, 2007, **850**(1–2), 575–580.
372 Z. Zhang, J. Yao, X. Wu, J. Zou and J. Zhu, An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection, *Chromatographia*, 2009, **70**(3–4), 399–405.
373 L. Goldwirt, F. Lemaitre, N. Zahr, R. Farinotti and C. Fernandez, A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: Application to plasma and brain pharmacokinetics, *J. Pharm. Biomed. Anal.*, 2012, **66**, 325–333.
374 H. Sumiyoshi, Y. Fujiwara, T. Ohune, N. Yamaoka, K. Tamura and M. Yamakido, High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1995, **670**(2), 309–316.
375 W. Zhang, G. E. Dutschman, X. Li, M. Ye and Y.-C. Cheng, Quantitation of Irinotecan and its two major metabolites using a liquid chromatography–electrospray ionization tandem mass spectrometric, *J. Chromatogr., B: Biomed. Appl.*, 2009, **877**(27), 3038–3044.
376 G. Boyd, J. F. Smyth, D. I. Jodrell and J. Cummings, High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid

forms of camptothecin and SN-38 in tissue culture media and cancer cells, *Anal. Biochem.*, 2001, **297**(1), 15–24.

377 D. F. Chollet, L. Goumaz, A. Renard, G. Montay, L. Vernillet, V. Arnera, *et al.*, Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1998, **718**(1), 163–175.

378 T. S. Owens, H. Dodds, K. Fricke, S. K. Hanna and K. R. Crews, High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma, *J. Chromatogr., B: Biomed. Appl.*, 2003, **788**(1), 65–74.

379 A. M. Vali, B. Shafaghi and S. Dadashzadeh, Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma, *J. Chromatogr., B: Biomed. Appl.*, 2005, **818**(2), 205–212.

380 X. Yang, Z. Hu, S. Chan, B. Goh, W. Duan, E. Chan, *et al.*, Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in the rat, *J. Chromatogr., B: Biomed. Appl.*, 2005, **821**(2), 221–228.

381 D. J. Park, J. H. Won, A. R. Cho, H. J. Yun, J. H. Heo, T. H. Hwhang, *et al.*, Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography, *J. Chromatogr., B: Biomed. Appl.*, 2014, **962**, 147–152.

382 A. Jain, A. Gulbake, A. Jain, S. Shilpi, P. Hurkat, S. Kashaw, *et al.*, Development and validation of the HPLC method for simultaneous estimation of Paclitaxel and topotecan, *J. Chromatogr. Sci.*, 2014, **52**(7), 697–703.

383 F. Bai, M. Kirstein, S. Hanna, L. Iacono, B. Johnston and C. Stewart, Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection, *J. Chromatogr., B: Biomed. Appl.*, 2003, **784**(2), 225–232.

384 J. Chen and J. P. Balthasar, High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma, *J. Chromatogr., B: Biomed. Appl.*, 2005, **816**(1–2), 183–192.

385 G. Ahn, D. M. Park, J. W. Park, J.-Y. Cho, S.-j Rhee, H.-Y. Kim, *et al.*, Development and validation of a microfluidic chip-based nano-liquid chromatography–triplequadrupole tandem mass spectrometry method for a sensitive and reliable quantification of 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma, *Anal. Bioanal. Chem.*, 2013, **405**(30), 9817–9824.

386 C. Arellano, P. Gandia, L. Bettuing, J. Woodley and E. Chatelut, Quantification of topotecan by liquid chromatography–mass spectrometry (LC–MS), Application to intestinal transport using rat everted gut sacs, *J. Chromatogr., B: Biomed. Appl.*, 2010, **878**(7–8), 645–652.

387 E. Ghazaly, J. Perry, C. Kitromilidou, T. Powles and S. Joel, Development and validation of an ultra-high performance LC–MS/MS assay for intracellular SN-38 in human solid tumour cell lines: Comparison with a validated HPLC-fluorescence method, *J. Chromatogr., B: Biomed. Appl.*, 2014, **969**, 213–218.

388 P. Herviou, D. Richard, L. Roche, J. Pinguet, F. Libert, A. Eschalier, *et al.*, Determination of irinotecan and SN38 in human plasma by TurboFlow liquid chromatography-tandem mass spectrometry, *J. Pharm. Biomed. Anal.*, 2016, **118**, 284–291. PubMed PMID: 26580826. Epub 2015/11/19. eng.

389 X. Liu and A. B. Hummon, Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids, *J. Am. Soc. Mass Spectrom.*, 2015, **26**(4), 577–586. PubMed PMID: 25604392. Pubmed Central PMCID: PMC4361235. Epub 2015/01/22. eng.

390 S. Basu, M. Zeng, T. Yin, S. Gao and M. Hu, Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1015–1016**, 34–41. PubMed PMID: 26894853. Pubmed Central PMCID: PMC5215916. Epub 2016/02/20. eng.

391 C. Hurtado-Sanchez Mdel, M. I. Acedo-Valenzuela, I. Duran-Meras and M. I. Rodriguez-Caceres, Determination of chemotherapeutic drugs in human urine by capillary electrophoresis with UV and fluorimetric detection using solid-supported liquid-liquid extraction for sample clean-up, *J. Sep. Sci.*, 2015, **38**(11), 1990–1997. PubMed PMID: 25820908. Epub 2015/03/31. eng.

392 K. R. Hande, Etoposide: four decades of development of a topoisomerase II inhibitor, *Eur. J. Cancer*, 1998, **34**(10), 1514–1521.

393 A. Klasen, R. Kessari, L. Mercier, C. Valade, J. Grill, R. Desmaris, *et al.*, Stability of etoposide solutions in disposable infusion devices for day hospital cancer practices, *Drugs R&D*, 2014, **14**(1), 13–23. PubMed PMID: 24627337. Pubmed Central PMCID: PMC3964295. Epub 2014/03/15. eng.

394 A. H. Algan, M. Gumustas, A. Karatas and S. A. Ozkan, A selective and sensitive stability-indicating HPLC method for the validated assay of etoposide from commercial dosage form and polymeric tubular nanocarriers, *J. Pharm. Biomed. Anal.*, 2016, **124**, 382–389. PubMed PMID: 26971031. Epub 2016/03/14. eng.

395 S. Pang, N. Zheng, C. A. Felix, J. Scavuzzo, R. Boston and I. A. Blair, Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients

by liquid chromatography/tandem mass spectrometry, *J. Mass Spectrom.*, 2001, **36**(7), 771–781.

396 B. S. Sachin, I. A. Najar, S. C. Sharma, M. K. Verma, M. V. Reddy, R. Anand, *et al.*, Simultaneous determination of etoposide and a piperine analogue (PA-1) by UPLC–qTOF-MS: Evidence that PA-1 enhances the oral bioavailability of etoposide in mice, *J. Chromatogr., B: Biomed. Appl.*, 2010, **878**(9–10), 823–830.

397 U. B. Soetebeer, M.-O. Schierenberg, H. Schulz, G. Hempel, P. Andresen and G. Blaschke, Simultaneous Quantification of Etoposide and Etoposide Phosphate in Human Plasma by Capillary Electrophoresis Using Laser-Induced Native Fluorescence Detection, *Anal. Chem.*, 2001, **73**(10), 2178–2182.

398 Q. Chen, N. Li, W. Zhang, J. Chen and Z. Chen, Simultaneous determination of vinblastine and its monomeric precursors vindoline and catharanthine in Catharanthus roseus by capillary electrophoresis-mass spectrometry, *J. Sep. Sci.*, 2011, **34**(20), 2885–2892.

399 Q. Chen, W. Zhang, Y. Zhang, J. Chen and Z. Chen, Identification and quantification of active alkaloids inCatharanthus roseus by liquid chromatography–ion trap mass spectrometry, *Food Chem.*, 2013, **139**(1–4), 845–852.

400 M. M. Gupta, D. V. Singh, A. K. Tripathi, R. Pandey, R. K. Verma, S. Singh, *et al.*, Simultaneous Determination of Vincristine, Vinblastine, Catharanthine, and Vindoline in Leaves of Catharanthus roseus by High-Performance Liquid Chromatography, *J. Chromatogr. Sci.*, 2005, **43**(9), 450–453.

401 L. Zhang, Q.-H. Gai, Y.-G. Zu, L. Yang, Y.-L. Ma and Y. Liu, Simultaneous quantitative determination of five alkaloids in Catharanthus roseus by HPLC-ESI-MS/MS, *Chin. J. Nat. Med.*, 2014, **12**(10), 786–793.

402 Z. Liu, H. L. Wu, Y. Li, H. W. Gu, X. L. Yin, L. X. Xie, *et al.*, Rapid and simultaneous determination of five vinca alkaloids in Catharanthus roseus and human serum using trilinear component modeling of liquid chromatography-diode array detection data, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1026**, 114–123. PubMed PMID: 26321366. Epub 2015/09/01. eng.

403 Q. Pan, M. Z. Saiman, N. R. Mustafa, R. Verpoorte and K. Tang, A simple and rapid HPLC-DAD method for simultaneously monitoring the accumulation of alkaloids and precursors in different parts and different developmental stages of Catharanthus roseus plants, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1014**, 10–16. PubMed PMID: 26854826. Epub 2016/02/09. eng.

404 L. Barthe, J.-P. Ribet, M. Pélissou, M.-J. Degude, J. Fahy and A. Duflos, Optimization of the separation of Vinca alkaloids by non-aqueous capillary electrophoresis, *J. Chromatogr. A*, 2002, **968**(1–2), 241–250.

405 S. Achanta, M. Ngo, A. Veitenheimer, L. K. Maxwell and J. R. Wagner, Simultaneous quantification of vinblastine and desacetylvinblastine concentrations in canine plasma and urine samples using LC–APCI–MS/MS, *J. Chromatogr., B: Biomed. Appl.*, 2013, **913–914**, 147–154.

406 T. Cheng, D. Si and C. Liu, Rapid and sensitive LC-MS method for pharmacokinetic study of vinorelbine in rats, *Biomed. Chromatogr.*, 2009, **23**(9), 909–911.

407 G. Corona, B. Casetta, S. Sandron, E. Vaccher and G. Toffoli, Rapid and sensitive analysis of vincristine in human plasma using on-line extraction combined with liquid chromatography/tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2008, **22**(4), 519–525.

408 C. W. N. Damen, H. Rosing, M. M. Tibben, M. J. van Maanen, J. S. Lagas, A. H. Schinkel, *et al.*, A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2008, **868**(1–2), 102–109.

409 J. B. Dennison, J. L. Renbarger, D. O. Walterhouse, D. R. Jones and S. D. Hall, Quantification of Vincristine and its Major Metabolite in Human Plasma by High-Performance Liquid Chromatography/Tandem Mass Spectrometry, *Ther. Drug Monit.*, 2008, **30**(3), 357–364.

410 S. Gao, J. Zhou, F. Zhang, H. Miao, Y. Yun, J. Feng, *et al.*, Rapid and Sensitive Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry Method for the Analysis of Paclitaxel, Docetaxel, Vinblastine, and Vinorelbine in Human Plasma, *Ther. Drug Monit.*, 2014, **36**(3), 394–400.

411 T. Kosjek, T. Dolinšek, D. Gramec, E. Heath, P. Strojan, G. Sersa, *et al.*, Determination of vinblastine in tumour tissue with liquid chromatography–high resolution mass spectrometry, *Talanta*, 2013, **116**, 887–893.

412 C. Lin, J. Cai, X. Yang, L. Hu and G. Lin, Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study, *Biomed. Chromatogr.*, 2014, **29**(1), 97–102.

413 G. Ling, P. Zhang, J. Sun, W. Zhang, Q. Fu, T. Zhang, *et al.*, An LC-MS/MS method for simultaneous determination of vincristine and verapamil in rat plasma after oral administration of a dual agent formulation, *Biomed. Chromatogr.*, 2011, **25**(9), 963–969.

414 M. Niwa and T. Kawashiro, Sensitive measurement of vinorelbine in dog plasma by liquid chromatography-electrospray ionization tandem mass spectrometry utilizing transitions from double-charged precursor ions, *Biomed. Chromatogr.*, 2011, **25**(4), 517–523.

415 H. Pin, L. Hong-min, Y. Ming and L. Qin, A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies, *Biomed. Chromatogr.*, 2011, **26**(7), 797–801.

416 J. Qian, Y. Wang, J. Chang, J. Zhang, J. Wang and X. Hu, Rapid and sensitive determination of vinorelbine in human plasma by liquid chromatography–tandem mass spectrometry and its pharmacokinetic application, *J. Chromatogr., B: Biomed. Appl.*, 2011, **879**(9–10), 662–668.

417 X. Zhao, X. Liu, Y. Wang, J. Zhong, Y. Chen and G. Wang, Determination of vinflunine in rat plasma by liquid chromatography-electrospray ionization mass spec-

trometry for a pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2006, **41**(3), 906–911. PubMed PMID: 16460899. Epub 2006/02/08. eng.

418 R.-H. Zhu, H.-D. Li, H.-L. Cai, Z.-P. Jiang, P. Xu, L.-B. Dai, *et al.*, Validated HILIC–MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2014, **96**, 31–36.

419 G. Zorza, D. Pellerin, V. Fortune and C. Puozzo, A Simple and Sensitive High-Performance Liquid Chromatographic Method for the Determination of Vinflunine and 4-O-Deacetylvinflunine From Human Blood, *Ther. Drug Monit.*, 2010, **32**(6), 734–740.

420 G. Zorza, J. C. Van Heugen, J. De Graeve and C. Puozzo, Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces, *J. Chromatogr., B: Biomed. Appl.*, 2007, **853**(1–2), 294–302.

421 F. Yang, H. Wang, P. Hu and J. Jiang, Validation of an UPLC-MS-MS Method for Quantitative Analysis of Vincristine in Human Urine After Intravenous Administration of Vincristine Sulfate Liposome Injection, *J. Chromatogr. Sci.*, 2015, **53**(6), 974–978. PubMed PMID: 25520304. Epub 2014/12/19. eng.

422 N. Negreira, N. Mastroianni, M. López de Alda and D. Barceló, Multianalyte determination of 24 cytostatics and metabolites by liquid chromatography–electrospray–tandem mass spectrometry and study of their stability and optimum storage conditions in aqueous solution, *Talanta*, 2013, **116**, 290–299.

423 Q.-W. Zhou, D. Wu, Q. Meng, H.-B. Tang, Z.-R. Wei, Y. Kuang, *et al.*, Rapid and Sensitive Detection of Vinorelbine in the Urine of Tumor Patients by Capillary Electrophoresis with Tris(2,2^|^prime; -bipyridyl)ruthenium(II)-based Electrochemiluminescence Assay, *Anal. Sci.*, 2013, **29**(7), 757–760.

424 M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon and A. T. McPhail, Plant antitumor agents, VI, The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, *J. Am. Chem. Soc.*, 1971, **93**(9), 2325–2327.

425 F. Guéritte-Voegelein, V. Sénilh, B. David, D. Guénard and P. Potier, Chemical studies of 10-deacetyl baccatin III, *Tetrahedron*, 1986, **42**(16), 4451–4460.

426 T. Baati, T. Schembri, C. Villard, F. Correard, D. Braguer and M.-A. Estève, An ultrasensitive LC–MS/MS method with liquid phase extraction to determine paclitaxel in both cell culture medium and lysate promising quantification of drug nanocarriers release in vitro, *J. Pharm. Biomed. Anal.*, 2015, **115**, 300–306.

427 S. D. Baker, M. Zhao, P. He, M. A. Carducci, J. Verweij and A. Sparreboom, Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry, *Anal. Biochem.*, 2004, **324**(2), 276–284.

428 P. Colin, L. De Smet, L. De Bock, W. Goeteyn, K. Boussery, C. Vervaet, *et al.*, Enzymatic tumour tissue digestion coupled to SPE–UPLC–Tandem Mass Spectrometry as a tool to explore paclitaxel tumour penetration, *Talanta*, 2014, **129**, 119–125.

429 G. Corona, C. Elia, B. Casetta, S. Frustaci and G. Toffoli, High-throughput plasma docetaxel quantification by liquid chromatography–tandem mass spectrometry, *Clin. Chim. Acta*, 2011, **412**(3–4), 358–364.

430 M. A. Fernández-Peralbo, F. Priego-Capote, M. D. Luque de Castro, A. Casado-Adam, A. Arjona-Sánchez and F. C. Muñoz-Casares, LC–MS/MS quantitative analysis of paclitaxel and its major metabolites in serum, plasma and tissue from women with ovarian cancer after intraperitoneal chemotherapy, *J. Pharm. Biomed. Anal.*, 2014, **91**, 131–137.

431 J. J. M. A. Hendrikx, H. Rosing, A. H. Schinkel, J. H. M. Schellens and J. H. Beijnen, Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS, *Biomed. Chromatogr.*, 2014, **28**(2), 302–310.

432 Q. Huang, G.-J. Wang, J.-G. Sun, X.-L. Hu, Y.-H. Lu and Q. Zhang, Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry, *Rapid Commun. Mass Spectrom.*, 2007, **21**(6), 1009–1018.

433 T. K. Kim, I. S. Kim and H. H. Yoo, Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-beta-cyclodextrin, *Biomed. Chromatogr.*, 2013, **27**(3), 306–310.

434 M. A. Marzinke, A. R. Breaud and W. Clarke, The development and clinical validation of a turbulent-flow liquid chromatography–tandem mass spectrometric method for the rapid quantitation of docetaxel in serum, *Clin. Chim. Acta*, 2013, **417**, 12–18.

435 A. Navarrete, M. P. Martínez-Alcázar, I. Durán, E. Calvo, B. Valenzuela, C. Barbas, *et al.*, Simultaneous online SPE–HPLC–MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma, *J. Chromatogr., B: Biomed. Appl.*, 2013, **921–922**, 35–42.

436 R. Rigo-Bonnin, S. Cobo-Sacristán, N. Gonzalo-Diego, H. Colom, C. Muñoz-Sánchez, A. Urruticoechea, *et al.*, Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography–tandem mass spectrometry, *J. Pharm. Biomed. Anal.*, 2016, **117**, 140–149.

437 H. Yamaguchi, A. Fujikawa, H. Ito, N. Tanaka, A. Furugen, K. Miyamori, *et al.*, A rapid and sensitive LC/ESI–MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study, *J. Chromatogr., B: Biomed. Appl.*, 2012, **893–894**, 157–161.

438 H. Yamaguchi, A. Fujikawa, H. Ito, N. Tanaka, A. Furugen, K. Miyamori, *et al.*, Quantitative determination of paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3′-hydroxypaclitaxel, in human plasma using column-switch-

ing liquid chromatography/tandem mass spectrometry, *Biomed. Chromatogr.*, 2013, **27**(4), 539–544.

439 X. Zhao, K. Bi, X. Wang, X. Xue, B. He, Y. Cui, *et al.*, A UFLC-MS/MS method coupled with one-step protein precipitation for determination of docetaxel in rat plasma: comparative pharmacokinetic study of modified nanostructured lipid carrier, *J. Pharm. Biomed. Anal.*, 2013, **83**, 202–208.

440 J. Wang, Z. Lan, L. Zhang, H. Guo, Z. Liu and Y. Yu, A Rapid and Sensitive UPLC-MS/MS Method for Determination of Docetaxel in Rabbit Plasma: Pharmacokinetic Study of New Lung-Targeting Docetaxel Liposome at Low Dose, *Cell Biochem. Biophys.*, 2015, **73**(3), 623–629. PubMed PMID: 27259303. Epub 2016/06/05. eng.

441 B. Liu, X. Gou, X. Bai, X. Hou, D. Li, G. Zhong, *et al.*, Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts, *J. Pharm. Biomed. Anal.*, 2015, **107**, 346–354. PubMed PMID: 25645339. Epub 2015/02/04. eng.

442 C. A. Crutchfield, M. A. Marzinke and W. A. Clarke, Quantification of Docetaxel in Serum Using Turbulent Flow Liquid Chromatography Electrospray Tandem Mass Spectrometry (TFC-HPLC-ESI-MS/MS), *Methods Mol. Biol.*, 2016, **1383**, 121–124. PubMed PMID: 26660181. Epub 2015/12/15. eng.

443 H. Choudhury, B. Gorain, S. Karmakar and T. K. Pal, Development and validation of RP-HPLC method: scope of application in the determination of oil solubility of paclitaxel, *J. Chromatogr. Sci.*, 2014, **52**(1), 68–74.

444 S. Kollipara, G. Bende and R. N. Saha, Rapid and sensitive liquid chromatographic method for determination of paclitaxel from parenteral formulation and nanoparticles, *Indian J. Pharm. Sci.*, 2010, **72**(4), 465.

445 A. Mohammadi, F. Esmaeili, R. Dinarvand, F. Atyabi and R. B. Walker, Development and Validation of a Stability-Indicating Method for the Quantitation of Paclitaxel in Pharmaceutical Dosage Forms, *J. Chromatogr. Sci.*, 2009, **47**(7), 599–604.

446 M. Suno, T. Ono, S. Iida, N. Umetsu, K. Ohtaki, T. Yamada, *et al.*, Improved high-performance liquid chromatographic detection of paclitaxel in patient's plasma using solid-phase extraction, and semi-micro-bore C18 separation and UV detection, *J. Chromatogr., B: Biomed. Appl.*, 2007, **860**(1), 141–144.

447 R. K. Tekade, Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples, *J. Biomed. Res*, 2013, **27**(5), 394–405.

448 J. Thiesen and I. Krämer, Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers, *Pharm. World Sci.*, 1999, **21**(3), 137–141.

449 V. K. Venishetty, N. Parikh, R. Sistla, F. J. Ahmed and P. V. Diwan, Application of Validated RP-HPLC Method for Simultaneous Determination of Docetaxel and Ketoconazole in Solid Lipid Nanoparticles, *J. Chromatogr. Sci.*, 2011, **49**(2), 136–141.

450 J. Vial, M. Cohen, P. Sassiat and D. Thiébaut, Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis, *Curr. Med. Res. Opin.*, 2008, **24**(7), 2019–2033.

451 Y. Wei, Z. Xue, Y. Ye, P. Wang, Y. Huang and L. Zhao, Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation, *Biomed. Chromatogr.*, 2014, **28**(2), 204–212.

452 I. Khan, Z. Iqbal, A. Khan, M. Hassan, F. Nasir, A. Raza, *et al.*, A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1033–1034**, 261–270. PubMed PMID: 27592284. Epub 2016/09/07. eng.

453 E. Saadat, F. Ravar, P. Dehghankelishadi and F. A. Dorkoosh, Development and Validation of a Rapid RP-HPLC-DAD Analysis Method for the Simultaneous Quantitation of Paclitaxel and Lapatinib in a Polymeric Micelle Formulation, *Sci. Pharm.*, 2016, **84**(2), 333–345. PubMed PMID: 27222608. Pubmed Central PMCID: PMC4871185. Epub 2016/05/26. eng.

454 G. Hempel, D. Lehmkuhl, S. Krümpelmann, G. Blaschke and J. Boos, Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography, *J. Chromatogr. A*, 1996, **745**(1–2), 173–179.

455 S. Boutayeb, F. Z. Zakkouri, M. Aitelhaj, M. Mesmoudi, A. Boutayeb, W. Boutayeb, *et al.*, Bilan des inhibiteurs de protéine tyrosine kinase dans le traitement des cancers, *Pathol. Biol.*, 2012, **60**(4), 229–233.

456 M. Miura and N. Takahashi, Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods, *Drug Metab. Pharmacokinet.*, 2016, **31**(1), 12–20. PubMed PMID: 26732608. Epub 2016/01/07. eng.

457 Y. Hsieh, G. Galviz, Q. Zhou and C. Duncan, Hydrophilic interaction liquid chromatography/tandemmass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma, *Rapid Commun. Mass Spectrom.*, 2009, **23**(9), 1364–1370.

458 R. L. Oostendorp, J. H. Beijnen, J. H. M. Schellens and O. v Tellingen, Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography, *Biomed. Chromatogr.*, 2007, **21**(7), 747–754.

459 P. de Bruijn, S. Sleijfer, M.-H. Lam, R. H. J. Mathijssen, E. A. C. Wiemer and W. J. Loos, Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry, *J. Pharm. Biomed. Anal.*, 2010, **51**(4), 934–941.

460 N. A. G. Lankheet, N. Steeghs, H. Rosing, J. H. M. Schellens, J. H. Beijnen and A. D. R. Huitema,

Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry, *Ther. Drug Monit.*, 2013, **35**(2), 168–176.

461 L. Couchman, M. Birch, R. Ireland, A. Corrigan, S. Wickramasinghe, D. Josephs, *et al.*, An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry, *Anal. Bioanal. Chem.*, 2012, **403**(6), 1685–1695.

462 J. Klawitter, Y. L. Zhang, J. Klawitter, N. Anderson, N. J. Serkova and U. Christians, Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture, *Biomed. Chromatogr.*, 2009, **23**(12), 1251–1258.

463 S. Pursche, O. G. Ottmann, G. Ehninger and E. Schleyer, High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations, *J. Chromatogr., B: Biomed. Appl.*, 2007, **852**(1–2), 208–216.

464 I. Garrido-Cano, A. García-García, J. Peris-Vicente, E. Ochoa-Aranda and J. Esteve-Romero, A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines, *Talanta*, 2015, **144**, 1287–1295.

465 M. G. Kassem, E. Ezzeldin, H. M. Korashy and G. A. E. Mostafa, High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study, *J. Chromatogr., B: Biomed. Appl.*, 2013, **939**, 73–79.

466 D. Ivanovic, M. Medenica, B. Jancic and A. Malenovic, Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec® capsules, *J. Chromatogr., B: Biomed. Appl.*, 2004, **800**(1–2), 253–258.

467 M. Medenica, B. Jancic, D. Ivanovic and A. Malenovic, Experimental design in reversed-phase high-performance liquid chromatographic analysis of imatinib mesylate and its impurity, *J. Chromatogr. A*, 2004, **1031**(1–2), 243–248.

468 A. Nageswari, K. V. S. R. K. Reddy and K. Mukkanti, Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms, *J. Pharm. Biomed. Anal.*, 2012, **66**, 109–115.

469 W. J. Szczepek, B. Kosmacińska, A. Bielejewska, W. Łuniewski, M. Skarzyński and D. Rozmarynowska, Identification of imatinib mesylate degradation products obtained under stress conditions, *J. Pharm. Biomed. Anal.*, 2007, **43**(5), 1682–1691.

470 V. V. Vivekanand, D. Sreenivas Rao, G. Vaidyanathan, N. M. Sekhar, S. Avijit Kelkar and P. Ramachandra Puranik, A validated LC method for imatinib mesylate, *J. Pharm. Biomed. Anal.*, 2003, **33**(5), 879–889.

471 L. Ye, Y. Huang, J. Li, G. Xiang and L. Xu, Non-aqueous capillary electrophoresis of imatinib mesylate and related substances, *J. Sep. Sci.*, 2012, **35**(16), 2108–2113.

472 A. Awidi, I. I. Salem, N. Najib, R. Mefleh and B. Tarawneh, Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison, *Leuk. Res.*, 2010, **34**(6), 714–717.

473 G. Bende, S. Kollipara, S. Movva, G. Moorthy and R. Saha, Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study, *J. Chromatogr. Sci.*, 2010, **48**(5), 334–341.

474 M. Birch, P. E. Morgan, S. Handley, A. Ho, R. Ireland and R. J. Flanagan, Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib, *Biomed. Chromatogr.*, 2013, **27**(3), 335–342.

475 A. Davies, A. K. Hayes, K. Knight, S. J. Watmough, M. Pirmohamed and R. E. Clark, Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography, *Leuk. Res.*, 2010, **34**(6), 702–707.

476 A.-A. Golabchifar, M.-R. Rouini, B. Shafaghi, S. Rezaee, A. Foroumadi and M.-R. Khoshayand, Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design, *Talanta*, 2011, **85**(5), 2320–2329.

477 G. Guetens, H. Prenen, G. De Boeck, A. van Oosterom, P. Schöffski, M. Highley, *et al.*, Simultaneous determination of AMN107 and Imatinib (Gleevec®, Glivec®, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection, *J. Chromatogr., B: Biomed. Appl.*, 2007, **846**(1–2), 341–345.

478 M. Miura, N. Takahashi and K. I. Sawada, Quantitative Determination of Imatinib in Human Plasma with High-Performance Liquid Chromatography and Ultraviolet Detection, *J. Chromatogr. Sci.*, 2011, **49**(5), 412–415.

479 E. Pirro, S. De Francia, F. De Martino, S. Racca, F. Di Carlo, C. Fava, *et al.*, A New HPLC-UV Validated Method for Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Leukemic Patients, *J. Chromatogr. Sci.*, 2011, **49**(10), 753–757.

480 O. Roth, O. Spreux-Varoquaux, S. Bouchet, P. Rousselot, S. Castaigne, S. Rigaudeau, *et al.*, Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS, *Clin. Chim. Acta*, 2010, **411**(3–4), 140–146.

481 E. Schleyer, S. Pursche, C. Kohne, U. Schuler, U. Renner, H. Gschaidmeier, *et al.*, Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations, *J. Chromatogr., B: Biomed. Appl.*, 2004, **799**(1), 23–36.

482 K. L. Tan, R. Ankathil and S. H. Gan, Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection, *J. Chromatogr., B: Biomed. Appl.*, 2011, **879**(30), 3583–3591.

483 M. Teoh, P. Narayanan, K. S. Moo, S. Radhakrisman, R. Pillappan, N. I. Bukhari, *et al.*, HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice, *Pak. J. Pharm. Sci.*, 2010, **23**(1), 35–41.

484 T. Velpandian, R. Mathur, N. K. Agarwal, B. Arora, L. Kumar and S. K. Gupta, Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples, *J. Chromatogr., B: Biomed. Appl.*, 2004, **804**(2), 431–434.

485 N. Widmer, A. Béguin, B. Rochat, T. Buclin, T. Kovacsovics, M. A. Duchosal, *et al.*, Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection, *J. Chromatogr., B: Biomed. Appl.*, 2004, **803**(2), 285–292.

486 I. Andriamanana, I. Gana, B. Duretz and A. Hulin, Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS, *J. Chromatogr., B: Biomed. Appl.*, 2013, **926**, 83–91.

487 C. Arellano, P. Gandia, T. Lafont, R. Jongejan and E. Chatelut, Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC–MS/MS assay and ultrafiltration method, *J. Chromatogr., B: Biomed. Appl.*, 2012, **907**, 94–100.

488 R. Bakhtiar, L. Khemani, M. Hayes, T. Bedman and F. Tse, Quantification of the anti-leukemia drug STI571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry, *J. Pharm. Biomed. Anal.*, 2002, **28**(6), 1183–1194.

489 R. Bakhtiar, J. Lohne, L. Ramos, L. Khemani, M. Hayes and F. Tse, High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2002, **768**(2), 325–340.

490 F. Bianchi, E. Caffarri, S. Cavalli, C. Lagrasta, M. Musci, F. Quaini, *et al.*, Development and validation of an high performance liquid chromatography–tandem mass spectrometry method for the determination of imatinib in rat tissues, *J. Pharm. Biomed. Anal.*, 2013, **73**, 103–107.

491 S. Bouchet, E. Chauzit, D. Ducint, N. Castaing, M. Canal-Raffin, N. Moore, *et al.*, Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS, *Clin. Chim. Acta*, 2011, **412**(11–12), 1060–1067.

492 A. Chahbouni, J. C. G. den Burger, R. M. Vos, A. Sinjewel and A. J. Wilhelm, Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry, *Ther. Drug Monit.*, 2009, **31**(6), 683–687.

493 A. D'Avolio, M. Simiele, S. De Francia, A. Ariaudo, L. Baietto, J. Cusato, *et al.*, HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC), *J. Pharm. Biomed. Anal.*, 2012, **59**, 109–116.

494 S. De Francia, A. D'Avolio, F. De Martino, E. Pirro, L. Baietto, M. Siccardi, *et al.*, New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(18–19), 1721–1726.

495 L. Götze, A. Hegele, S. K. Metzelder, H. Renz and W. A. Nockher, Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma, *Clin. Chim. Acta*, 2012, **413**(1–2), 143–149.

496 G. Guetens, G. De Boeck, M. Highley, H. Dumez, A. T. Van Oosterom and E. A. de Bruijn, Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometry, *J. Chromatogr. A*, 2003, **1020**(1), 27–34.

497 A. Haouala, B. Zanolari, B. Rochat, M. Montemurro, K. Zaman, M. A. Duchosal, *et al.*, Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(22), 1982–1996.

498 Z. Iqbal, M. Elliott, D. G. Watson, T. Holyoake and H. Jørgensen, Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS, *Pak. J. Pharm. Sci.*, 2011, **24**(3), 285–291.

499 J.-F. Jourdil, J. Tonini and F. Stanke-Labesque, Simultaneous quantitationof azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography–tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2013, **919–920**, 1–9.

500 N. A. G. Lankheet, M. J. X. Hillebrand, H. Rosing, J. H. M. Schellens, J. H. Beijnen and A. D. R. Huitema, Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry, *Biomed. Chromatogr.*, 2013, **27**(4), 466–476.

501 M. Marull and B. Rochat, Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography–triple-quadrupole and linear ion

trap mass spectrometers, *J. Mass Spectrom.*, 2006, **41**(3), 390–404.

502 K. Mičová, D. Friedecký, E. Faber, A. Polýnková and T. Adam, Flow injection analysis vs, ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma, *Clin. Chim. Acta*, 2010, **411**(23–24), 1957–1962.

503 J. M. Moreno, A. Wojnicz, J. L. Steegman, M. F. Cano-Abad and A. Ruiz-Nuño, Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma, *Biomed. Chromatogr.*, 2013, **27**(4), 502–508.

504 R. A. Parise, R. K. Ramanathan, M. J. Hayes and M. J. Egorin, Liquid chromatographic–mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma, *J. Chromatogr., B: Biomed. Appl.*, 2003, **791**(1–2), 39–44.

505 F. Streit, L. Binder, A. Hafke, G. Brandhorst, F. Braulke, D. Haase, *et al.*, Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients, *Ther. Drug Monit.*, 2011, **33**(5), 632–643.

506 K. Titier, S. p Picard, D. Ducint, E. Teilhet, N. Moore, P. Berthaud, *et al.*, Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry, *Ther. Drug Monit.*, 2005, **27**(5), 634–640.

507 N. P. van Erp, D. de Wit, H.-J. Guchelaar, H. Gelderblom, T. J. Hessing and J. d Hartigh, A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2013, **937**, 33–43.

508 M. Zhang, G. A. Moore, L. J. Fernyhough, M. L. Barclay and E. J. Begg, Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry, *Anal. Bioanal. Chem.*, 2012, **404**(6–7), 2091–2096.

509 Y. Zhang, S. Qiang, Z. Yu, W. Zhang, Z. Xu, L. Yang, *et al.*, LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma, *J. Chromatogr. Sci.*, 2014, **52**(4), 344–350.

510 M. Herbrink, N. de Vries, H. Rosing, A. D. Huitema, B. Nuijen, J. H. Schellens, *et al.*, Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry, *Ther. Drug Monit.*, 2016, **38**(6), 649–656. PubMed PMID: 27749781. Epub 2016/10/18. eng.

511 A. S. Abdelhameed, M. W. Attwa and A. A. Kadi, An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma, *Biomed. Chromatogr.*, 2017, **31**(2), DOI: 10.1002/bmc.3793. PubMed PMID: 27450926. Epub 2016/07/28. eng.

512 C. Qi, Q. Cai, P. Zhao, X. Jia, N. Lu, L. He, *et al.*, The metal-organic framework MIL-101(Cr) as efficient adsorbent in a vortex-assisted dispersive solid-phase extraction of imatinib mesylate in rat plasma coupled with ultra-performance liquid chromatography/mass spectrometry: Application to a pharmacokinetic study, *J. Chromatogr. A*, 2016, **1449**, 30–38. PubMed PMID: 27139217. Epub 2016/05/04. eng.

513 T. O. Ajimura, K. B. Borges, A. F. Ferreira, F. A. de Castro and C. M. de Gaitani, Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients, *Electrophoresis*, 2011, **32**(14), 1885–1892.

514 A. Elhamili and J. Bergquist, A method for quantitative analysis of an anticancer drug in human plasma with CE-ESI-TOF-MS, *Electrophoresis*, 2011, **32**(13), 1778–1785.

515 A. G. Gonzalez, L. Taraba, J. Hranicek, P. Kozlik and P. Coufal, Determination of dasatinib in the tablet dosage form by ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis, *J. Sep. Sci.*, 2017, **40**(2), 400–406. PubMed PMID: 27805766. Epub 2016/11/03. eng.

516 M. Dziadosz, R. Lessig and H. Bartels, HPLC–DAD protein kinase inhibitor analysis in human serum, *J. Chromatogr., B: Biomed. Appl.*, 2012, **893–894**, 77–81.

517 R. Nakahara, Y. Satho and H. Itoh, High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry, *J. Clin. Lab. Anal.*, 2016, **30**(6), 1028–1030. PubMed PMID: 27194024. Epub 2016/10/30. eng.

518 S. X. Xiang, H. L. Wu, C. Kang, L. X. Xie, X. L. Yin, H. W. Gu, *et al.*, Fast quantitative analysis of four tyrosine kinase inhibitors in different human plasma samples using three-way calibration-assisted liquid chromatography with diode array detection, *J. Sep. Sci.*, 2015, **38**(16), 2781–2788. PubMed PMID: 26017356. Epub 2015/05/29. eng.

519 M. T. Furlong, S. Agrawal, D. Hawthorne, M. Lago, S. Unger, L. Krueger, *et al.*, A validated LC–MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2012, **58**, 130–135.

520 S. Roche, G. McMahon, M. Clynes and R. O'Connor, Development of a high-performance liquid chromatographic–mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib, *J. Chromatogr., B: Biomed. Appl.*, 2009, **877**(31), 3982–3990.

521 S. B. Kondra, V. Madireddy, M. Chilukuri, N. Papadasu and L. Jonnalagadda, A validated stability-indicative UPLC method for nilotinib hydrochloride for the determination

of process-related and degradation impurities, *J. Chromatogr. Sci.*, 2014, **52**(8), 880–885.

522 M. Miura, N. Takahashi and K.-i Sawada, High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma, *Biomed. Chromatogr.*, 2010, **24**(7), 789–793.

523 M. Yuki, Y. Yamakawa, T. Uchida, T. Nambu, T. Kawaguchi, A. Hamada, *et al.*, High-Performance Liquid Chromatographic Assay for the Determination of Nilotinib in Human Plasma, *Biol. Pharm. Bull.*, 2011, **34**(7), 1126–1128.

524 R. A. Parise, M. J. Egorin, S. M. Christner, D. D. Shah, W. Zhou and J. H. Beumer, A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(20–21), 1894–1900.

525 S. Veeraraghavan, S. Thappali, S. Viswanadha, S. Chennupati, S. Nalla, M. Golla, *et al.*, Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC–MS/MS: Application to a pharmacokinetic study, *J. Pharm. Biomed. Anal.*, 2014, **94**, 125–131.

526 K. K. Kumar, K. E. V. Nagoji and R. V. Nadh, A Validated RP-HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard, *Indian J. Pharm. Sci.*, 2012, **74**(6), 580–583.

527 E. Saadat, P. Dehghan Kelishady, F. Ravar, F. Kobarfard and F. A. Dorkoosh, Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products, *J. Chromatogr. Sci.*, 2015, **53**(6), 932–939.

528 V. Escudero-Ortiz, J. J. Pérez-Ruixo and B. Valenzuela, Development and Validation of a High-Performance Liquid Chromatography Ultraviolet Method for Lapatinib Quantification in Human Plasma, *Ther. Drug Monit.*, 2013, **35**(6), 796–802.

529 M. Ohgami, M. Homma, Y. Suzuki, K. Naito, M. Yamada, S. Mitsuhashi, *et al.*, A Simple High-Performance Liquid Chromatography for Determining Lapatinib and Erlotinib in Human Plasma, *Ther. Drug Monit.*, 2016, **38**(6), 657–662. PubMed PMID: 27851685. Epub 2016/11/17. eng.

530 F. Bai, B. B. Freeman Iii, C. H. Fraga, M. Fouladi and C. F. Stewart, Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC–ESI-MS/MS), *J. Chromatogr., B: Biomed. Appl.*, 2006, **831**(1–2), 169–175.

531 J. Musijowski, M. Filist and P. J. Rudzki, Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma, *Acta Pol. Pharm.*, 2014, **71**(6), 1029–1036.

532 C. Karunakara, U. Aparna, V. Chandregowda and C. G. Reddy, Separation and Determination of Process-Related Impurities of Erlotinib Using Reverse-Phase HPLC with a Photo-Diode Array Detector, *Anal. Sci.*, 2012, **28**(3), 305.

533 L. Faivre, C. Gomo, O. Mir, F. Taieb, A. Schoemann-Thomas, S. Ropert, *et al.*, A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma, *J. Chromatogr., B: Biomed. Appl.*, 2011, **879**(23), 2345–2350.

534 E. R. Lepper, S. M. Swain, A. R. Tan, W. D. Figg and A. Sparreboom, Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor, *J. Chromatogr., B: Biomed. Appl.*, 2003, **796**(1), 181–188.

535 W. Zhang, L. L. Siu, M. J. Moore and E. X. Chen, Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2005, **814**(1), 143–147.

536 Y. Zhen, A. Thomas-Schoemann, L. Sakji, P. Boudou-Rouquette, N. Dupin, L. Mortier, *et al.*, An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients, *J. Chromatogr., B: Biomed. Appl.*, 2013, **928**, 93–97.

537 R. Honeywell, K. Yarzadah, E. Giovannetti, N. Losekoot, E. F. Smit, M. Walraven, *et al.*, Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2010, **878**(15–16), 1059–1068.

538 T. Ishida, T. Naito and J. Kawakami, Simultaneous determination of erlotinib and its isomeric major metabolites in human plasma using isocratic liquid chromatography-tandem mass spectrometry and its clinical application, *Biomed. Chromatogr.*, 2014, **29**(5), 643–646.

539 N. A. G. Lankheet, E. E. Schaake, H. Rosing, J. A. Burgers, J. H. M. Schellens, J. H. Beijnen, *et al.*, Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue, *Bioanalysis*, 2012, **4**(21), 2563–2577.

540 A. R. Masters, C. J. Sweeney and D. R. Jones, The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2007, **848**(2), 379–383.

541 A. Svedberg, H. Gréen, A. Vikström, J. Lundeberg and S. Vikingsson, A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma, *J. Pharm. Biomed. Anal.*, 2015, **107**, 186–195.

542 S. R. S. Thappali, Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid Chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation, *Sci. Pharm.*, 2012, **80**(3), 633–646.

543 M. Zhao, P. He, M. A. Rudek, M. Hidalgo and S. D. Baker, Specific method for determination of OSI-774 and its metaboliteOSI-420 in human plasma by using liquid chromatography–tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2003, **793**(2), 413–420.

544 H. Hayashi, Y. Kita, H. Iihara, K. Yanase, Y. Ohno, C. Hirose, *et al.*, Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer, *Biomed. Chromatogr.*, 2016, **30**(7), 1150–1154. PubMed PMID: 26525154. Epub 2015/11/04. eng.

545 R. W. Sparidans, H. Rosing, J. J. Rood, J. H. Schellens and J. H. Beijnen, Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1033–1034**, 390–398. PubMed PMID: 27639128. Epub 2016/09/18. eng.

546 H. M. Maher, N. Z. Alzoman and S. M. Shehata, Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2016, **1028**, 100–110. PubMed PMID: 27336702. Epub 2016/06/24. eng.

547 H. M. Maher, N. Z. Alzoman and S. M. Shehata, Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies, *J. Pharm. Biomed. Anal.*, 2016, **124**, 216–227. PubMed PMID: 26966895. Epub 2016/03/12. eng.

548 J. Rodríguez, G. Castañeda, L. Muñoz, D. Navarro and J. C. Villa, Simultaneous determination of erlotinib and metabolites in human urine using capillary electrophoresis, *Electrophoresis*, 2014, **35**(10), 1489–1495.

549 F. Navid, R. Christensen, P. Minkin, C. F. Stewart, W. L. Furman and S. Baker, Stability of Sunitinib in Oral Suspension, *Ann. Pharmacother.*, 2008, **42**(7), 962–966.

550 B. Blanchet, C. Saboureau, A. S. Benichou, B. Billemont, F. Taieb, S. Ropert, *et al.*, Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma, *Clin. Chim. Acta*, 2009, **404**(2), 134–139.

551 M.-C. Etienne-Grimaldi, N. Renée, H. Izzedine and G. Milano, A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma, *J. Chromatogr., B: Biomed. Appl.*, 2009, **877**(29), 3757–3761.

552 X. Chen, Z. Wang, M. Liu, M. Liao, X. Wang, H. Du, *et al.*, Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies, *Biomed. Chromatogr.*, 2015, **29**(5), 679–688.

553 N. A. G. Lankheet, C. U. Blank, H. Mallo, S. Adriaansz, H. Rosing, J. H. M. Schellens, *et al.*, Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient, *J. Anal. Toxicol.*, 2011, **35**(8), 558–565.

554 P. Minkin, M. Zhao, Z. Chen, J. Ouwerkerk, H. Gelderblom and S. Baker, Quantification of sunitinib in human plasma by high-performance liquid chromatography–tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2008, **874**(1–2), 84–88.

555 J. Musijowski, E. Piórkowska and P. J. Rudzki, Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry, *J. Sep. Sci.*, 2014, **37**(19), 2652–2658.

556 R. K. Oberoi, R. K. Mittapalli, J. Fisher and W. F. Elmquist, Sunitinib LC–MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies, *Chromatographia*, 2013, **76**(23–24), 1657–1665.

557 F. Qiu, W. Bian, J. Li and Z. Ge, Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry, *Biomed. Chromatogr.*, 2012, **27**(5), 615–621.

558 R. Rais, M. Zhao, P. He, L. Xu, J. F. Deeken and M. A. Rudek, Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study, *Biomed. Chromatogr.*, 2012, **26**(11), 1315–1324.

559 Q. Zhou and J. M. Gallo, Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography–electrospray ionization-tandem mass spectrometry and pharmacokinetic application, *J. Pharm. Biomed. Anal.*, 2010, **51**(4), 958–964.

560 J. Rodríguez, G. Castañeda, L. Muñoz and J. C. Villa, Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by non-aqueous capillary electrophoresis time of flight mass spectrometry, *Electrophoresis*, 2015, **36**(14), 1580–1587.

561 A. S. Ivanov, Synthesis and Characterization of Organic Impurities in Bortezomib Anhydride Produced by a Convergent Technology, *Sci. Pharm.*, 2012, **80**(1), 67–75.

562 P. André, S. Cisternino, F. Chiadmi, A. Toledano, J. Schlatter, O. Fain, *et al.*, Stability of bortezomib 1 mg/mL solution in plastic syringe and glass vial, *Ann. Pharmacother.*, 2005, **39**(9), 1462–1466.

563 S. R. Byrn, P. A. Tishmack, M. J. Milton and H. van de Velde, Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile, *AAPS PharmSciTech*, 2011, **12**(2), 461–467.

564 J. P. Vanderloo, M. L. Pomplun, L. C. Vermeulen and J. M. Kolesar, Stability of unused reconstituted bortezo-

mib in original manufacturer vials, *J. Oncol. Pharm. Pract.*, 2011, **17**(4), 400–402.

565 J. Clemens, M. Longo, A. Seckinger, D. Hose, W. E. Haefeli, J. Weiss, *et al.*, Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry, *J. Chromatogr. A*, 2014, **1345**, 128–138.

566 D. R. Jones, Z. Wu, D. Chauhan, K. C. Anderson and J. Peng, A Nano Ultra-Performance Liquid Chromatography–High Resolution Mass Spectrometry Approach for Global Metabolomic Profiling and Case Study on Drug-Resistant Multiple Myeloma, *Anal. Chem.*, 2014, **86**(7), 3667–3675.

567 Z. Islambulchilar, S. Ghanbarzadeh, S. Emami, H. Valizadeh and P. Zakeri-Milani, Development and validation of an HPLC method for the analysis of sirolimus in drug products, *Adv. Pharm. Bull.*, 2012, **2**(2), 135–139.

568 M. Kamberi, K. Fu, J. Lu, G. M. Chemaly and D. Feder, A sensitive high-throughput HPLC assay for simultaneous determination of everolimus and clobetasol propionate, *J. Chromatogr. Sci.*, 2008, **46**(1), 23–29.

569 S. Poujol, F. Bressolle, I. Solassol and F. Pinguet, Stability of ready-to-use temsirolimus infusion solution (100 mg/L) in polypropylene containers under different storage conditions, *Ann. Pharm. Fr.*, 2012, **70**(3), 155–162.

570 M. Ricciutelli, P. Di Martino, L. Barboni and S. Martelli, Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC, *J. Pharm. Biomed. Anal.*, 2006, **41**(3), 1070–1074.

571 M. Korecka and L. M. Shaw, Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice, *Ann. Transplant.*, 2009, **14**(2), 61–72.

572 P. J. Taylor, Therapeutic Drug Monitoring of Immunosuppressant Drugs by High-Performance Liquid Chromatography–Mass Spectrometry, *Ther. Drug Monit.*, 2004, **26**(2), 215–219.

573 P. J. Taylor, C.-H. Tai, M. E. Franklin and P. I. Pillans, The current role of liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressant and antiretroviral drugs, *Clin. Biochem.*, 2011, **44**(1), 14–20.

574 Z. Yang and S. Wang, Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants, *J. Immunol. Methods*, 2008, **336**(2), 98–103.

575 D. W. Holt, T. Lee and A. Johnston, Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection, *Clin. Ther.*, 2000, **22**, B38–B48.

576 L. Alberto Pini, D. Gallesi, D. Brovia, A. Bertolini, D. Pinetti, V. Ruggieri, *et al.*, Switching from HPLC/UV to MEIA for whole blood sirolimus quantitation: comparison of methods, *J. Clin. Lab. Anal.*, 2006, **20**(6), 239–244.

577 S. Becker, J. Thiery and U. Ceglarek, Evaluation of a Novel Commercial Assay for the Determination of Cyclosporine A, Tacrolimus, Sirolimus, and Everolimus by Liquid Chromatography–Tandem Mass Spectrometric Assay, *Ther. Drug Monit.*, 2013, **35**(1), 129–132.

578 L. Bouzas, J. Hermida and J. C. Tutor, Determination of blood sirolimus concentrations in liver and kidney transplant recipients using the Innofluor® fluorescence polarization immunoassay: Comparison with the microparticle enzyme immunoassay and high-performance liquid chromatography-ultraviolet method, *Upsala J. Med. Sci.*, 2009, **114**(1), 55–61.

579 E. Dailly, G. Deslandes, M. Hourmant, T. Petit, C. Renaud, M. Treilhaud, *et al.*, Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations, *J. Clin. Lab. Anal.*, 2008, **22**(4), 282–285.

580 D. W. Holt, D. A. McKeown, T. D. Lee, D. Hicks, P. Cal and A. Johnston, The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection, *Transplant. Proc.*, 2004, **36**(10), 3223–3225.

581 S. Maleki, S. Graves, S. Becker, R. Horwatt, D. Hicks, R. M. Stroshane, *et al.*, Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography, *Clin. Ther.*, 2000, **22**, B25–B37.

582 N. Mano, M. Sato, M. Nozawa, Y. Matsumoto, M. Mori, H. Yamaguchi, *et al.*, An accurate quantitative LC/ESI–MS/MS method for sirolimus in human whole blood, *J. Chromatogr., B: Biomed. Appl.*, 2011, **879**(13–14), 987–992.

583 D. J. A. R. Moes, R. R. Press, J. W. de Fijter, H.-J. Guchelaar and J. den Hartigh, Liquid Chromatography-Tandem Mass Spectrometry Outperforms Fluorescence Polarization Immunoassay in Monitoring Everolimus Therapy in Renal Transplantation, *Ther. Drug Monit.*, 2010, **32**(4), 413–419.

584 P. Salm, P. J. Taylor and P. I. Pillans, The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients, *Clin. Ther.*, 2000, **22**, B71–B85.

585 F. B. Vicente, F. A. Smith, Y. Peng and S. Wang, Evaluation of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatography/tandem mass spectrometry, *Clin. Chem. Lab. Med.*, 2006, **44**(4), 497–499.

586 D. Żochowska, I. Bartłomiejczyk, A. Kamińska, G. Senatorski and L. Pączek, High-Performance Liquid Chromatography Versus Immunoassay for the Measurement of Sirolimus: Comparison of Two Methods, *Transplant. Proc.*, 2006, **38**(1), 78–80.

587 K. L. Johnson-Davis, J. M. Juenke, R. L. Thomas and T. Bradshaw, Everolimus method comparison between Waters MassTrak Immunosuppressants XE (IUO) kit and an in-house laboratory developed LC-MS/MS method in

renal transplant patients, *Ann. Clin. Lab. Sci.*, 2015, **45**(1), 27–31. PubMed PMID: 25696007. Epub 2015/02/20. eng.

588 D. Buthiau, A. S. Bargnoux, S. Badiou, T. Sutra, A. M. Dupuy, G. P. Pageaux, *et al.*, Evaluation of QMS everolimus assay using Indiko analyzer: comparison with an ultra-performance liquid chromatography-tandem mass spectrometry method, *Ther. Drug Monit.*, 2015, **37**(2), 275–278. PubMed PMID: 25254414. Epub 2014/09/26. eng.

589 S. Baldelli, S. Murgia, S. Merlini, S. Zenoni, N. Perico, G. Remuzzi, *et al.*, High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus, *J. Chromatogr., B: Biomed. Appl.*, 2005, **816**(1–2), 99–105.

590 S. Baldelli, S. Zenoni, S. Merlini, N. Perico and D. Cattaneo, Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection, *Clin. Chim. Acta*, 2006, **364**(1–2), 354–358.

591 T. Y. Boudennaia and K. L. Napoli, Validation of a Practical Liquid Chomatography With Ultraviolet Detection Method for Quantification of Whole-Blood Everolimus in a Clinical TDM Laboratory, *Ther. Drug Monit.*, 2005, **27**(2), 171–177.

592 M. A. Campanero, E. Cardenas, B. Sádaba, E. García-Quetglas, M. J. Muñoz-Juarez, I. Gil-Aldea, *et al.*, Therapeutic drug monitoring for sirolimus in whole blood of organ transplants by high-performance liquid chromatography with ultraviolet detection, *J. Chromatogr. A*, 2004, **1031**(1–2), 265–273.

593 D. Cattaneo, N. Perico and F. Gaspari, Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection, *J. Chromatogr., B: Biomed. Appl.*, 2002, **774**(2), 187–194.

594 E. Connor, M. Sakamoto, K. Fujikawa, T. Law and N. Rifai, Measurement of Whole Blood Sirolimus by an HPLC Assay Using Solid-Phase Extraction and UV Detection, *Ther. Drug Monit.*, 2002, **24**(6), 751–756.

595 G. S. Di Marco, M. C. Camargo de Andrade, C. R. Felipe, F. Alfieri, A. Gooding, H. T. Silva Júnior, *et al.*, Determination of Sirolimus Blood Concentration Using High-Performance Liquid Chromatography with Ultraviolet Detection, *Ther. Drug Monit.*, 2003, **25**(5), 558–564.

596 K. L. Napoli, A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection, *Clin. Ther.*, 2000, **22**, B14–B24.

597 K. L. Napoli and B. D. Kahan, Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1994, **654**(1), 111–120.

598 N. Ansermot, M. Fathi, J.-L. Veuthey, J. Desmeules, S. Rudaz and D. Hochstrasser, Simultaneous quantification of cyclosporine, tacrolimus, sirolimus and everolimus in whole blood by liquid chromatography–electrospray mass spectrometry, *Clin. Biochem.*, 2008, **41**(9), 728–735.

599 A. Buchwald, K. Winkler and T. Epting, Validation of an LC-MS/MS method to determine five immunosuppressants with deuterated internal standards including MPA, *BMC Clin. Pharmacol.*, 2012, **12**(1), 2.

600 U. Ceglarek, J. Lembcke, G. Martin Fiedler, M. Werner, H. Witzigmann, J. Peter Hauss, *et al.*, Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry, *Clin. Chim. Acta*, 2004, **346**(2), 181–190.

601 U. Christians, W. Jacobsen, N. Serkova, L. Z. Benet, C. Vidal, K.-F. Sewing, *et al.*, Automated, fast and sensitive quantification of drugs in blood by liquid chromatography–mass spectrometry with on-line extraction: immunosuppressants, *J. Chromatogr. B: Biomed. Sci. Appl.*, 2000, **748**(1), 41–53.

602 M. Deters, G. Kirchner, K. Resch and V. Kaever, Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS), *Clin. Chem. Lab. Med.*, 2002, **40**(3), 285–292. PubMed PMID: 12005219.

603 M. Ivanova, C. Artusi, G. Polo, M. Zaninotto and M. Plebani, High-throughput LC-MS/MS method for monitoring sirolimus and everolimus in the routine clinical laboratory, *Clin. Chem. Lab. Med.*, 2011, **49**(7), DOI: 10.1515/CCLM.2011.192.

604 G. I. Kirchner, C. Vidal, W. Jacobsen, A. Franzke, K. Hallensleben, U. Christians, *et al.*, Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography–electrospray mass spectrometry, *J. Chromatogr. B: Biomed. Sci. Appl.*, 1999, **721**(2), 285–294.

605 T. Koal, M. Deters, B. Casetta and V. Kaever, Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction–high performance liquid chromatography–tandem mass spectrometry, *J. Chromatogr., B: Biomed. Appl.*, 2004, **805**(2), 215–222.

606 A. Meinitzer, G. Gartner, S. Pilz and M. Stettin, Ultra Fast Liquid Chromatography-Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Cyclosporin A, Tacrolimus, Sirolimus, and Everolimus in Whole Blood Using Deuterated Internal Standards for Cyclosporin A and Everolimus, *Ther. Drug Monit.*, 2010, **32**(1), 61–66.

607 D. M. Mueller and K. M. Rentsch, Sensitive quantification of sirolimus and everolimus by LC–MS/MS with online sample cleanup, *J. Chromatogr., B: Biomed. Appl.*, 2010, **878**(13–14), 1007–1012.

608 R. W. A. Peake, C. R. Hartigan, C. L. Esposito, M. D. Kellogg, J. Gabler, S. Wang, *et al.*, Multicenter Evaluation of the Thermo Scientific Prelude for Measurement of Immunosuppressant Drugs Using Sample Preparation Liquid Chromatography–Tandem Mass Spectrometry, *Ther. Drug Monit.*, 2015, **37**(2), 161–171.

609 C. Seger, K. Tentschert, W. Stöggl, A. Griesmacher and S. L. Ramsay, A rapid HPLC-MS/MS method for the simultaneous quantification of cyclosporine A, tacrolimus, siro-

limus and everolimus in human blood samples, *Nat. Protoc.*, 2009, **4**(4), 526–534.

610 M. Vogeser, C. Fleischer, B. Meiser, J. Groetzner, U. Spöhrer and D. Seidel, Quantification of Sirolimus by Liquid Chromatography-Tandem Mass Spectrometry Using On-Line Solid-Phase Extraction, *Clin. Chem. Lab. Med.*, 2002, **40**(1), DOI: 10.1515/CCLM.2002.008.

611 S. Wang and A. Miller, A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction, *Clin. Chem. Lab. Med.*, 2008, **46**(11), DOI: 10.1515/CCLM.2008.303.

612 C. Heideloff, D. Payto and S. Wang, Comparison of a Stable Isotope-Labeled and an Analog Internal Standard for the Quantification of Everolimus by a Liquid Chromatography–Tandem Mass Spectrometry Method, *Ther. Drug Monit.*, 2013, **35**(2), 246–250.

613 M. Korecka, S. G. Solari and L. M. Shaw, Sensitive, High Throughput HPLC-MS/MS Method With On-line Sample Clean-up for Everolimus Measurement, *Ther. Drug Monit.*, 2006, **28**(4), 484–490.

614 M. A. Korecka, R. Patel and L. M. Shaw, Evaluation of Performance of New, Isotopically Labeled Internal Standard ([13c2d4]RAD001) for Everolimus Using a Novel High-Performance Liquid Chromatography Tandem Mass Spectrometry Method, *Ther. Drug Monit.*, 2011, **33**(4), 460–463.

615 N. Brignol, L. M. McMahon, S. Luo and F. L. S. Tse, High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood, *Rapid Commun. Mass Spectrom.*, 2001, **15**(12), 898–907.

616 L. M. McMahon, S. Luo, M. Hayes and F. L. Tse, High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system, *Rapid Commun. Mass Spectrom.*, 2000, **14**(21), 1965–1971.

617 G. Deslandes, M. Gregoire, C. Renaud, C. Monteil-Ganiere, C. Azoulay, A. Pineau, *et al.*, Comparison Between an Automated and Manual Extraction for the Determination of Immunosuppressive Drugs Whole Blood Concentrations by Liquid Chromatography Tandem Mass Spectrometry, *J. Clin. Lab. Anal.*, 2016, **30**(6), 924–929. PubMed PMID: 27086934. Epub 2016/10/30. eng.

618 J. C. G. den Burger, A. J. Wilhelm, A. Chahbouni, R. M. Vos, A. Sinjewel and E. L. Swart, Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry, *Anal. Bioanal. Chem.*, 2012, **404**(6–7), 1803–1811.

619 R. A. Koster, J.-W. C. Alffenaar, B. Greijdanus and D. R. A. Uges, Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery, *Talanta*, 2013, **115**, 47–54.

620 R. N. Rao, P. K. Maurya, M. Ramesh, R. Srinivas and S. B. Agwane, Development of a validated high-throughput LC-ESI-MS method for determination of sirolimus on dried blood spots, *Biomed. Chromatogr.*, 2010, **24**(12), 1356–1364.

621 K. Sadilkova, B. Busby, J. A. Dickerson, J. C. Rutledge and R. M. Jack, Clinical validation and implementation of a multiplexed immunosuppressant assay in dried blood spots by LC–MS/MS, *Clin. Chim. Acta*, 2013, **421**, 152–156.

622 J. van der Heijden, Y. de Beer, K. Hoogtanders, M. Christiaans, G. J. de Jong, C. Neef, *et al.*, Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography-mass spectrometry, *J. Pharm. Biomed. Anal.*, 2009, **50**(4), 664–670.

623 P. J. Taylor, P. Salm, S. V. Lynch and P. I. Pillans, Simultaneous Quantification of Tacrolimus and Sirolimus, in Human Blood, by High-Performance Liquid Chromatography-Tandem Mass Spectrometry, *Ther. Drug Monit.*, 2000, **22**(5), 608–612.

624 A. Volosov, K. L. Napoli and S. J. Soldin, Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography—tandem mass-spectrometry, *Clin. Biochem.*, 2001, **34**(4), 285–290.

625 S. Giovagnoli, T. Cassano, L. Pace, A. Magini, A. Polchi, B. Tancini, *et al.*, Evaluation of a LC-MS method for everolimus preclinical determination in brain by using [(13) C2D4]RAD001 internal standard, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2015, **985**, 155–163. PubMed PMID: 25682337. Epub 2015/02/16. eng.

626 P. Morgan, M. Nwafor and M. Tredger, Use of a small particle solid-core packing for improved efficiency and rapid measurement of sirolimus and everolimus by LC-MS/MS, *Biomed. Chromatogr.*, 2016, **30**(6), 983–985. PubMed PMID: 26419504. Epub 2015/10/01. eng.

627 N. Mochizuki, E. Suka, K. Matsumoto, O. Akimoto, K. Ohno, T. Shimamura, *et al.*, Liquid chromatographic method for the determination of sirolimus in blood using electrochemical detection, *Biomed. Chromatogr.*, 2009, **23**(3), 267–272.

628 W. Buchberger, M. Ferdig, R. Sommer and T. D. T. Vo, A novel technique for on-capillary preconcentration of anionic compounds applied to the trace analysis of rapamycin in human blood by capillary electrophoresis, *Electrophoresis*, 2005, **26**(1), 161–165.

629 Y. Zhang, F. Li, M. Li and J. Kang, Screening of mammalian target of rapamycin inhibitors in natural product extracts by capillary electrophoresis in combination with high performance liquid chromatography-tandem mass spectrometry, *J. Chromatogr. A*, 2015, **1388**, 267–273.

630 W. Buchberger, M. Ferdig, R. Sommer and T. D. T. Vo, Trace analysis of rapamycin in human blood by micellar electrokinetic chromatography, *Anal. Bioanal. Chem.*, 2004, **380**(1), 68–71.